Document:

Credit Agreement

 EXHIBIT 10.93 

 
  

 
 Published CUSIP Number: 45616EAA8

 CREDIT AGREEMENT 
 Dated as of August 15, 2012 
 among 

INDUSTRIAL INCOME OPERATING PARTNERSHIP LP, 
 a Delaware limited partnership, 
 as the Borrower 

and 
 BANK OF
AMERICA, N.A., 
 as Administrative Agent, Swing Line Lender and L/C Issuer, 

KEYBANK NATIONAL ASSOCIATION, 
 as Syndication Agent, 
  
 WELLS FARGO BANK, NATIONAL ASSOCIATION 
 REGIONS BANK 

and 

JPMORGAN CHASE BANK, N.A. 
 as Co-Documentation Agents 
 The Other Lenders Party Hereto

 MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED 

and 
 KEYBANC
CAPITAL MARKETS, 
 As Joint Lead Arrangers and Joint Bookrunners 

 
  

 

 TABLE OF CONTENTS 

 

							
	ARTICLE I. DEFINITIONS AND ACCOUNTING TERMS	  	 	1	  
	1.01	 	 DEFINED TERMS
	  	 	1	  
	1.02	 	 OTHER INTERPRETIVE PROVISIONS
	  	 	27	  
	1.03	 	 ACCOUNTING TERMS
	  	 	28	  
	1.04	 	 ROUNDING
	  	 	28	  
	1.05	 	 TIMES OF DAY
	  	 	29	  
	1.06	 	 LETTER OF CREDIT AMOUNTS
	  	 	29	  
		
	ARTICLE II. THE COMMITMENTS AND CREDIT EXTENSIONS	  	 	29	  
	2.01	 	 COMMITTED LOANS
	  	 	29	  
	2.02	 	 BORROWINGS, CONVERSIONS AND CONTINUATIONS OF
COMMITTED LOANS
	  	 	29	  
	2.03	 	 INTENTIONALLY OMITTED
	  	 	30	  
	2.04	 	 LETTERS OF CREDIT
	  	 	30	  
	2.05	 	 SWING LINE LOANS
	  	 	39	  
	2.06	 	 PREPAYMENTS
	  	 	42	  
	2.07	 	 TERMINATION OR REDUCTION OF
COMMITMENTS
	  	 	43	  
	2.08	 	 REPAYMENT OF LOANS
	  	 	43	  
	2.09	 	 INTEREST
	  	 	43	  
	2.10	 	 FEES
	  	 	44	  
	2.11	 	 COMPUTATION OF INTEREST AND FEES;
RETROACTIVE ADJUSTMENTS OF APPLICABLE RATE
	  	 	44	  
	2.12	 	 EVIDENCE OF DEBT.
	  	 	45	  
	2.13	 	 PAYMENTS GENERALLY; ADMINISTRATIVE AGENT’S
CLAWBACK
	  	 	46	  
	2.14	 	 SHARING OF PAYMENTS BY LENDERS
	  	 	47	  
	2.15	 	 EXTENSION OF MATURITY DATE
	  	 	48	  
	2.16	 	 INCREASE IN COMMITMENTS
	  	 	49	  
	2.17	 	 CASH COLLATERAL
	  	 	50	  
	2.18	 	 DEFAULTING LENDERS
	  	 	51	  
	2.19	 	 ADDITION AND REMOVAL OF UNENCUMBERED
PROPERTIES
	  	 	53	  
		
	ARTICLE III. TAXES, YIELD PROTECTION AND ILLEGALITY	  	 	54	  
	3.01	 	 TAXES
	  	 	54	  
	3.02	 	 ILLEGALITY
	  	 	59	  
	3.03	 	 INABILITY TO DETERMINE RATES
	  	 	59	  
	3.04	 	 INCREASED COSTS; RESERVES ON EURODOLLAR
RATE LOANS
	  	 	60	  
	3.05	 	 COMPENSATION FOR LOSSES
	  	 	61	  
	3.06	 	 MITIGATION OBLIGATIONS; REPLACEMENT OF
LENDERS
	  	 	62	  
	3.07	 	 SURVIVAL
	  	 	62	  
		
	ARTICLE IV. CONDITIONS PRECEDENT TO CREDIT EXTENSIONS	  	 	62	  
	4.01	 	 CONDITIONS OF INITIAL CREDIT EXTENSION
	  	 	62	  
	4.02	 	 CONDITIONS TO ALL CREDIT EXTENSIONS
	  	 	64	  
		
	ARTICLE V. REPRESENTATIONS AND WARRANTIES	  	 	65	  
	5.01	 	 EXISTENCE, QUALIFICATION AND POWER
	  	 	65	  
	5.02	 	 AUTHORIZATION; NO CONTRAVENTION
	  	 	65	  
	5.03	 	 GOVERNMENTAL AUTHORIZATION; OTHER CONSENTS
	  	 	65	  
	5.04	 	 BINDING EFFECT
	  	 	65	  
	5.05	 	 FINANCIAL STATEMENTS; NO MATERIAL ADVERSE
EFFECT
	  	 	65	  
	5.06	 	 LITIGATION
	  	 	66	  
	5.07	 	 NO DEFAULT
	  	 	66	  
	5.08	 	 OWNERSHIP OF PROPERTY; LIENS
	  	 	66	  
	5.09	 	 ENVIRONMENTAL COMPLIANCE
	  	 	66	  
	5.10	 	 TAXES
	  	 	66	  

  
 - i -

							
	5.11	 	 ERISA COMPLIANCE
	  	 	67	  
	5.12	 	 SUBSIDIARIES; EQUITY INTERESTS
	  	 	67	  
	5.13	 	 MARGIN REGULATIONS; INVESTMENT COMPANY
ACT
	  	 	68	  
	5.14	 	 DISCLOSURE
	  	 	68	  
	5.15	 	 COMPLIANCE WITH LAWS
	  	 	68	  
	5.16	 	 TAXPAYER IDENTIFICATION NUMBER
	  	 	68	  
	5.17	 	 INTELLECTUAL PROPERTY; LICENSES, ETC
	  	 	68	  
	5.18	 	 REIT STATUS
	  	 	69	  
	5.19	 	 UNENCUMBERED PROPERTIES
	  	 	69	  
		
	ARTICLE VI. AFFIRMATIVE COVENANTS	  	 	71	  
	6.01	 	 FINANCIAL STATEMENTS AND OTHER
INFORMATION
	  	 	71	  
	6.02	 	 NOTICES
	  	 	72	  
	6.03	 	 PAYMENT OF TAXES
	  	 	73	  
	6.04	 	 PRESERVATION OF EXISTENCE, ETC
	  	 	73	  
	6.05	 	 MAINTENANCE OF PROPERTIES
	  	 	73	  
	6.06	 	 MAINTENANCE OF INSURANCE
	  	 	73	  
	6.07	 	 COMPLIANCE WITH LAWS
	  	 	73	  
	6.08	 	 BOOKS AND RECORDS
	  	 	73	  
	6.09	 	 INSPECTION RIGHTS
	  	 	74	  
	6.10	 	 USE OF PROCEEDS AND LETTERS OF
CREDIT
	  	 	74	  
	6.11	 	 REIT STATUS
	  	 	74	  
	6.12	 	 SUBSIDIARY GUARANTEES
	  	 	74	  
		
	ARTICLE VII. NEGATIVE COVENANTS	  	 	75	  
	7.01	 	 LIENS
	  	 	75	  
	7.02	 	 INVESTMENTS
	  	 	75	  
	7.03	 	 INTENTIONALLY DELETED
	  	 	75	  
	7.04	 	 FUNDAMENTAL CHANGES
	  	 	75	  
	7.05	 	 INTENTIONALLY DELETED
	  	 	76	  
	7.06	 	 RESTRICTED PAYMENTS
	  	 	76	  
	7.07	 	 CHANGE IN NATURE OF BUSINESS
	  	 	76	  
	7.08	 	 TRANSACTIONS WITH AFFILIATES
	  	 	76	  
	7.09	 	 INTENTIONALLY DELETED
	  	 	76	  
	7.10	 	 USE OF PROCEEDS
	  	 	76	  
	7.11	 	 FINANCIAL COVENANTS
	  	 	76	  
	7.12	 	 KEYBANK LINE OF CREDIT
	  	 	78	  
		
	ARTICLE VIII. EVENTS OF DEFAULT AND REMEDIES	  	 	78	  
	8.01	 	 EVENTS OF DEFAULT
	  	 	78	  
	8.02	 	 REMEDIES UPON EVENT OF DEFAULT
	  	 	80	  
	8.03	 	 APPLICATION OF FUNDS
	  	 	80	  
		
	ARTICLE IX. ADMINISTRATIVE AGENT	  	 	81	  
	9.01	 	 APPOINTMENT AND AUTHORITY
	  	 	81	  
	9.02	 	 RIGHTS AS A LENDER
	  	 	81	  
	9.03	 	 EXCULPATORY PROVISIONS
	  	 	82	  
	9.04	 	 RELIANCE BY ADMINISTRATIVE AGENT
	  	 	83	  
	9.05	 	 DELEGATION OF DUTIES
	  	 	83	  
	9.06	 	 RESIGNATION OF ADMINISTRATIVE AGENT
	  	 	83	  
	9.07	 	 NON-RELIANCE ON ADMINISTRATIVE AGENT
AND OTHER LENDERS
	  	 	85	  
	9.08	 	 NO OTHER DUTIES, ETC
	  	 	85	  
	9.09	 	 ADMINISTRATIVE AGENT MAY FILE PROOFS OF
CLAIM
	  	 	85	  
	9.10	 	 LENDER REPLY PERIOD.
	  	 	86	  

  
 - ii -

							
	ARTICLE X. MISCELLANEOUS	  	 	87	  
	10.01	 	 AMENDMENTS, ETC
	  	 	87	  
	10.02	 	 NOTICES; EFFECTIVENESS; ELECTRONIC COMMUNICATION
	  	 	88	  
	10.03	 	 NO WAIVER; CUMULATIVE REMEDIES;
ENFORCEMENT
	  	 	90	  
	10.04	 	 EXPENSES; INDEMNITY; DAMAGE WAIVER
	  	 	91	  
	10.05	 	 PAYMENTS SET ASIDE
	  	 	93	  
	10.06	 	 SUCCESSORS AND ASSIGNS
	  	 	93	  
	10.07	 	 TREATMENT OF CERTAIN INFORMATION;
CONFIDENTIALITY
	  	 	98	  
	10.08	 	 RIGHT OF SETOFF
	  	 	99	  
	10.09	 	 INTEREST RATE LIMITATION
	  	 	99	  
	10.10	 	 COUNTERPARTS; INTEGRATION; EFFECTIVENESS
	  	 	99	  
	10.11	 	 SURVIVAL OF REPRESENTATIONS AND
WARRANTIES
	  	 	100	  
	10.12	 	 SEVERABILITY
	  	 	100	  
	10.13	 	 REPLACEMENT OF LENDERS
	  	 	100	  
	10.14	 	 GOVERNING LAW; JURISDICTION; ETC
	  	 	101	  
	10.15	 	 WAIVER OF JURY TRIAL
	  	 	102	  
	10.16	 	 NO ADVISORY OR FIDUCIARY
RESPONSIBILITY
	  	 	102	  
	10.17	 	 ELECTRONIC EXECUTION OF ASSIGNMENTS AND
CERTAIN OTHER DOCUMENTS
	  	 	103	  
	10.18	 	 USA PATRIOT ACT
	  	 	103	  
	10.19	 	 TIME OF THE ESSENCE
	  	 	103	  
	10.20	 	 ENTIRE AGREEMENT
	  	 	103	  
		
	TRUST GUARANTY	  			
		
	SUBSIDIARY GUARANTY	  			

  
 - iii -

 CREDIT AGREEMENT 

This CREDIT AGREEMENT is entered into as of August 15, 2012, among INDUSTRIAL INCOME OPERATING PARTNERSHIP LP, a Delaware
limited partnership (the “Borrower”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), and BANK OF AMERICA, N.A., as Administrative Agent, Swing
Line Lender and L/C Issuer. 
 The Borrower has requested that the Lenders provide a revolving credit facility, and the Lenders
are willing to do so on the terms and conditions set forth herein. 
 In consideration of the mutual covenants and agreements
herein contained, the parties hereto covenant and agree as follows: 
 ARTICLE I. DEFINITIONS AND ACCOUNTING TERMS

 1.01 Defined Terms. As used in this Agreement, the following terms shall have the meanings set forth below:

 “Adjusted EBITDA” means, Consolidated EBITDA less, with respect to Properties owned by the Consolidated
Group, the Capital Expenditure Reserve, and less, with respect to Properties owned by Unconsolidated Affililiates, the Consolidated Group Pro Rata Share of the Capital Expenditure Reserve. 

“Administrative Agent” means Bank of America in its capacity as administrative agent under any of the Loan Documents, or
any successor administrative agent. 
 “Administrative Agent’s Office” means the Administrative
Agent’s address and, as appropriate, account as set forth on Schedule 10.02, or such other address or account as the Administrative Agent may from time to time notify to the Borrower and the Lenders. 

“Administrative Questionnaire” means an Administrative Questionnaire in substantially the form of Exhibit E-2 or
any other form approved by the Administrative Agent. 
 “Affiliate” means, with respect to any Person, another
Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified, provided, however, in no event shall the Administrative Agent or any Lender or
any of their respective Affiliates be an Affiliate of Borrower or other Loan Parties. 
 “Aggregate
Commitments” means the Commitments of all the Lenders. 
 “Agreement” means this Credit Agreement.

 “Applicable Percentage” means with respect to any Lender at any time, the percentage (carried out to the
ninth decimal place) of the Aggregate Commitments represented by such Lender’s Commitment at such time, subject to adjustment as provided in Section 2.18. If the commitment of each Lender to make Loans and the obligation of the L/C
Issuer to make L/C Credit Extensions have been terminated pursuant to Section 8.02 or if the Aggregate Commitments have expired, then the Applicable Percentage of each Lender shall be determined

  

- 1 - 

 
based on the Applicable Percentage of such Lender most recently in effect, giving effect to any subsequent assignments. The initial Applicable Percentage of each Lender is set forth opposite the
name of such Lender on Schedule 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable. 
 “Applicable Rate” means the following percentages per annum, based upon the Consolidated Leverage Ratio as set forth in the most recent Compliance Certificate received by the
Administrative Agent pursuant to Section 6.01(c): 
 Applicable Rate 

 

							
	 Pricing

Level
	  	 Consolidated Leverage

Ratio
	  	Eurodollar Rate +
Letters of Credit	  	Base Rate
	 1
	  	£ 50%	  	175.0 bps	  	75.0 bps
	 2
	  	> 50% and £ 55%	  	200.0 bps	  	100.0 bps
	 3
	  	> 55% and £ 60%	  	225.0 bps	  	125.0 bps
	 4
	  	> 60%	  	250.0 bps	  	150.0 bps

 Any increase or decrease in the Applicable Rate resulting from a change in the Consolidated Leverage
Ratio shall become effective as of the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to Section 6.01(c); provided, however, that if a Compliance Certificate is not
delivered when due in accordance with such Section, then, upon the request of the Required Lenders, Pricing Level 4 shall apply as of the first Business Day after the date on which such Compliance Certificate was required to have been delivered and
shall remain in effect until the date on which such Compliance Certificate is delivered. The Applicable Rate in effect from the Closing Date through the date of the next change in the Applicable Rate pursuant to the preceding sentence shall be
determined based upon Pricing Level 1. 
 Notwithstanding anything to the contrary contained in this definition, the
determination of the Applicable Rate for any period shall be subject to the provisions of Section 2.11(b). 

“Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender
or (c) an entity or an Affiliate of an entity that administers or manages a Lender. 
 “Arrangers” means
Merrill Lynch, Pierce, Fenner & Smith Incorporated, and KeyBanc Capital Markets LLC in their capacity as joint lead arrangers and joint bookrunners. 
 “Asset Under Development” means any Property (a) for which the Consolidated Group is actively pursuing construction, renovation, or expansion of such Property or (b) or for
which no construction has commenced but all necessary entitlements have been obtained in order to allow the Consolidated Group to commence constructing improvements on such Property. Notwithstanding the foregoing, tenant improvements in a previously
constructed Property shall not be considered an Asset Under Development and with respect to any existing Property only the renovation or expansion portion of such Property shall be considered an Asset Under Development. 

  

- 2 - 

 “Assignee Group” means two or more Eligible Assignees that are Affiliates
of one another or two or more Approved Funds managed by the same investment advisor. 
 “Assignment and
Assumption” means an assignment and assumption entered into by a Lender and an assignee (with the consent of any party whose consent is required by Section 10.06(b)), and accepted by the Administrative Agent, in substantially
the form of Exhibit E-1 or any other form (including electronic documentation generated by MarkitClear or other electronic platform) approved by the Administrative Agent. 

“Audited Financial Statements” means the audited consolidated balance sheet of the Trust, the Borrower and its
Subsidiaries for the fiscal year ended December 31, 2011, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year of the Trust, the Borrower and its Subsidiaries, including
the notes thereto. From and after the Closing, Audited Financial Statements shall mean the most recent Audited Financial Statements delivered pursuant to Section 5.05(a). 
 “Availability Period” means the period from and including the Closing Date to the earliest of (a) the Maturity Date, (b) the date of termination of the Aggregate Commitments
pursuant to Section 2.07, and (c) the date of termination of the commitment of each Lender to make Loans and of the obligation of the L/C Issuer to make L/C Credit Extensions pursuant to Section 8.02. 

“Bank of America” means Bank of America, N.A. and its successors. 

“Base Rate” means for any day a fluctuating rate per annum equal to the highest of (a) the Federal Funds Rate plus
1/2 of 1%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate,” and (c) the Eurodollar Rate plus 1.00%. The “prime rate” is a rate set by Bank
of America based upon various factors including Bank of America’s costs and desired return, general economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such
announced rate. Any change in such prime rate announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change. 

“Base Rate Committed Loan” means a Committed Loan that is a Base Rate Loan. 

“Base Rate Loan” means a Loan that bears interest based on the Base Rate. 

“Borrower” has the meaning specified in the introductory paragraph hereto. 

“Borrower Materials” has the meaning specified in Section 10.02 (c). 

“Borrowing” means a Committed Borrowing, or a Swing Line Borrowing, as the context may require. 

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to
close under the Laws of, or are in fact closed in, the state where the Administrative Agent’s Office is located and, if such day relates to any Eurodollar Rate Loan, means any such day that is also a London Banking Day. 

  

- 3 - 

 “Capital Expenditure Reserve” means $0.10 per square foot of leasable space
(as annualized for the applicable ownership period). 
 “Capital Lease Obligations” of any Person means the
obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for as
capital leases on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. 
 “Capitalization Rate” means, seven and one-half percent (7.50%). 

“Cash Collateralize” means to pledge and deposit with or deliver to the Administrative Agent, for the benefit of the
Administrative Agent, L/C Issuer or Swing Line Lender (as applicable) and the Lenders, as collateral for L/C Obligations, Obligations in respect of Swing Line Loans, or obligations of Lenders to fund participations in respect of either thereof (as
the context may require), cash or deposit account balances or, if the L/C Issuer or Swing Line Lender benefitting from such collateral shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and
substance satisfactory to (a) the Administrative Agent and (b) the L/C Issuer or the Swing Line Lender (as applicable). “Cash Collateral” shall have a meaning correlative to the foregoing and shall include the proceeds of such
cash collateral and other credit support. 
 “Cash Equivalents” means, as of any date: 

(i) securities issued or directly and fully guaranteed or insured by the United States Government or any agency or
instrumentality thereof having maturities of not more than one year from such date; 
 (ii) mutual funds
organized under the United States Investment Company Act rated AAm or AAm-G by S&P and P-1 by Moody’s; 

(iii) certificates of deposit or other interest-bearing obligations of a bank or trust company which is a member in good
standing of the Federal Reserve System having a short term unsecured debt rating of not less than A-1 by S&P and not less than P-1 by Moody’s (or in each case, if no bank or trust company is so rated, the highest comparable rating then
given to any bank or trust company, but in such case only for funds invested overnight or over a weekend) provided that such investments shall mature or be redeemable upon the option of the holders thereof on or prior to a date one month from the
date of their purchase; 
 (iv) certificates of deposit or other interest-bearing obligations of a bank or trust
company which is a member in good standing of the Federal Reserve System having a short term unsecured debt rating of not less than A-1+ by S&P, and not less than P-1 by Moody’s and which has a long term unsecured debt rating of not less
than A1 by Moody’s (or in each case, if no bank or trust company is so rated, the highest comparable rating then given to any bank or trust company, but in such case only for funds invested overnight or over a weekend) provided that such
investments shall mature or be redeemable upon the option of the holders thereof on or prior to a date three months from the date of their purchase; 

  

- 4 - 

 (v) bonds or other obligations having a short term unsecured debt rating of
not less than A-1+ by S&P and P-1+ by Moody’s and having a long term debt rating of not less than A1 by Moody’s issued by or by authority of any state of the United States, any territory or possession of the United States, including
the Commonwealth of Puerto Rico and agencies thereof, or any political subdivision of any of the foregoing; 

(vi) repurchase agreements issued by an entity rated not less than A-1+ by S&P, and not less than P-1 by Moody’s
which are secured by U.S. Government securities of the type described in clause (i) of this definition maturing on or prior to a date one month from the date the repurchase agreement is entered into; 

(vii) short term promissory notes rated not less than A-1+ by S&P, and not less than P-1 by Moody’s maturing or
to be redeemable upon the option of the holders thereof on or prior to a date one month from the date of their purchase; and 
 (viii) commercial paper (having original maturities of not more than 365 days) rated at least A-1+ by S&P and P-1 by Moody’s and issued by a foreign or domestic issuer who, at the time of the
investment, has outstanding long-term unsecured debt obligations rated at least A1 by Moody’s. 
 “Change in
Law” means the occurrence, after the date of this Agreement, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation (including without
limitation Regulation D) or treaty or in the administration, interpretation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of
law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued
in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or
foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued. 

“Change of Control” means the occurrence of any one of the following events (other than to the extent permitted under
Section 7.04): 
 (a) during any twelve (12) month period on or after the Effective Date, individuals who at the
beginning of such period constituted the Board of Directors or Trustees of Trust (the “Board”) (together with any new directors whose election by the Board or whose nomination for election by the shareholders of Trust was approved
by a vote of at least a majority of the members of the Board then in office who either were members of the Board at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason (other
than death or disability) to constitute a majority of the members of the Board then in office; 

  

- 5 - 

 (b) any Person or group (as that term is used in Section 13(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator
of any such plan and the rules and regulations thereunder) shall have acquired beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of a percentage (based on voting power, in the event different classes of stock shall have
different voting powers) of the voting stock of Trust equal to at least thirty percent (30%); 
 (c) Trust consolidates with, is
acquired by, or merges into or with any Person (other than a consolidation or merger in which the Trust is the continuing or surviving entity); or 
 (d) Trust fails to own, directly or indirectly, seventy percent (70%) of the Ownership Interests of Borrower and be the sole general partner of Borrower. 

“Closing Date” means the first date all the conditions precedent in Section 4.01 are satisfied or waived in
accordance with Section 10.01. 
 “Code” means the Internal Revenue Code of 1986. 

“Commitment” means, as to each Lender, its obligation to (a) make Committed Loans to the Borrower pursuant to
Section 2.01, (b) purchase participations in L/C Obligations, and (c) purchase participations in Swing Line Loans, in an aggregate principal amount at any one time outstanding not to exceed the amount set forth opposite such
Lender’s name on Schedule 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. 

“Committed Borrowing” means a borrowing consisting of simultaneous Committed Loans of the same Type and, in the case of
Eurodollar Rate Loans, having the same Interest Period made by each of the Lenders pursuant to Section 2.01. 

“Committed Loan” has the meaning specified in Section 2.01. 

“Committed Loan Notice” means a notice of (a) a Committed Borrowing, (b) a conversion of Committed Loans from
one Type to the other, or (c) a continuation of Eurodollar Rate Loans, pursuant to Section 2.02(a), which, if in writing, shall be substantially in the form of Exhibit A. 

“Compliance Certificate” means a certificate substantially in the form of Exhibit D. 

“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however
denominated) or that are franchise Taxes or branch profits Taxes. 
 “Consolidated Debt Service” means, for any
period, without duplication, (a) Recurring Interest Expense for such period plus (b) the aggregate amount of scheduled principal payments attributable to Total Indebtedness (excluding optional prepayments and prepayment premiums and
scheduled balloon principal payments in respect of any such Indebtedness which is not 

  

- 6 - 

 
amortized through periodic installments of principal and interest over the term of such Indebtedness) required to be made during such period by any member of the Consolidated Group plus
(c) a percentage of all such scheduled principal payments required to be made during such period by any Unconsolidated Affiliate on Indebtedness (excluding optional prepayments and prepayment premiums and scheduled balloon principal payments
with respect to any such indebtedness which is not amortized through periodic installments of principal and interest over the term of such Indebtedness) taken into account in calculating Recurring Interest Expense, equal to the greater of
(x) the percentage of the principal amount of such Indebtedness for which any member of the Consolidated Group is liable and (y) the Consolidated Group Pro Rata Share of such Unconsolidated Affiliate. 

“Consolidated EBITDA” means, Consolidated Net Income plus, to the extent deducted from revenues in determining
Consolidated Net Income, (i) Recurring Interest Expense, (ii) expense for taxes paid or accrued, (iii) depreciation, (iv) amortization, (v) impairment charges, (vi) amounts deducted as a result of the application of FAS
141, (vii) non-cash expenses related to employee and trustee stock and stock option plans, (viii) non-recurring financing and acquisition related fees and costs and (ix) extraordinary losses incurred other than in the ordinary course
of business, minus, to the extent included in Consolidated Net Income, extraordinary gains realized other than in the ordinary course of business. For the avoidance of doubt, Consolidated EBITDA shall not include gains and losses from asset sales.

 “Consolidated Fixed Charge Coverage Ratio” means the ratio of Adjusted EBITDA to Fixed Charges. 

“Consolidated Group” shall mean the Trust, the Borrower and all Subsidiaries which are required to be consolidated with
them for financial reporting purposes under GAAP. 
 “Consolidated Group Pro Rata Share” shall mean, with
respect to any Unconsolidated Affiliate, the pro rata share of the ownership interests held by the Consolidated Group, in the aggregate, in such Unconsolidated Affiliate, without duplication. 

“Consolidated Leverage Ratio” means, at any time, Total Indebtedness divided by Total Asset Value, expressed as a
percentage. 
 “Consolidated Net Income” shall mean, for any period, the sum, without duplication, of
(i) net earnings (or loss) after taxes of the Consolidated Group (adjusted by eliminating any such earnings or loss attributable to Unconsolidated Affiliates) plus (ii) the applicable Consolidated Group Pro Rata Share of net earnings (or
loss) of all Unconsolidated Affiliates for such period, in each case determined in accordance with GAAP (provided, however, that lease payments attributable to Sale-Leaseback Master Leases which are generally excluded from “consolidated net
income” in accordance with GAAP shall nonetheless be included as earnings for purposes of this definition). 

“Consolidated Tangible Net Worth” means, at any time, total assets (excluding accumulated depreciation and intangible
assets) minus total liabilities, calculated in accordance with GAAP. However, for the purpose of this calculation, intangible assets resulting from the application of FAS141 shall not be excluded from Consolidated Tangible Net Worth. 

  

- 7 - 

 “Contractual Obligation” means, as to any Person, any provision of any
security issued by such Person or of any material agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound. 
 “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise
voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. 
 “Credit Extension” means each of the following: (a) a Borrowing and (b) an L/C Credit Extension. 
 “Debt Instruments” means any instrument evidencing a debt, including mortgage notes and mezzanine notes. 
 “Debtor Relief Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium,
rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally. 

“Default” means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the
passage of time, or both, would be an Event of Default. 
 “Default Rate” means (a) when used with respect
to Obligations other than Letter of Credit Fees, an interest rate equal to (i) the Base Rate plus (ii) the Applicable Rate, if any, applicable to Base Rate Loans plus (iii) 2% per annum; provided,
however, that with respect to a Eurodollar Rate Loan, the Default Rate shall be an interest rate equal to the interest rate (including any Applicable Rate) otherwise applicable to such Loan plus 2% per annum, and (b) when used with
respect to Letter of Credit Fees, a rate equal to the Applicable Rate plus 2% per annum. 
 “Defaulting
Lender” means, subject to Section 2.18(b), any Lender that (a) has failed to (i) fund all or any portion of its Loans within two Business Days of the date such Loans were required to be funded hereunder unless such Lender
notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender’s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable
default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, the L/C Issuer, the Swing Line Lender or any other Lender any other amount required to be paid by it hereunder
(including in respect of its participation in Letters of Credit or Swing Line Loans) within two Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent, the L/C Issuer or the Swing Line Lender in writing that
it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund a Loan hereunder and states that such
position is based on such Lender’s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied),
(c) has failed, within five Business Days after written request by the Administrative 

  

- 8 - 

 
Agent or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding obligations hereunder subject to and in accordance with
the terms hereof (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrower), or (d) has, or has a
direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, or (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors
or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity; provided that a Lender
shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any Equity Interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result
in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate,
disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (a) through (d) above, and of the
effective date of such status, shall be prima facie evidence thereof, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.18(b)) as of the date established therefor by the Administrative Agent in a written
notice of such determination, which shall be delivered by the Administrative Agent to the Borrower, the L/C Issuer, the Swing Line Lender and each other Lender promptly following such determination. 

“Disposition” or “Dispose” means the sale, transfer, assignment, contribution, license, lease or other
disposition (including any sale and leaseback transaction) of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated
therewith. 
 “Dollar” and “$” mean lawful money of the United States. 

“Eligible Assignee” means any Person that meets the requirements to be an assignee under
Section 10.06(b)(iii), and (v) (subject to such consents, if any, as may be required under Section 10.06(b)(iii)). 
 “Environmental Laws” means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees or governmental restrictions relating
to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems. 

“Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of
environmental remediation, fines, penalties or indemnities), of the Borrower, any other Loan Party or any of their respective Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law, (b) the
generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or
(e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. 

  

- 9 - 

 “Equity Interests” means, with respect to any Person, all of the shares of
capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such
Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or
such other interests), and all of the other ownership or profit interests in such Person (including partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other
interests are outstanding on any date of determination. 
 “ERISA” means the Employee Retirement Income
Security Act of 1974. 
 “ERISA Affiliate” means any trade or business (whether or not incorporated) under
common control with the Borrower within the meaning of Section 414(b) or (c) of the Code (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code). 

“ERISA Event” means (a) a Reportable Event with respect to a Pension Plan; (b) the withdrawal of the Borrower
or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which such entity was a “substantial employer” as defined in Section 4001(a)(2) of ERISA or a cessation of operations that is
treated as such a withdrawal under Section 4062(e) of ERISA; (c) a complete or partial withdrawal by the Borrower or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization; (d) the
filing of a notice of intent to terminate, the treatment of a Pension Plan amendment as a termination under Section 4041 or 4041A of ERISA; (e) the institution by the PBGC of proceedings to terminate a Pension Plan; (f) any event or
condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan; (g) the determination that any Pension Plan is considered an at-risk plan within the
meaning of Section 430 of the Code or Section 303 of ERISA or the determination that any Multiemployer Plan is considered a plan in endangered or critical status within the meaning of Sections 431 and 432 of the Code or Sections 304 and
305 of ERISA; or (h) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon the Borrower or any ERISA Affiliate. 

“Eurodollar Rate” means: 
 (a) for any Interest Period with respect to a Eurodollar Rate Loan, the rate per annum equal to (i) the British Bankers Association LIBOR Rate (“BBA LIBOR”), as published by Reuters (or
such other commercially available source providing quotations of BBA LIBOR as may be reasonably designated by the Administrative Agent from time to time) at approximately 11:00 a.m., London time, two London Banking Days prior to the commencement of
such Interest Period, for Dollar deposits (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period or, (ii) if such rate is not available at such time for any reason, the rate per annum reasonably
determined by the Administrative Agent to be the rate at which deposits in Dollars for delivery on the first day of such Interest Period in same day funds in the approximate amount of the Eurodollar Rate Loan being made, continued or converted and
with a term equivalent to such Interest Period would be offered by Bank of America’s London Branch to major banks in the London interbank eurodollar market at their request at approximately 1:00 p.m. (London time) two London Banking Days prior
to the commencement of such Interest Period; and 

  

- 10 - 

 (b) for any interest calculation with respect to a Base Rate Loan on any date, the rate per
annum equal to (i) BBA LIBOR, at approximately 1:00 p.m., London time determined two London Banking Days prior to such date for Dollar deposits being delivered in the London interbank market for a term of one month commencing that day or
(ii) if such published rate is not available at such time for any reason, the rate per annum reasonably determined by the Administrative Agent to be the rate at which deposits in Dollars for delivery on the date of determination in same day
funds in the approximate amount of the Base Rate Loan being made or maintained and with a term equal to one month would be offered by Bank of America’s London Branch to major banks in the London interbank Eurodollar market at their request at
the date and time of determination. 
 “Eurodollar Rate Loan” means a Committed Loan that bears interest at a
rate based upon the Eurodollar Rate. 
 “Event of Default” has the meaning specified in
Section 8.01. 
 “Excluded Taxes” means, any of the following Taxes imposed on or with respect to
any Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise or similar Taxes, and branch profits or similar Taxes, in each case,
(i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof)
or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to
a law in effect on the date on which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under Section 10.13) or (ii) such Lender changes its Lending Office,
except in each case to the extent that, pursuant to Section 3.01(a)(ii) or (c), amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender
immediately before it changed its Lending Office, (c) Taxes attributable to such Recipient’s failure or inability to comply with Section 3.01(e) and (d) any U.S. federal withholding Taxes imposed pursuant to FATCA. 

“Existing Credit Agreement” means that certain Borrowing Base Revolving Line of Credit Agreement, dated as of
December 23, 2010 by and among Industrial Income Operating Partnership LP, IIT Real Estate Holdco LLC and each of the Project Borrowers referenced therein and J.P. Morgan Chase Bank, N.A. as Administrative Agent and the Lenders referenced
therein. 
 “FASB ASC” means the Accounting Standards Codification of the Financial Accounting Standards Board.

 “Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on
overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal 

  

- 11 - 

 
Reserve Bank of New York on the Business Day next succeeding such day; provided that (a) if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on
such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so published on such next succeeding Business Day, the Federal Funds Rate for such day shall be the average
rate (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) charged to Bank of America on such day on such transactions as reasonably determined by the Administrative Agent. 

“Financeable Ground Lease” means, except as otherwise approved by the Required Lenders a ground lease that provides
reasonable and customary protections for a potential leasehold mortgagee (“Mortgagee”) which include, among other things (a) a remaining term, including any optional extension terms exercisable unilaterally by the tenant, of no less
than twenty-five (25) years from the Closing Date, (b) that the ground lease will not be terminated until the Mortgagee has received notice of a default, has had a reasonable opportunity to cure or complete foreclosure, and has failed to
do so, (c) provision for a new lease on the same terms to the Mortgagee as tenant if the ground lease is terminated for any reason or other protective provisions reasonably acceptable to Administrative Agent, (d) non-merger of the fee and
leasehold estates, (e) transferability of the tenant’s interest under the ground lease without any requirement for consent of the ground lessor unless based on reasonable objective criteria as to the creditworthiness or line of business of
the transferee or delivery of customary assignment and assumption agreements from the transferor and transferee, and (f) that insurance proceeds and condemnation awards (from leasehold interest) will be applied pursuant to the terms of the
applicable leasehold mortgage. 
 “Fixed Charges” shall mean, for any period, the sum of (i) Consolidated
Debt Service and (ii) all dividends actually paid on account of preferred stock or preferred operating partnership units of the Borrower or any other Person in the Consolidated Group (including dividends actually paid to Unconsolidated
Affiliates but excluding dividends paid to members of the Consolidated Group). 
 “Foreign Lender” means any
Lender that is organized under the Laws of a jurisdiction other than that in which the Borrower is resident for tax purposes (including such a Lender when acting in the capacity of the L/C Issuer). For purposes of this definition, the United States,
each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction. 
 “FRB”
means the Board of Governors of the Federal Reserve System of the United States. 
 “Fronting Exposure” means,
at any time there is a Defaulting Lender, (a) with respect to the L/C Issuer, such Defaulting Lender’s Applicable Percentage of the outstanding L/C Obligations other than L/C Obligations as to which such Defaulting Lender’s
participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof, and (b) with respect to the Swing Line Lender, such Defaulting Lender’s Applicable Percentage of Swing Line Loans
other than Swing Line Loans as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof. 

  

- 12 - 

 “Fund” means any Person (other than a natural person) that is (or will be)
engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities. 
 “GAAP” means generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of
Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to
the circumstances as of the date of determination, consistently applied. 
 “Governmental Authority” means the
government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative,
judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank). 

“Guarantee Obligation” means, as to any Person (the “guaranteeing person”), any obligation (determined without
duplication) of (a) the guaranteeing person or (b) another Person (including, without limitation, any bank under any letter of credit) to induce the creation of which the guaranteeing person has issued a reimbursement or similar
obligation, in either case guaranteeing or in effect guaranteeing any Indebtedness, leases, dividends or other obligations (the “primary obligations”) of any other third Person (the “primary obligor”) in any manner, whether
directly or indirectly, including, without limitation, any obligation of the guaranteeing person, whether or not contingent, (i) to purchase any such primary obligation or any property constituting direct or indirect security therefor,
(ii) to advance or supply funds (1) for the purchase or payment of any such primary obligation or (2) to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the
primary obligor, (iii) to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation or
(iv) otherwise to assure or hold harmless the owner of any such primary obligation against loss in respect thereof; provided, however, that the term Guarantee Obligation shall not include endorsements of instruments for deposit or collection in
the ordinary course of business. The amount of any Guarantee Obligation of any guaranteeing person shall be deemed to be the maximum stated amount of the primary obligation relating to such Guarantee Obligation (or, if less, the maximum stated
liability set forth in the instrument embodying such Guarantee Obligation), provided, that in the absence of any such stated amount or stated liability, the amount of such Guarantee Obligation shall be such guaranteeing person’s maximum
reasonably anticipated liability in respect thereof as determined by the Borrower in good faith. 

“Guarantors” means, collectively, the Trust and all Subsidiary Guarantors. 

“Guaranty” means collectively the Guaranty from the Trust and the Subsidiary Guaranty from the Subsidiary Guarantors
made in favor of the Administrative Agent and the Lenders, substantially in the forms of Exhibits F-1 and F-2, as the same may be amended, supplemented or otherwise modified from time to time. 

  

- 13 - 

 “Hazardous Materials” means all explosive or radioactive substances or
wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other
similar substances or wastes of any nature regulated pursuant to any Environmental Law. 
 “Indebtedness” of
any Person at any date means without duplication, (a) all indebtedness of such Person for borrowed money including without limitation any repurchase obligation or liability of such Person with respect to securities, accounts or notes receivable
sold by such Person, (b) all obligations of such Person for the deferred purchase price of property or services (other than current trade liabilities incurred in the ordinary course of business and payable in accordance with customary
practices), to the extent such obligations constitute indebtedness for the purposes of GAAP, (c) any other indebtedness of such Person which is evidenced by a note, bond, debenture or similar instrument, (d) all Capital Lease Obligations,
(e) all Guarantee Obligations of such Person in respect of Indebtedness of another Person (excluding in any calculation of consolidated Indebtedness of the Consolidated Group, Guarantee Obligations of one member of the Consolidated Group in
respect of primary obligations of any other member of the Consolidated Group), (f) the face amount of all letters of credit issued for the account of such Person and, without duplication, all unreimbursed amounts drawn thereunder, but excluding
the underlying obligation for which the letter of credit is being provided, if duplicative; (g) all currently payable obligations of such Person with respect to any Swap Contracts; and (h) all amounts outstanding under the Key Bank Line of
Credit. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefore as a result of such Person’s ownership
interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefore (excluding customary limited exceptions for certain acts or types of liability such as
environmental liability, fraud and other customary non-recourse carve-outs). 
 “Indemnified Taxes” means
(a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.

 “Indemnitees” has the meaning specified in Section 10.04(b). 

“Information” has the meaning specified in Section 10.07. 

“Interest Payment Date” means, (a) as to any Loan other than a Base Rate Loan, the last day of each Interest Period
applicable to such Loan and the Maturity Date; provided, however, that if any Interest Period for a Eurodollar Rate Loan exceeds three months, the respective dates that fall every three months after the beginning of such Interest
Period shall also be Interest Payment Dates; and (b) as to any Base Rate Loan (including a Swing Line Loan), the last Business Day of each March, June, September and December and the Maturity Date. 

“Interest Period” means as to each Eurodollar Rate Loan, the period commencing on the date such Eurodollar Rate Loan is
disbursed or converted to or continued as a Eurodollar Rate Loan and ending on the date one, two, three or six months thereafter, as selected by the Borrower in its Committed Loan Notice provided that: 

  

- 14 - 

 (i) any Interest Period that would otherwise end on a day that is not a
Business Day shall be extended to the next succeeding Business Day unless, in the case of a Eurodollar Rate Loan, such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day;

 (ii) any Interest Period pertaining to a Eurodollar Rate Loan that begins on the last Business Day of a
calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and 

(iii) no Interest Period shall extend beyond the Maturity Date. 

“Investment” means, as to any Person, (without duplication) any direct or indirect acquisition or investment by such
Person, whether by means of (a) the purchase or other acquisition of capital stock or other securities of another Person, (b) a loan, advance or capital contribution to, guarantee or assumption of debt of, or purchase or other acquisition
of any other debt or equity participation or interest in, another Person, including any partnership or joint venture interest in such other Person and any arrangement pursuant to which the investor Guarantees Indebtedness of such other Person, or
(c) the purchase or other acquisition (in one transaction or a series of transactions) of assets of another Person that constitute a business unit. 
 “Investment Grade Rating” means a credit rating of BBB-/Baa3 (or the equivalent) or higher from Fitch, Inc., Moody’s or S&P. 

“IRS” means the United States Internal Revenue Service. 

“ISP” means, with respect to any Letter of Credit, the “International Standby Practices 1998” published by the
Institute of International Banking Law & Practice, Inc. (or such later version thereof as may be in effect at the time of issuance). 
 “Issuer Documents” means with respect to any Letter of Credit, the Letter of Credit Application, and any other document, agreement and instrument entered into by the L/C Issuer and the
Borrower (or any Subsidiary) or in favor of the L/C Issuer and relating to such Letter of Credit. 
 “KeyBank Line of
Credit” means a line of credit in the maximum amount of $40,000,000 pursuant to that certain Revolving Credit Agreement dated as of June 8, 2011, between Borrower and KeyBank National Association. 

“Laws” means, collectively, all international, foreign, Federal, state and local statutes, treaties, rules, guidelines,
regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and
all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law. 

  

- 15 - 

 “L/C Advance” means, with respect to each Lender, such Lender’s
funding of its participation in any L/C Borrowing in accordance with its Applicable Percentage. 
 “L/C
Borrowing” means an extension of credit resulting from a drawing under any Letter of Credit which has not been reimbursed on the date when made or refinanced as a Committed Borrowing. 

“L/C Credit Extension” means, with respect to any Letter of Credit, the issuance thereof or extension of the expiry date
thereof, or the increase of the amount thereof. 
 “L/C Issuer” means Bank of America in its capacity as issuer
of Letters of Credit hereunder, or any successor issuer of Letters of Credit hereunder. 
 “L/C Obligations”
means, as at any date of determination, the aggregate amount available to be drawn under all outstanding Letters of Credit plus the aggregate of all Unreimbursed Amounts, including all L/C Borrowings. For purposes of computing the amount
available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired
by its terms but any amount may still be drawn thereunder by reason of the operation of Rule 3.14 of the ISP, such Letter of Credit shall be deemed to be “outstanding” in the amount so remaining available to be drawn. 

“Lender” has the meaning specified in the introductory paragraph hereto and, as the context requires, includes the Swing
Line Lender. 
 “Lending Office” means, as to any Lender, the office or offices of such Lender described as
such in such Lender’s Administrative Questionnaire, or such other office or offices as a Lender may from time to time notify the Borrower and the Administrative Agent. 
 “Letter of Credit” means any standby letter of credit issued hereunder. 
 “Letter of Credit Application” means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time in use by the L/C Issuer. 

“Letter of Credit Expiration Date” means the day that is five (5) Business Days prior to the Maturity Date then in
effect. 
 “Letter of Credit Fee” has the meaning specified in Section 2.04(h). 

“Letter of Credit Sublimit” means $50,000,000. The Letter of Credit Sublimit is part of, and not in addition to, the
Aggregate Commitments. 
 “Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement,
encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title
retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing). 

  

- 16 - 

 “Loan” means an extension of credit by a Lender to the Borrower under
Article II in the form of a Committed Loan or a Swing Line Loan. 
 “Loan Documents” means this
Agreement, each Note, each Issuer Document, any agreement creating or perfecting rights in Cash Collateral pursuant to the provisions of Section 2.17 of this Agreement, and the Guaranty. 

“Loan Parties” means, collectively, the Borrower and each Guarantor. 

“Loan Year” means the one year period commencing on the Closing Date and each successive one year period thereafter.

 “London Banking Day” means any day on which dealings in Dollar deposits are conducted by and between banks
in the London interbank eurodollar market. 
 “Material Acquisition” mean an acquisition of assets with a total
cost that is more than ten percent (10%) of the Total Asset Value based on the most recent Compliance Certificate submitted prior to such acquisition. 
 “Material Adverse Effect” means a material adverse effect on (i) the business, property or financial condition of the Consolidated Group (collectively taken as a whole),
(ii) the ability of the Borrower or the Trust to perform its material obligations under the Loan Documents to which it is a party, (iii) the ability of the Loan Parties collectively taken as a whole to perform their material obligations
under the Loan Documents, or (iv) the validity or enforceability of any of the material provisions of Loan Documents or the material rights or remedies of the Administrative Agent and the Lenders thereunder. 

“Material Indebtedness” means Indebtedness (other than the Loans and Letters of Credit) or obligations in respect of one
or more Swap Contracts, of any one or more of the Borrower and its Subsidiaries in an aggregate principal amount exceeding $25,000,000 for Recourse Indebtedness and $125,000,000 for all other Indebtedness. For purposes of determining Material
Indebtedness, the “principal amount” of the obligations of the Borrower or any Subsidiary in respect of any Swap Contracts at any time shall be the aggregate amount (giving effect to any netting agreements) that the Borrower or such
Subsidiary would be required to pay if such Swap Contract were terminated at such time. 
 “Material
Subsidiary” means any Subsidiary of the Borrower with assets having a fair market value of $1,000,000 or more. 

“Maturity Date” means August 15, 2015, subject to extension in accordance with Section 2.15. 

“Moody’s” means Moody’s Investors Service, Inc. and any successor thereto. 

“Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which
the Borrower or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions. 

  

- 17 - 

 “Multiple Employer Plan” means a Plan which has two or more contributing
sponsors (including the Borrower or any ERISA Affiliate) at least two of whom are not under common control, as such a plan is described in Section 4064 of ERISA. 
 “Net Operating Income” means, with respect to any Property for any period, (i) revenues therefrom (including, without limitation, expense reimbursement, loss of rent income and lease
termination fees appropriately amortized to the extent there is no new tenant in the space for which the lease termination fee was paid), calculated, in each case, in accordance with GAAP, less (ii) the costs of maintaining such Property,
including, without limitation, real estate taxes, insurance, repairs, maintenance, actual property management fees paid to third parties or charged internally at a market rate and bad debt expense but excluding depreciation, amortization, interest
expense, tenant improvements, leasing commissions, and capital expenditures, calculated, in each case, in accordance with GAAP. 

“Non-Defaulting Lender” means, at any time, each Lender that is not a Defaulting Lender at such time. 

“Note” means a promissory note made by the Borrower in favor of a Lender evidencing Loans made by such Lender,
substantially in the form of Exhibit C. 
 “Obligations” means all advances to, and debts, liabilities,
obligations, covenants and duties of, any Loan Party arising under any Loan Document with respect to any Loan or Letter of Credit, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now
existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such
proceeding, regardless of whether such interest and fees are allowed claims in such proceeding. 
 “Organization
Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to
any limited liability company, the certificate or articles of formation or organization and operating agreement; and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or
other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its
formation or organization and, if applicable, any certificate or articles of formation or organization of such entity. 

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former
connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising solely from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or
perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document). 
 “Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution,

  

- 18 - 

 
delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are
Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 3.06). 

“Outstanding Amount” means (i) with respect to Committed Loans and Swing Line Loans on any date, the aggregate
outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of Committed Loans and Swing Line Loans, as the case may be, occurring on such date; and (ii) with respect to any L/C Obligations on any
date, the amount of such L/C Obligations on such date after giving effect to any L/C Credit Extension occurring on such date and any other changes in the aggregate amount of the L/C Obligations as of such date, including as a result of any
reimbursements by the Borrower of Unreimbursed Amounts. 
 “Participant” has the meaning specified in
Section 10.06(d). 
 “PBGC” means the Pension Benefit Guaranty Corporation. 

“Pension Act” means the Pension Protection Act of 2006. 

“Pension Funding Rules” means the rules of the Code and ERISA regarding minimum required contributions (including any
installment payment thereof) to Pension Plans and set forth in, with respect to plan years ending prior to the effective date of the Pension Act, Section 412 of the Code and Section 302 of ERISA, each as in effect prior to the Pension Act
and, thereafter, Section 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA. 

“Pension Plan” means any employee pension benefit plan (including a Multiple Employer Plan and other than a
Multiemployer Plan) that is maintained or is contributed to by the Borrower and any ERISA Affiliate and is either covered by Title IV of ERISA or is subject to the minimum funding standards under Section 412 of the Code. 

“Permitted Encumbrances” means: 
 (a) Liens imposed by law for taxes, assessments or governmental charges or levies that are not yet due or are being contested in compliance with Section 6.03; 

(b) landlords’, operators’, carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s and other
like Liens, arising in the ordinary course of business and securing obligations that are not overdue by more than 60 days, are being contested in good faith and by appropriate proceedings or for which a bond in the full amount thereof has been
posted; 
 (c) pledges and deposits made in the ordinary course of business in compliance with workers’ compensation,
unemployment insurance and other social security laws or regulations; 
 (d) deposits to secure the performance of bids, trade
contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; 

  

- 19 - 

 (e) judgment liens in respect of judgments that do not constitute an Event of Default under
Section 8.01(h); 
 (f) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by
law or arising in the ordinary course of business that do not secure any material monetary obligations and do not materially detract from the value of the affected property or materially interfere with the ordinary conduct of business of the
Borrower or any Subsidiary; 
 (g) Liens in existence on the date hereof, and extensions, renewals and replacements of such
Liens, as long as such extension, renewal and replacement Liens do not spread to any property other than property encumbered by such Liens on the date hereof; 
 (h) Liens on Properties first acquired by Borrower or a Subsidiary after the date hereof and which are in place at the time such Properties are so acquired; 

(i) Liens and rights of setoff of banks and securities intermediaries in respect of deposit accounts and securities accounts maintained in
the ordinary course of business and Liens of a collecting bank arising in the ordinary course of business under Section 4-210 of the UCC; 
 (j) assignments of past due receivables for collection purposes only; 
 (k) leases
or subleases granted in the ordinary course of business; 
 (l) additional Liens on property or assets securing additional
obligations not to exceed $3,000,000 at any time outstanding; 
 (m) Liens arising in connection with any Indebtedness permitted
hereunder; 
 (n) Liens of any Subsidiary in favor of the Borrower or any of the other Loan Parties; and 

(o) any netting or set-off right under any swap agreement. 
 “Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. 

“Platform” has the meaning specified in Section 10.02(c). 

“Property” means any real estate owned by the Borrower, any Subsidiary, or an Unconsolidated Affiliate, and operated or
intended to be operated as an investment property. 
 “Property Investment Value” means, at any time with
respect to any Property in which a person has a direct or indirect ownership interest, the undepreciated book value of such interest determined in accordance with GAAP. 
 “Property Value” means: (i) with respect to any Property owned directly or indirectly by the Borrower or Guarantor for less than four full calendar quarters, the current Property
Investment Value of such Property; and (ii) with respect to any Property owned directly or 

  

- 20 - 

 
indirectly by the Borrower, or Guarantor for four or more full calendar quarters, the greater of (i) the Net Operating Income for such Property for the most recently completed calendar
quarter annualized divided by the Capitalization Rate and (ii) zero. A Property contributed to a joint venture by the Borrower or Guarantor shall be deemed to have been owned by such joint venture from the date of such contribution. 

“Recipient” means the Administrative Agent, any Lender, the L/C Issuer or any other recipient of any payment to be made
by or on account of any obligation of any Loan Party hereunder. 
 “Recourse Indebtedness” means any
Indebtedness of the Borrower or any other member of the Consolidated Group with respect to which the liability of the obligor is not limited to the obligor’s interest in specified assets securing such Indebtedness, subject to customary limited
exceptions for certain acts or types of liability. 
 “Recurring Interest Expense” means, for any period
without duplication, the sum of (a) the amount of interest (without duplication, whether accrued, paid or capitalized) on Total Indebtedness actually payable by members of the Consolidated Group during such period, plus (b) the applicable
Consolidated Group Pro Rata Share of any interest (without duplication, whether accrued, paid or capitalized) on Indebtedness actually payable by Unconsolidated Affiliates during such period, whether recourse or non-recourse, but excluding
non-recurring amortized financing related expenses. 
 “Register” has the meaning specified in
Section 10.06(c). 
 “Related Parties” means, with respect to any Person, such Person’s
Affiliates and the partners, directors, officers, employees, trustees of such Person and of such Person’s Affiliates. 

“Reportable Event” means any of the events set forth in Section 4043(c) of ERISA, other than events for which the
30 day notice period has been waived. 
 “Request for Credit Extension” means (a) with respect to a
Borrowing, conversion or continuation of Committed Loans, a Committed Loan Notice, (b) with respect to an L/C Credit Extension, a Letter of Credit Application, and (c) with respect to a Swing Line Loan, a Swing Line Loan Notice.

 “Required Lenders” means, at any time, at least two Lenders having Total Credit Exposures representing more
than 50% of the Total Credit Exposures of all Lenders. The Total Credit Exposure of any Defaulting Lender shall be disregarded in determining Required Lenders at any time; provided that, the amount of any participation in any Swing Line Loan and
Unreimbursed Amounts that such Defaulting Lender has failed to fund that have not been reallocated to and funded by another Lender shall be deemed to be held by the Lender that is the Swing Line Lender or L/C Issuer, as the case may be, in making
such determination. 
 “Responsible Officer” means the chief executive officer, president, vice president,
chief financial officer, treasurer, assistant treasurer or controller of a Loan Party, and solely for purposes of the delivery of incumbency certificates pursuant to Section 4.01, the secretary or any assistant secretary of a Loan Party
and, solely for purposes of notices given pursuant to Article II, any other officer or employee of the applicable Loan Party so designated by any of the 

  

- 21 - 

 
foregoing officers in a notice to the Administrative Agent. Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively presumed to have been
authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party and such Responsible Officer shall be deemed
to be acting solely in such person’s representative capacity and not in their individual capacity. 
 “Restricted
Payment” means any cash dividend, cash distribution or other cash payment with respect to any equity interests in the Borrower or any Subsidiary, excluding (i) any dividend, distribution or other payment by a member of the Consolidated
Group to another member of the Consolidated Group (including in connection with the issuance of equity interests), (ii) any redemption of equity interests by a member of the Consolidated Group (including pursuant to a share buyback program);
(iii) any distribution or other payment by an Unconsolidated Affiliate to a member of the Consolidated Group (including promote payments in connection with development joint ventures and regular distributions of cash flow from Unconsolidated
Affiliates); and (iv) any distribution or other payment by any Subsidiary or Unconsolidated Affiliate which is a partnership, limited liability company or joint venture or mezzanine lender and operated in the ordinary course of business.

 “Revolving Credit Exposure” means, as to any Lender at any time, the aggregate principal amount at such time
of its outstanding Committed Loans and such Lender’s participation in L/C Obligations and Swing Line Loans at such time. 

“Sale-Leaseback Master Lease” shall mean a master lease entered into by a buyer of a Property, as lessor, and the seller
of such Property, as lessee, in connection with a transaction whereby such seller leases all or a portion of such Property after closing. 
 “S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc. and any successor thereto. 

“SEC” means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal
functions. 
 “Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability
company or other business entity of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by
reason of the happening of a contingency) are at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person. Unless otherwise specified, all
references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of the Borrower. 
 “Subsidiary Guarantor” means each Subsidiary that is the owner of an Unencumbered Property, and any other Subsidiary that elects to become a party to the Subsidiary Guaranty. 

“Subsidiary Guaranty” means the guaranty to be executed and delivered by the Subsidiary Guarantors, substantially in the
form of Exhibit F-2, as the same may be amended, supplemented or otherwise modified from time to time. 

  

- 22 - 

 “Swap Contract” means (a) any and all rate swap transactions, basis
swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward
bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency
options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement,
and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc.,
any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including any such obligations or liabilities under any
Master Agreement. 
 “Swing Line Borrowing” means a borrowing of a Swing Line Loan pursuant to
Section 2.05. 
 “Swing Line Lender” means Bank of America in its capacity as provider of Swing
Line Loans, or any successor swing line lender hereunder. 
 “Swing Line Loan” has the meaning specified in
Section 2.05(a). 
 “Swing Line Loan Notice” means a notice of a Swing Line Borrowing pursuant to
Section 2.05(b), which, if in writing, shall be substantially in the form of Exhibit B. 
 “Swing
Line Sublimit” means $50,000,000. The Swing Line Sublimit is part of, and not in addition to, the Aggregate Commitments. 
 “Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental
Authority, including any interest, additions to tax or penalties applicable thereto. 
 “Total Asset Value”
means, as of the date of calculation, the aggregate, without duplication, of: (a) for the first 12 months after closing of the facility, the Property Investment Value and thereafter (b) (i) the Property Value of all Properties (other
than land assets and Assets Under Development) owned by members of the Consolidated Group; plus (ii) the Consolidated Group’s Pro Rata Share of the Property Value of Properties (other than Assets Under Development) owned by Unconsolidated
Affiliates; plus (iii) an amount equal to the then current book value of each land asset and Asset Under Development owned by members of the Consolidated Group; plus (iv) an amount equal to the Consolidated Group Pro Rata Share of the then
current book value of each land asset and Asset Under Development owned by an Unconsolidated Affiliate; plus (v) unrestricted cash and cash equivalents owned directly or indirectly by members of the Consolidated Group; plus (vi) the
applicable Consolidated Group Pro Rata Share of unrestricted cash and cash equivalents owned directly or indirectly by Borrower or Guarantor through an Unconsolidated Affiliate; plus (vii) Borrower’s and Guarantor’s investments in
Debt Investments (based on current book value); plus (viii) an amount equal to the Consolidated Group Pro Rata Share of investments in Debt Investments owned by an Unconsolidated Affiliate (based on current book value); plus (ix) proceeds
due from transfer agent. 

  

- 23 - 

 “Total Credit Exposure” means, as to any Lender at any time, the unused
Commitments and Revolving Credit Exposure of such Lender at such time. 
 “Total Indebtedness” shall mean, as
of any date of determination, without duplication, the sum of: (a) all Indebtedness of the Consolidated Group outstanding at such date, determined on a consolidated basis; plus (b) the greater of (i) the applicable Consolidated Group
Pro Rata Share of all Indebtedness of each Unconsolidated Affiliate (other than Indebtedness of such Unconsolidated Affiliate to a member of the Consolidated Group) and (ii) the amount of Indebtedness of such Unconsolidated Affiliate which is
also Recourse Indebtedness of a member of the Consolidated Group. 
 “Total Outstandings” means the aggregate
Outstanding Amount of all Loans and all L/C Obligations. 
 “Total Secured Indebtedness” means, as of any date
of determination, that portion of Total Indebtedness which is secured by a Lien on a Property, any ownership interests in any Subsidiary or Unconsolidated Affiliate or any other assets which had, in each case, in the aggregate, a value in excess of
the amount of the applicable Indebtedness at the time such Indebtedness was incurred. Such Indebtedness that is secured only with a pledge of ownership interests and is also recourse to the Borrower or any Guarantor shall not be treated as Secured
Indebtedness. For the avoidance of doubt, the KeyBank Line of Credit shall be included in Total Secured Indebtedness. 

“Total Secured Recourse Indebtedness” means, as of any date of determination, that portion of Total Secured Indebtedness
with respect to which the liability of the obligor is not limited to the obligor’s interest in specified assets securing such Indebtedness (subject to customary limited exceptions for certain acts or types of liability such as environmental
liability, fraud and other customary non-recourse carve-outs); provided that Indebtedness of a single-purpose entity (or any holding company or other entity which owns such single-purpose entity) which is secured by substantially all of the assets
of such single-purpose entity (or any holding company or other entity which owns such single-purpose entity) but for which there is no recourse to another Person beyond the single-purpose entity or holding company or other entity which owns such
single-purpose entity (other than with respect to customary limited exceptions for certain acts or types of liability such as environmental liability, fraud and other customary non-recourse carve-outs) shall not be considered a part of Total Secured
Recourse Indebtedness even if such Indebtedness is fully recourse to such single-purpose entity (or any holding company or other entity which owns such single-purpose entity) and unsecured guarantees provided by Borrower or the Trust of mortgage
loans to Subsidiaries or Unconsolidated Affiliates shall not be included in Total Secured Recourse Indebtedness. For the avoidance of doubt, the KeyBank Line of Credit shall be included in Total Secured Recourse Indebtedness. 

“Total Unencumbered Property Pool Value” shall mean, as of any date of calculation, the aggregate, without duplication,
of: (a) the Unencumbered Property Values of all Unencumbered Properties (other than any that are Assets Under Development); plus (b) an amount equal to one 

  

- 24 - 

 
hundred percent (100%) of the then-current book value of each Unencumbered Property that is an Asset Under Development; provided that no more than twenty five percent (25%) of Total
Unencumbered Property Pool Value may be attributable to, (i) Assets Under Development, or (ii) Unencumbered Properties that are ground leased under Financeable Ground Leases (as opposed to being owned in fee simple by the Borrower or a
Subsidiary Guarantor). 
 “Total Unsecured Indebtedness” means, as of any date of determination, that portion
of Total Indebtedness which does not constitute Total Secured Indebtedness. For the avoidance of doubt, the KeyBank Line of Credit shall not be included in Total Unsecured Indebtedness. 

“Trust” means Industrial Income Trust Inc., the general partner of Borrower. 

“Type” means with respect to a Committed Loan, its character as a Base Rate Loan or a Eurodollar Rate Loan. 

“UCP” means, with respect to any Letter of Credit, the Uniform Customs and Practice for Documentary Credits,
International Chamber of Commerce (“ICC”) Publication No. 600 (or such later version thereof as may be in effect at the time of issuance). 
 “Unconsolidated Affiliate” means, any Person in which the Consolidated Group, directly or indirectly, has any ownership interest of $1,000,000 or more (valued as of the most recent
quarterly financial statement), whose financial results are not consolidated under GAAP with the financial results of the Consolidated Group. 
 “Unencumbered Asset Pool Leverage Ratio” means, for any period, Total Unsecured Indebtedness to Total Unencumbered Property Pool Value. For the avoidance of doubt, Indebtedness under the
Key Bank Line of Credit shall not be included within Total Unsecured Indebtedness. 
 “Unencumbered Debt Yield”
means, at any time, Unencumbered Property NOI for the most recent quarter annualized divided by Total Unsecured Indebtedness (expressed as a percentage). 
 “Unencumbered Property” means, a Property that is designated by the Borrower as an Unencumbered Property and: (i) is completed and located in the continental United States or,
subject to the limitations in the definition of Total Unencumbered Property Pool Value, which is an Asset Under Development; (ii) is 100% owned in fee simple (or, subject to the limitation set forth in the definition of Unencumbered Asset
Value, is ground leased pursuant to a Financeable Ground Lease) by the Borrower or a wholly owned Subsidiary that is a Guarantor (provided that until the KeyBank Line of Credit is repaid and terminated no Property owned directly by the Borrower
shall constitute an Unencumbered Property for purposes of the various covenants contained herein even though it may otherwise meet the criteria set forth in this definition); (iii) is not subject to any Liens or encumbrances other than clauses
(a), (b), (c), (d), (f), (j), (k) and (n) of the definition of Permitted Encumbrances; (iv) is not subject to any agreement (including (a) any agreement governing Indebtedness incurred in order to finance or refinance the
acquisition of such Property, and (b) if applicable, the organizational documents of Borrower or any Guarantor) which prohibits or limits the ability of the Borrower or any Guarantor, as the case may be, to create, incur, assume or suffer to
exist any Lien upon any assets or Equity Interests of the Borrower, or any Guarantor except for covenants that are not materially more restrictive than 

  

- 25 - 

 
the covenants to be contained in the Credit Agreement, in favor of holders of unsecured Indebtedness of the Borrower and the Guarantors not prohibited hereunder; (v) is not subject to any
agreement (including (a) any agreement governing Indebtedness incurred in order to finance or refinance the acquisition of such Property, and (b) if applicable, the organizational documents of Borrower or any Guarantor) which entitles any
Person to the benefit of any Lien on any assets or Equity Interests of the Borrower or any Guarantor or would entitle any Person to the benefit of any Lien on such assets or Equity Interests upon the occurrence of any contingency (including, without
limitation, pursuant to an “equal and ratable” clause) other than any agreement entered into in connection with the financing of such Property and the pledge of such Property as security for any financing pending the Closing of such
financing, provided that such Property shall cease to be an Unencumbered Property upon the closing of such financing; (vi) is not subject to any agreement (including (a) any agreement governing Indebtedness incurred in order to finance or
refinance the acquisition of such Property, and (b) if applicable, the organizational documents of Borrower or any Guarantor) which prohibits or limits the ability of the Borrower or any Guarantor, as the case may be, to make Restricted
Payments to Borrower or any Guarantor or prevents the Subsidiary from transferring such Property (other than (x) any restriction with respect to a Property imposed pursuant to an agreement entered into for the sale or disposition of such
Property pending the closing of such sale or disposition, and (y) any restriction with respect to a Subsidiary imposed pursuant to an agreement entered into for the sale or disposition of all or substantially all the Equity Interests or assets
of such Subsidiary pending the closing of such sale or disposition); and (vii) is not the subject of any issues which would impact the operation of such Property. No Property owned by a Subsidiary shall be deemed to be an Unencumbered Property
unless (a) both such Property and all Equity Interests of the Subsidiary held directly or indirectly by the Borrower are not subject to any Lien, (b) each intervening entity between the entity immediately below IIT Real Estate Holdco LLC
and such Subsidiary does not have any Indebtedness for borrowed money or, if such entity has any Indebtedness, such Indebtedness is unsecured and such entity is a Guarantor, and (c) not subject to insolvency proceedings, inability to pay debts
or subject to any writ or warrant of attachment. A Property that is subject to an option to purchase shall not be disqualified by the requirement in clause (vi) from being an Unencumbered Property so long as the Property can be transferred
subject to the rights of the optionee provided that if the option to purchase is for a fixed price as distinguished from a market price, the Unencumbered Asset Value for such Property shall be equal to the lesser of (x) the amount determined in
accordance with the definition of Unencumbered Asset Value, or (y) the option price for such Property. 

“Unencumbered Property NOI” means, with respect to any Unencumbered Property for any period, the Net Operating Income
for such Unencumbered Property for such period, less the Capital Expenditure Reserve. For such properties owned for less than one full quarter, the Unencumbered Property NOI for such full quarter shall be determined on a proforma basis based on
performance during such partial quarter, which performance information may be derived from information provided by the prior owner of such Unencumbered Property for that portion of such partial quarter prior to the acquisition of such Unencumbered
Property, or if such information is not reasonably available, based on in place Net Operating Income. 
 “Unencumbered
Property Value” means for an Unencumbered Property (a) for the first 12 months after closing of the Credit Facility, the Property Investment Value of such Unencumbered Property and thereafter (b) (i) with respect to any
Unencumbered Property owned by the Borrower or Guarantor for less than four full calendar quarters, the current Property 

  

- 26 - 

 
Investment Value for such Unencumbered Property; and (ii) with respect to any Unencumbered Property owned by the Borrower or Guarantor for four or more full calendar quarters (other than an
Asset Under Development), the greater of (A) Unencumbered Property NOI for such Unencumbered Property for the most recently completed calendar quarter annualized divided by the Capitalization Rate and (B) zero and (iii) with respect
to any Asset Under Development, the then current book value. 
 “Unrestricted Cash and Cash Equivalents” means,
in the aggregate, all cash and Cash Equivalents which are not pledged for the benefit of any party (whether a creditor, seller or otherwise) having a claim (whether liquidated or not) against a member of the Consolidated Group, to be valued for
purposes of this Agreement at 100% of its then-current book value, as determined under GAAP. 
 “United States”
and “U.S.” mean the United States of America. 
 “Unreimbursed Amount” has the meaning
specified in Section 2.04(c)(i). 
 “Unused Fee Rate” has the meaning specified in
Section 2.10. 
 “U.S. Person” means any Person that is a “United States Person” as
defined in Section 7701(a)(30) of the Code. 
 1.02 Other Interpretive Provisions. With reference to this Agreement
and each other Loan Document, unless otherwise specified herein or in such other Loan Document: 
 (a) The definitions of terms
herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include,”
“includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word
“shall.” Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including any Organization Document) shall be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference
herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words “hereto,” “herein,” “hereof” and “hereunder,” and words of similar
import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Exhibits and Schedules shall be
construed to refer to Articles and Sections of, and Exhibits and Schedules to, the Loan Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory provisions consolidating, amending,
replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, and (vi) unless the context otherwise
requires, the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and
contract rights. 

  

- 27 - 

 (b) In the computation of periods of time from a specified date to a later specified date,
the word “from” means “from and including;” the words “to” and “until” each mean “to but excluding;” and the word “through” means “to and
including.” 
 (c) Section headings herein and in the other Loan Documents are included for convenience of reference
only and shall not affect the interpretation of this Agreement or any other Loan Document. 
 1.03 Accounting Terms.
(a) Generally. All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted
pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as
otherwise specifically prescribed herein. Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness of the Borrower and its
Subsidiaries shall be deemed to be carried at 100% of the outstanding principal amount thereof, and the effects of FASB ASC 825 and FASB ASC 470-20 on financial liabilities shall be disregarded. 

(b) Changes in GAAP. If at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth
in any Loan Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof
in light of such change in GAAP (subject to the approval of the Required Lenders); provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and
(ii) the Borrower shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such
ratio or requirement made immediately before and after giving effect to such change in GAAP. 
 (c) Consolidation of Variable
Interest Entities. All references herein to consolidated financial statements of the Trust, the Borrower and its Subsidiaries or to the determination of any amount for the Trust, the Borrower and its Subsidiaries on a consolidated basis or any
similar reference shall, in each case, be deemed to include each variable interest entity that the Borrower is required to consolidate pursuant to FASB ASC 810 as if such variable interest entity were a Subsidiary as defined herein. 

1.04 Rounding. Any financial ratios required to be maintained by the Borrower pursuant to this Agreement shall be calculated by
dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there
is no nearest number). 

  

- 28 - 

 1.05 Times of Day. Unless otherwise specified, all references herein to times of day
shall be references to Eastern time (daylight or standard, as applicable). 
 1.06 Letter of Credit Amounts. Unless
otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time; provided, however, that with respect to any Letter of Credit that, by its
terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after
giving effect to all such increases, whether or not such maximum stated amount is in effect at such time. 
 ARTICLE II. THE
COMMITMENTS AND CREDIT EXTENSIONS 
 2.01 Committed Loans. Subject to the terms and conditions set forth herein, each
Lender severally agrees to make loans (each such loan, a “Committed Loan”) to the Borrower from time to time, on any Business Day during the Availability Period, in an aggregate amount not to exceed at any time outstanding the
amount of such Lender’s Commitment; provided, however, that after giving effect to any Committed Borrowing, (i) the Total Outstandings shall not exceed the Aggregate Commitments, and (ii) the Revolving Credit Exposure of
any Lender shall not exceed such Lender’s Commitment. Within the limits of each Lender’s Commitment, and subject to the other terms and conditions hereof, the Borrower may borrow under this Section 2.01, prepay under
Section 2.06, and reborrow under this Section 2.01. Committed Loans may be Base Rate Loans or Eurodollar Rate Loans, as further provided herein. 
 2.02 Borrowings, Conversions and Continuations of Committed Loans. 
 (a)
Each Committed Borrowing, each conversion of Committed Loans from one Type to the other, and each continuation of Eurodollar Rate Loans shall be made upon the Borrower’s irrevocable notice to the Administrative Agent, which may be given by
telephone. Each such notice must be received by the Administrative Agent not later than 1:00 p.m. (i) three Business Days prior to the requested date of any Borrowing of, conversion to or continuation of Eurodollar Rate Loans or of any
conversion of Eurodollar Rate Loans to Base Rate Committed Loans, and (ii) on the requested date of any Borrowing of Base Rate Committed Loans. Each telephonic notice by the Borrower pursuant to this Section 2.02(a) must be
confirmed promptly by delivery to the Administrative Agent of a written Committed Loan Notice, appropriately completed and signed by a Responsible Officer of the Borrower. Each Borrowing of, conversion to or continuation of Eurodollar Rate Loans
shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof. Except as provided in Sections 2.04(c) and 2.05(c), each Borrowing of or conversion to Base Rate Committed Loans shall be in a principal
amount of $500,000 or a whole multiple of $100,000 in excess thereof provided that the amount of a Base Rate Committed Loan may be in an amount equal to the entire unpaid balance of the Commitments or the amount that is required to finance the
reimbursement of an L/C Borrowing. Each Committed Loan Notice (whether telephonic or written) shall specify (i) whether the Borrower is requesting a Committed Borrowing, a conversion of Committed Loans from one Type to the other, or a
continuation of Eurodollar Rate Loans, (ii) the requested date of the Borrowing, conversion or continuation, as the case may be (which shall be a Business Day), (iii) the principal amount of Committed Loans to be borrowed, converted or
continued, (iv) the Type of Committed Loans to be borrowed or to which existing Committed Loans are to be converted, 

  

- 29 - 

 
and (v) if applicable, the duration of the Interest Period with respect thereto. If the Borrower fails to specify a Type of Committed Loan in a Committed Loan Notice or if the Borrower fails
to give a timely notice requesting a conversion or continuation, then the applicable Committed Loans shall be made as, or converted to, Eurodollar Rate Loans with an Interest Period of 30 days. Any such automatic conversion to Eurodollar Rate Loans
with an Interest Period of 30 days shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Eurodollar Rate Loans. If the Borrower requests a Borrowing of, conversion to, or continuation of
Eurodollar Rate Loans in any such Committed Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month. 
 (b) Following receipt of a Committed Loan Notice, the Administrative Agent shall promptly notify each Lender of the amount of its Applicable Percentage of the applicable Committed Loans, and if no timely
notice of a conversion or continuation is provided by the Borrower, the Administrative Agent shall notify each Lender of the details of any automatic conversion to Eurodollar Rate Loans with an Interest Period of one month described in the preceding
subsection. In the case of a Committed Borrowing, each Lender shall make the amount of its Committed Loan available to the Administrative Agent in immediately available funds at the Administrative Agent’s Office not later than 12:00 noon on the
Business Day specified in the applicable Committed Loan Notice. Upon satisfaction in all material respects of the applicable conditions set forth in Section 4.02 (and, if such Borrowing is the initial Credit Extension,
Section 4.01), the Administrative Agent shall make all funds so received promptly available to the Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the Borrower on the books of
Bank of America with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Borrower; provided,
however, that if, on the date the Committed Loan Notice with respect to such Borrowing is given by the Borrower, there are L/C Borrowings outstanding, then the proceeds of such Borrowing, first, shall be applied to the payment in full
of any such L/C Borrowings, and second, shall be made available to the Borrower as provided above. 
 (c) Except as
otherwise provided herein, a Eurodollar Rate Loan may be continued or converted only on the last day of an Interest Period for such Eurodollar Rate Loan. During the existence of an Event of Default, no Loans may be requested as, converted to or
continued as Eurodollar Rate Loans without the consent of the Required Lenders. 
 (d) The Administrative Agent shall promptly
notify the Borrower and the Lenders of the interest rate applicable to any Interest Period for Eurodollar Rate Loans upon determination of such interest rate. At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify
the Borrower and the Lenders of any change in Bank of America’s prime rate used in determining the Base Rate promptly following the public announcement of such change. 
 (e) After giving effect to all Committed Borrowings, all conversions of Committed Loans from one Type to the other, and all continuations of Committed Loans as the same Type, there shall not be more than
five (5) Interest Periods in effect with respect to Committed Loans. 
 2.03 Intentionally Omitted. 

2.04 Letters of Credit. 

  

- 30 - 

 (a) The Letter of Credit Commitment. 

(i) Subject to the terms and conditions set forth herein, (A) the L/C Issuer agrees, in reliance upon the agreements
of the Lenders set forth in this Section 2.04, (1) from time to time on any Business Day during the period from the Closing Date until the Letter of Credit Expiration Date, to issue Letters of Credit for the account of the Borrower
or its Subsidiaries, and to amend or extend Letters of Credit previously issued by it, in accordance with subsection (b) below, and (2) to honor drawings under the Letters of Credit; and (B) the Lenders severally agree to participate
in Letters of Credit issued for the account of the Borrower or its Subsidiaries and any drawings thereunder; provided that after giving effect to any L/C Credit Extension with respect to any Letter of Credit, (x) the Total Outstandings
shall not exceed the Aggregate Commitments, (y) Revolving Credit Exposure of any Lender shall not exceed such Lender’s Commitment, and (z) the Outstanding Amount of the L/C Obligations shall not exceed the Letter of Credit Sublimit.
Each request by the Borrower for the issuance or amendment of a Letter of Credit shall be deemed to be a representation by the Borrower that the L/C Credit Extension so requested complies with the conditions set forth in the proviso to the preceding
sentence. Within the foregoing limits, and subject to the terms and conditions hereof, the Borrower’s ability to obtain Letters of Credit shall be fully revolving, and accordingly the Borrower may, during the foregoing period, obtain Letters of
Credit to replace Letters of Credit that have expired or that have been drawn upon and reimbursed. 
 (ii) The
L/C Issuer shall not issue any Letter of Credit, if the expiry date of the requested Letter of Credit would occur after the Letter of Credit Expiration Date, unless all the Lenders have approved such expiry date or the obligation has been Cash
Collateralized. 
 (iii) The L/C Issuer shall not be under any obligation to issue any Letter of Credit if:

 (A) any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to
enjoin or restrain the L/C Issuer from issuing the Letter of Credit, or any Law applicable to the L/C Issuer or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over the L/C Issuer
shall prohibit, or request that the L/C Issuer refrain from, the issuance of letters of credit generally or the Letter of Credit in particular or shall impose upon the L/C Issuer with respect to the Letter of Credit any restriction, reserve or
capital requirement (for which the L/C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon the L/C Issuer any unreimbursed loss, cost or expense which was not applicable on the Closing Date and
which the L/C Issuer in good faith deems material to it; 
 (B) the issuance of the Letter of Credit would
violate one or more policies of the L/C Issuer applicable to letters of credit generally; provided that Borrower may replace the L/C Issuer upon any failure of the L/C Issuer to issue a Letter of Credit in reliance on the clause (iii)(B) or (iii)(A)
with another institution that is a Lender; 

  

- 31 - 

 (C) except as otherwise agreed by the Administrative Agent and the L/C
Issuer, the Letter of Credit is in an initial stated amount less than $100,000; 
 (D) the Letter of Credit is to
be denominated in a currency other than Dollars; 
 (E) any Lender is at that time a Defaulting Lender, unless
the L/C Issuer has entered into arrangements, including the delivery of Cash Collateral, satisfactory to the L/C Issuer (in its sole discretion) with the Borrower or such Lender to eliminate the L/C Issuer’s actual or potential Fronting
Exposure (after giving effect to Section 2.18(a)(iv)) with respect to the Defaulting Lender arising from either the Letter of Credit then proposed to be issued or that Letter of Credit and all other L/C Obligations as to which the L/C
Issuer has actual or potential Fronting Exposure, as it may elect in its sole discretion; or 
 (F) the Letter of
Credit contains any provisions for automatic reinstatement of the stated amount after any drawing thereunder. 

(iv) The L/C Issuer shall not amend any Letter of Credit if the L/C Issuer would not be permitted at such time to issue
the Letter of Credit in its amended form under the terms hereof. 
 (v) The L/C Issuer shall be under no
obligation to amend any Letter of Credit if (A) the L/C Issuer would have no obligation at such time to issue the Letter of Credit in its amended form under the terms hereof, or (B) the beneficiary of the Letter of Credit does not accept
the proposed amendment to the Letter of Credit. 
 (vi) The L/C Issuer shall act on behalf of the Lenders with
respect to any Letters of Credit issued by it and the documents associated therewith, and the L/C Issuer shall have all of the benefits and immunities (A) provided to the Administrative Agent in Article IX with respect to any acts taken
or omissions suffered by the L/C Issuer in connection with Letters of Credit issued by it or proposed to be issued by it and Issuer Documents pertaining to such Letters of Credit as fully as if the term “Administrative Agent” as used in
Article IX included the L/C Issuer with respect to such acts or omissions, and (B) as additionally provided herein with respect to the L/C Issuer. 
 (b) Procedures for Issuance and Amendment of Letters of Credit; Auto-Extension Letters of Credit. 
 (i) Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the Borrower delivered to the L/C Issuer (with a copy to the Administrative Agent) in the form of a Letter of
Credit Application, appropriately completed and signed by a Responsible Officer of the Borrower. Such Letter of Credit Application may be sent by facsimile, by United States mail, by overnight courier, by electronic transmission using the system
provided by the L/C Issuer, by personal delivery or by any other means acceptable to the L/C Issuer. Such Letter of Credit Application must be received by the L/C Issuer and the Administrative Agent not later than 1:00 p.m. at least two Business
Days (or such later date and time as the Administrative Agent and the L/C Issuer may agree in a particular instance in their sole discretion) prior to the proposed issuance date 

  

- 32 - 

 
or date of amendment, as the case may be. In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail reasonably
satisfactory to the L/C Issuer: (A) the proposed issuance date of the requested Letter of Credit (which shall be a Business Day); (B) the amount thereof; (C) the expiry date thereof; (D) the name and address of the beneficiary
thereof; (E) the documents to be presented by such beneficiary in case of any drawing thereunder; (F) the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder; (G) the purpose and nature
of the requested Letter of Credit; and (H) such other matters as the L/C Issuer may require. In the case of a request for an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail
reasonably satisfactory to the L/C Issuer (A) the Letter of Credit to be amended; (B) the proposed date of amendment thereof (which shall be a Business Day); (C) the nature of the proposed amendment; and (D) such other matters as
the L/C Issuer may reasonably require. Additionally, the Borrower shall furnish to the L/C Issuer and the Administrative Agent such other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any
Issuer Documents, as the L/C Issuer or the Administrative Agent may reasonably require (provided such information is customarily required from other similar L/C applicants). Notwithstanding the foregoing, in the event of any conflict between the
Letter of Credit Application and the terms of this Agreement, the terms of this Agreement shall control. 
 (ii)
Promptly after receipt of any Letter of Credit Application, the L/C Issuer will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received a copy of such Letter of Credit Application from the
Borrower and, if not, the L/C Issuer will provide the Administrative Agent with a copy thereof. Unless the L/C Issuer has received written notice from any Lender, the Administrative Agent or any Loan Party, at least one Business Day prior to the
requested date of issuance or amendment of the applicable Letter of Credit, that one or more applicable conditions contained in Article IV shall not then be satisfied, then, subject to the terms and conditions hereof, the L/C Issuer shall, on
the requested date, issue a Letter of Credit for the account of the Borrower or the applicable Subsidiary or enter into the applicable amendment, as the case may be, in each case in accordance with the L/C Issuer’s usual and customary business
practices. Immediately upon the issuance of each Letter of Credit, each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the L/C Issuer a risk participation in such Letter of Credit in an amount equal to
the product of such Lender’s Applicable Percentage times the amount of such Letter of Credit. 

(iii) If the Borrower so requests in any applicable Letter of Credit Application, the L/C Issuer may, in its sole
discretion, agree to issue a Letter of Credit that has automatic extension provisions (each, an “Auto-Extension Letter of Credit”); provided that any such Auto-Extension Letter of Credit must permit the L/C Issuer to prevent
any such extension at least once in each twelve-month period (commencing with the date of issuance of such Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice Date”) in
each such twelve-month period to be agreed upon at the time such Letter of Credit is issued. Unless otherwise directed by the L/C Issuer, the Borrower shall not be required to make a specific request to the L/C Issuer for any such extension. Once an
Auto-Extension Letter of Credit has been issued, 

  

- 33 - 

 
the Lenders shall be deemed to have authorized (but may not require) the L/C Issuer to permit the extension of such Letter of Credit at any time to an expiry date not later than the Letter of
Credit Expiration Date; provided, however, that the L/C Issuer shall not permit any such extension if (A) the L/C Issuer has determined that it would not be permitted, or would have no obligation, at such time to issue such Letter
of Credit in its revised form (as extended) under the terms hereof (by reason of the provisions of clause (ii) or (iii) of Section 2.04(a) or otherwise), or (B) it has received notice (which may be by telephone or in
writing) on or before the day that is seven Business Days before the Non-Extension Notice Date from the Administrative Agent, any Lender or the Borrower that one or more of the applicable conditions specified in Section 4.02 is not then
satisfied, and in each such case directing the L/C Issuer not to permit such extension. 
 (iv) Promptly after
its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto or to the beneficiary thereof, the L/C Issuer will also deliver to the Borrower and the Administrative Agent a true and complete
copy of such Letter of Credit or amendment. 
 (c) Drawings and Reimbursements; Funding of Participations. 

(i) Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under such Letter of Credit, the
L/C Issuer shall notify the Borrower and the Administrative Agent thereof. Not later than 1:00 p.m. on the date of any payment by the L/C Issuer under a Letter of Credit (each such date, an “Honor Date”), the Borrower shall
reimburse the L/C Issuer through the Administrative Agent in an amount equal to the amount of such drawing (provided the Borrower shall not be in Default hereunder if such unreimbursed Amount is refinanced by a Committed Borrowing). If the Borrower
fails to so reimburse the L/C Issuer by such time, the Administrative Agent shall promptly notify each Lender of the Honor Date, the amount of the unreimbursed drawing (the “Unreimbursed Amount”), and the amount of such
Lender’s Applicable Percentage thereof. In such event, the Borrower shall be deemed to have requested a Committed Borrowing of Base Rate Loans to be disbursed on the Honor Date in an amount equal to the Unreimbursed Amount, without regard to
the minimum and multiples specified in Section 2.02 for the principal amount of Base Rate Loans, but subject to the amount of the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.02
(other than the delivery of a Committed Loan Notice). Any notice given by the L/C Issuer or the Administrative Agent pursuant to this Section 2.04(c)(i) may be given by telephone if immediately confirmed in writing; provided that
the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice. 

(ii) Each Lender shall upon any notice pursuant to Section 2.04(c)(i) make funds available (and the
Administrative Agent may apply Cash Collateral provided for this purpose) for the account of the L/C Issuer at the Administrative Agent’s Office in an amount equal to its Applicable Percentage of the Unreimbursed Amount not later than 1:00 p.m.
on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of Section 2.04(c)(iii), each Lender that so makes funds available shall be deemed to have made a Base Rate Committed Loan to
the Borrower in such amount. The Administrative Agent shall remit the funds so received to the L/C Issuer. 

  

- 34 - 

 (iii) With respect to any Unreimbursed Amount that is not fully refinanced
by a Committed Borrowing of Base Rate Loans because the conditions set forth in Section 4.02 cannot be satisfied, the Borrower shall be deemed to have incurred from the L/C Issuer an L/C Borrowing in the amount of the Unreimbursed Amount
that is not so refinanced, which L/C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the Default Rate. In such event, each Lender’s payment to the Administrative Agent for the account of the L/C
Issuer pursuant to Section 2.04(c)(ii) shall be deemed payment in respect of its participation in such L/C Borrowing and shall constitute an L/C Advance from such Lender in satisfaction of its participation obligation under this
Section 2.04. 
 (iv) Until each Lender funds its Committed Loan or L/C Advance pursuant to this
Section 2.04(c) to reimburse the L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Lender’s Applicable Percentage of such amount shall be solely for the account of the L/C Issuer. 

(v) Each Lender’s obligation to make Committed Loans or L/C Advances to reimburse the L/C Issuer for amounts drawn
under Letters of Credit, as contemplated by this Section 2.04(c), shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which
such Lender may have against the L/C Issuer, the Borrower or any other Person for any reason whatsoever; (B) the occurrence or continuance of a Default, or (C) any other occurrence, event or condition, whether or not similar to any of the
foregoing; provided, however, that each Lender’s obligation to make Committed Loans pursuant to this Section 2.04(c) is subject to the conditions set forth in Section 4.02 (other than delivery by the
Borrower of a Committed Loan Notice). No such making of an L/C Advance shall relieve or otherwise impair the obligation of the Borrower to reimburse the L/C Issuer for the amount of any payment made by the L/C Issuer under any Letter of Credit,
together with interest as provided herein. 
 (vi) If any Lender fails to make available to the Administrative
Agent for the account of the L/C Issuer any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.04(c) by the time specified in Section 2.04(c)(ii), then, without limiting the other
provisions of this Agreement, the L/C Issuer shall be entitled to recover from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on
which such payment is immediately available to the L/C Issuer at a rate per annum equal to the greater of the Federal Funds Rate and a rate determined by the L/C Issuer in accordance with banking industry rules on interbank compensation, plus any
administrative, processing or similar fees customarily charged by the L/C Issuer in connection with the foregoing. If such Lender pays such amount, the amount so paid (other than such fees and any interest in excess of the interest rate otherwise
applicable to such borrowing) shall constitute such Lender’s Committed Loan included in the relevant Committed Borrowing or L/C Advance in respect of the relevant L/C Borrowing, as the case may be. A certificate of the L/C Issuer submitted to
any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (vi) shall be conclusive absent demonstrable error. 

  

- 35 - 

 (d) Repayment of Participations. 

(i) At any time after the L/C Issuer has made a payment under any Letter of Credit and has received from any Lender such
Lender’s L/C Advance in respect of such payment in accordance with Section 2.04(c), if the Administrative Agent receives for the account of the L/C Issuer any payment in respect of the related Unreimbursed Amount or interest thereon
(whether directly from the Borrower or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Lender its Applicable Percentage thereof in the same funds as
those received by the Administrative Agent. 
 (ii) If any payment received by the Administrative Agent for the
account of the L/C Issuer pursuant to Section 2.04(c)(i) is required to be returned under any of the circumstances described in Section 10.05 (including pursuant to any settlement entered into by the L/C Issuer in its
discretion), each Lender shall pay to the Administrative Agent for the account of the L/C Issuer its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is
returned by such Lender, at a rate per annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement.

 (e) Obligations Absolute. The obligation of the Borrower to reimburse the L/C Issuer for each drawing under each Letter
of Credit and to repay each L/C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement under all circumstances, including the following (unless any of the following or
any other circumstances result from the gross negligence or willful misconduct of L/C Issuer). 
 (i) any lack of
validity or enforceability of such Letter of Credit, this Agreement, or any other Loan Document; 
 (ii) the
existence of any claim, counterclaim, setoff, defense or other right that the Borrower or any Subsidiary may have at any time against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such
transferee may be acting), the L/C Issuer (other than the defense that all amounts required to reimburse the L/C Issuer had already been paid) or any other Person, whether in connection with this Agreement, the transactions contemplated hereby or by
such Letter of Credit or any agreement or instrument relating thereto, or any unrelated transaction; 
 (iii) any
draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in
the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit; 

  

- 36 - 

 (iv) waiver by the L/C Issuer of any requirement that exists for the L/C
Issuer’s protection and not the protection of the Borrower or any waiver by the L/C Issuer which does not in fact materially prejudice the Borrower; 
 (v) honor of a demand for payment presented electronically even if such Letter of Credit requires that demand be in the form of a draft; 

(vi) any payment made by the L/C Issuer in respect of an otherwise complying item presented after the date specified as
the expiration date of, or the date by which documents must be received under such Letter of Credit if presentation after such date is authorized by the UCC, the ISP or the UCP, as applicable; 

(vii) any payment by the L/C Issuer under such Letter of Credit against presentation of a draft or certificate that does
not strictly comply with the terms of such Letter of Credit; or any payment made by the L/C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors,
liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit, including any arising in connection with any proceeding under any Debtor Relief Law; or 

(viii) any other circumstance or happening whatsoever, whether or not similar to any of the foregoing, including any other
circumstance that might otherwise constitute a defense available to, or a discharge of, the Borrower or any Subsidiary. 
 The
Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to it and, in the event of any claim of noncompliance with the Borrower’s instructions or other irregularity, the Borrower will
immediately notify the L/C Issuer. The Borrower shall be conclusively deemed to have waived any such claim against the L/C Issuer and its correspondents unless such notice is given as aforesaid. 

(f) Role of L/C Issuer. Each Lender and the Borrower agree that, in paying any drawing under a Letter of Credit, the L/C Issuer
shall not have any responsibility to obtain any document (other than any sight draft, certificates and documents expressly required by the Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the
authority of the Person executing or delivering any such document. None of the L/C Issuer, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of the L/C Issuer shall be liable to any
Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Lenders or the Required Lenders, as applicable; (ii) any action taken or omitted in the absence of gross negligence or willful
misconduct; or (iii) the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of Credit or Issuer Document. The Borrower hereby assumes all risks of the acts or omissions of any
beneficiary or transferee with respect to its use of any Letter of Credit; provided, however, that this assumption is not intended to, and shall not, preclude the Borrower’s pursuing such rights and remedies as it may have against
the beneficiary or transferee at law or under any other agreement. None of the L/C Issuer, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of the L/C Issuer shall be liable or
responsible for any of the matters described in clauses (i) through (v) of Section 2.04(e); provided, however, that anything in such clauses or otherwise set 

  

- 37 - 

 
forth herein to the contrary notwithstanding, the Borrower may have a claim against the L/C Issuer, and the L/C Issuer may be liable to the Borrower, to the extent, but only to the extent, of any
direct, as opposed to consequential or exemplary, damages suffered by the Borrower which the Borrower proves were caused by the L/C Issuer’s willful misconduct or gross negligence or the L/C Issuer’s willful failure to pay under any Letter
of Credit after the presentation to it by the beneficiary of a sight draft and certificate(s) strictly complying with the terms and conditions of a Letter of Credit. In furtherance and not in limitation of the foregoing, the L/C Issuer may accept
documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and the L/C Issuer shall not be responsible for the validity or sufficiency of any
instrument transferring or assigning or purporting to transfer or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason. The L/C Issuer
may send a Letter of Credit or conduct any communication to or from the beneficiary via the Society for Worldwide Interbank Financial Telecommunication (“SWIFT”) message or overnight courier, or any other commercially reasonable means of
communicating with a beneficiary. 
 (g) Applicability of ISP. Unless otherwise expressly agreed by the L/C Issuer and the
Borrower when a Letter of Credit is issued the rules of the ISP shall apply to each standby Letter of Credit, and (ii) the rules of the UCP shall apply to each commercial Letter of Credit. Notwithstanding the foregoing, the L/C Issuer shall not
be responsible to the Borrower for, and the L/C Issuer’s rights and remedies against the Borrower shall not be impaired by, any action or inaction of the L/C Issuer required under any law, order, or practice that is required or permitted to be
applied to any Letter of Credit or this Agreement, including the Law or any order of a jurisdiction where the L/C Issuer or the beneficiary is located, the practice stated in the ISP or UCP, as applicable, or in the decisions, opinions, practice
statements, or official commentary of the ICC Banking Commission, the Bankers Association for Finance and Trade—International Financial Services Association (BAFT-IFSA), or the Institute of International Banking Law & Practice, whether
or not any Letter of Credit chooses such law or practice. 
 (h) Letter of Credit Fees. The Borrower shall pay to the
Administrative Agent for the account of each Lender in accordance with its Applicable Percentage a Letter of Credit fee (the “Letter of Credit Fee”) for each Letter of Credit equal to the Applicable Rate times the daily
amount available to be drawn under such Letter of Credit; provided, however, any Letter of Credit Fees otherwise payable for the account of a Defaulting Lender with respect to any Letter of Credit as to which such Defaulting Lender has
not provided Cash Collateral satisfactory to the L/C Issuer pursuant to this Section 2.04 shall be payable, to the maximum extent permitted by applicable Law, to the other Lenders in accordance with the upward adjustments in their
respective Applicable Percentages allocable to such Letter of Credit pursuant to Section 2.18(a)(iv), with the balance of such fee, if any, payable to the L/C Issuer for its own account. For purposes of computing the daily amount
available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. Letter of Credit Fees shall be (i) due and payable on the first Business Day after the end of
each March, June, September and December, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand and (ii) computed on a quarterly basis in
arrears. If there is any change in the Applicable Rate during any quarter, the daily amount available to be drawn under each Letter of Credit shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that
such Applicable Rate was in effect. Notwithstanding anything to the contrary contained herein, upon the request of the Required Lenders, while any Event of Default exists, all Letter of Credit Fees shall accrue at the Default Rate. 

  

- 38 - 

 (i) Fronting Fee and Documentary and Processing Charges Payable to L/C Issuer. The
Borrower shall pay directly to the L/C Issuer for its own account a fronting fee with respect to each Letter of Credit, at the rate per annum specified in the fee letter among the Borrower, the Administrative Agent and the Arrangers, computed on the
daily amount available to be drawn under such Letter of Credit on a quarterly basis in arrears. Such fronting fee shall be due and payable on the tenth Business Day after the end of each March, June, September and December in respect of the most
recently-ended quarterly period (or portion thereof, in the case of the first payment), commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand. For
purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. In addition, the Borrower shall pay directly to the L/C
Issuer for its own account the reasonable and customary issuance, presentation, amendment and other processing fees, and other standard costs and charges, of the L/C Issuer relating to letters of credit as from time to time in effect. Such
reasonable and customary fees and standard costs and charges are due and payable on demand and are nonrefundable. 
 (j)
Conflict with Issuer Documents. In the event of any conflict between the terms hereof and the terms of any Issuer Document, the terms hereof shall control. 
 2.05 Swing Line Loans. 
 (a) The Swing Line. Subject to the terms and
conditions set forth herein, the Swing Line Lender, in reliance upon the agreements of the other Lenders set forth in this Section 2.05, shall make loans (each such loan, a “Swing Line Loan”) to the Borrower from time to
time on any Business Day during the Availability Period in an aggregate amount not to exceed at any time outstanding the amount of the Swing Line Sublimit, notwithstanding the fact that such Swing Line Loans, when aggregated with the Applicable
Percentage of the Outstanding Amount of Committed Loans and L/C Obligations of the Lender acting as Swing Line Lender, may exceed the amount of Swing Line Lender’s Commitment; provided, however, that after giving effect to any
Swing Line Loan, (i) the Total Outstandings shall not exceed the Aggregate Commitments, and (ii) Revolving Credit Exposure of any Lender other than the Swing Line Lender shall not exceed such Lender’s Commitment, and provided,
further, that the Borrower shall not use the proceeds of any Swing Line Loan to refinance any outstanding Swing Line Loan. Within the foregoing limits, and subject to the other terms and conditions hereof, the Borrower may borrow under this
Section 2.05, prepay under Section 2.06, and reborrow under this Section 2.05. Each Swing Line Loan shall be a Base Rate Loan. Immediately upon the making of a Swing Line Loan, each Lender shall be deemed to, and
hereby irrevocably and unconditionally agrees to, purchase from the Swing Line Lender a risk participation in such Swing Line Loan in an amount equal to the product of such Lender’s Applicable Percentage times the amount of such Swing
Line Loan. 
 (b) Borrowing Procedures. Each Swing Line Borrowing shall be made upon the Borrower’s irrevocable
notice to the Swing Line Lender and the Administrative Agent, which 

  

- 39 - 

 
may be given by telephone. Each such notice must be received by the Swing Line Lender and the Administrative Agent not later than 1:00 p.m. on the requested borrowing date, and shall specify
(i) the amount to be borrowed, which shall be a minimum of $100,000, and (ii) the requested borrowing date, which shall be a Business Day. Each such telephonic notice must be confirmed promptly by delivery to the Swing Line Lender and the
Administrative Agent of a written Swing Line Loan Notice, appropriately completed and signed by a Responsible Officer of the Borrower. Promptly after receipt by the Swing Line Lender of any telephonic Swing Line Loan Notice, the Swing Line Lender
will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has also received such Swing Line Loan Notice and, if not, the Swing Line Lender will notify the Administrative Agent (by telephone or in writing)
of the contents thereof. Unless the Swing Line Lender has received notice (by telephone or in writing) from the Administrative Agent (including at the request of any Lender) prior to 2:00 p.m. on the date of the proposed Swing Line Borrowing
(A) directing the Swing Line Lender not to make such Swing Line Loan as a result of the limitations set forth in the first proviso to the first sentence of Section 2.05(a), or (B) that one or more of the applicable conditions
specified in Article IV is not then satisfied, then, subject to the terms and conditions hereof, the Swing Line Lender will, not later than 3:00 p.m. on the borrowing date specified in such Swing Line Loan Notice, make the amount of its Swing
Line Loan available to the Borrower. 
 (c) Refinancing of Swing Line Loans. 

(i) The Swing Line Lender at any time in its sole discretion may request, on behalf of the Borrower (which hereby
irrevocably authorizes the Swing Line Lender to so request on its behalf), that each Lender make a Base Rate Committed Loan in an amount equal to such Lender’s Applicable Percentage of the amount of Swing Line Loans then outstanding. Such
request shall be made in writing (which written request shall be deemed to be a Committed Loan Notice for purposes hereof) and in accordance with the requirements of Section 2.02, without regard to the minimum and multiples specified
therein for the principal amount of Base Rate Loans, but subject to the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.02. The Swing Line Lender shall furnish the Borrower with a copy of the
applicable Committed Loan Notice promptly after delivering such notice to the Administrative Agent. Each Lender shall make an amount equal to its Applicable Percentage of the amount specified in such Committed Loan Notice available to the
Administrative Agent in immediately available funds (and the Administrative Agent may apply Cash Collateral available with respect to the applicable Swing Line Loan) for the account of the Swing Line Lender at the Administrative Agent’s Office
not later than 1:00 p.m. on the day specified in such Committed Loan Notice, whereupon, subject to Section 2.05(c)(ii), each Lender that so makes funds available shall be deemed to have made a Base Rate Committed Loan to the Borrower in
such amount. The Administrative Agent shall remit the funds so received to the Swing Line Lender. 
 (ii) If for
any reason any Swing Line Loan cannot be refinanced by such a Committed Borrowing in accordance with Section 2.05(c)(i), the request for Base Rate Committed Loans submitted by the Swing Line Lender as set forth herein shall be deemed to
be a request by the Swing Line Lender that each of the Lenders fund its risk participation in the relevant Swing Line Loan and each Lender’s payment to the Administrative Agent for the account of the Swing Line Lender pursuant to
Section 2.05(c)(i) shall be deemed payment in respect of such participation. 

  

- 40 - 

 (iii) If any Lender fails to make available to the Administrative Agent for
the account of the Swing Line Lender any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.05(c) by the time specified in Section 2.05(c)(i), the Swing Line Lender shall be
entitled to recover from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the
Swing Line Lender at a rate per annum equal to the greater of the Federal Funds Rate and a rate determined by the Swing Line Lender in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar
fees customarily charged by the Swing Line Lender in connection with the foregoing. If such Lender pays such amount (with interest and fees as aforesaid), the amount so paid (other than such fees and any interest in excess of the interest rate
otherwise applicable to such borrowing) shall constitute such Lender’s Committed Loan included in the relevant Committed Borrowing or funded participation in the relevant Swing Line Loan, as the case may be. A certificate of the Swing Line
Lender submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (iii) shall be conclusive absent demonstrable error. 

(iv) Each Lender’s obligation to make Committed Loans or to purchase and fund risk participations in Swing Line Loans
pursuant to this Section 2.05(c) shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which such Lender may have against the
Swing Line Lender, the Borrower or any other Person for any reason whatsoever, (B) the occurrence or continuance of a Default, or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing;
provided, however, that each Lender’s obligation to make Committed Loans pursuant to this Section 2.05(c) is subject to the conditions set forth in Section 4.02. No such funding of risk participations shall
relieve or otherwise impair the obligation of the Borrower to repay Swing Line Loans, together with interest as provided herein. 

(d) Repayment of Participations. 
 (i) At any time after any Lender has purchased and funded a risk participation in a Swing Line Loan, if the Swing Line Lender receives any payment on account of such Swing Line Loan, the Swing Line Lender
will distribute to such Lender its Applicable Percentage thereof in the same funds as those received by the Swing Line Lender. 
 (ii) If any payment received by the Swing Line Lender in respect of principal or interest on any Swing Line Loan is required to be returned by the Swing Line Lender under any of the circumstances
described in Section 10.05 (including pursuant to any settlement entered into by the Swing Line Lender in its discretion), each Lender shall pay to the Swing Line Lender its Applicable Percentage thereof on demand of the Administrative
Agent, plus interest thereon from the date of such demand to the date such amount is returned, at a rate per annum equal to the Federal Funds Rate. The Administrative Agent will make such demand upon the request of the Swing Line Lender. The
obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement. 

  

- 41 - 

 (e) Interest for Account of Swing Line Lender. The Swing Line Lender shall be
responsible for invoicing the Borrower for interest on the Swing Line Loans. Until each Lender funds its Base Rate Committed Loan or risk participation pursuant to this Section 2.05 to refinance such Lender’s Applicable Percentage
of any Swing Line Loan, interest in respect of such Applicable Percentage shall be solely for the account of the Swing Line Lender. 
 (f) Payments Directly to Swing Line Lender. The Borrower shall make all payments of principal and interest in respect of the Swing Line Loans directly to the Swing Line Lender. 

2.06 Prepayments. 
 (a) The Borrower may, upon notice to the Administrative Agent, at any time or from time to time voluntarily prepay Committed Loans in whole or in part without premium or penalty; provided that
(i) such notice must be received by the Administrative Agent not later than 1:00 p.m. (A) three Business Days prior to any date of prepayment of Eurodollar Rate Loans and (B) on the date of prepayment of Base Rate Committed Loans;
(ii) any prepayment of Eurodollar Rate Loans shall be in a principal amount of $5,000,000 or in increments of $100,000 in excess thereof; and (iii) any prepayment of Base Rate Committed Loans shall be in a principal amount of $500,000 or
increments of $100,000 in excess thereof or, in each case, if less, the entire principal amount thereof then outstanding. Each such notice shall specify the date and amount of such prepayment and the Type(s) of Committed Loans to be prepaid and, if
Eurodollar Rate Loans are to be prepaid, the Interest Period(s) of such Loans. The Administrative Agent will promptly notify each Lender of its receipt of each such notice, and of the amount of such Lender’s Applicable Percentage of such
prepayment. If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein. Any prepayment of a Eurodollar Rate Loan shall be
accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to Section 3.05. Subject to Section 2.18, each such prepayment shall be applied to the Committed Loans of the
Lenders in accordance with their respective Applicable Percentages. 
 (b) The Borrower may, upon notice to the Swing Line Lender
(with a copy to the Administrative Agent), at any time or from time to time, voluntarily prepay Swing Line Loans in whole or in part without premium or penalty; provided that (i) such notice must be received by the Swing Line Lender and
the Administrative Agent not later than 1:00 p.m. on the date of the prepayment, and (ii) any such prepayment shall be in a minimum principal amount of $100,000. Each such notice shall specify the date and amount of such prepayment. If such
notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein. 
 (c) If for any reason the Total Outstandings at any time exceed the Aggregate Commitments then in effect, the Borrower shall immediately prepay Loans and/or Cash Collateralize the L/C Obligations in an
aggregate amount equal to such excess; provided, however, that the Borrower shall not be required to Cash Collateralize the L/C Obligations pursuant to this Section 2.06(c) unless after the prepayment in full of the
Committed Loans and Swing Line Loans the Total Outstandings exceed the Aggregate Commitments then in effect. 

  

- 42 - 

 2.07 Termination or Reduction of Commitments. The Borrower may, upon notice to the
Administrative Agent, terminate the Aggregate Commitments, or from time to time permanently reduce the Aggregate Commitments; provided that (i) any such notice shall be received by the Administrative Agent not later than 1:00 p.m. five Business
Days prior to the date of termination or reduction, (ii) any such partial reduction shall be in an aggregate amount of $10,000,000 or any whole multiple of $1,000,000 in excess thereof, (iii) the Borrower shall not terminate or reduce the
Aggregate Commitments if, after giving effect thereto and to any concurrent prepayments hereunder, the Total Outstandings would exceed the Aggregate Commitments, and (iv) if, after giving effect to any reduction of the Aggregate Commitments,
the Letter of Credit Sublimit or the Swing Line Sublimit exceeds the amount of the Aggregate Commitments, such Sublimit shall be automatically reduced by the amount of such excess. The Administrative Agent will promptly notify the Lenders of any
such notice of termination or reduction of the Aggregate Commitments. Any reduction of the Aggregate Commitments shall be applied to the Commitment of each Lender according to its Applicable Percentage. All fees accrued until the effective date of
any termination of the Aggregate Commitments shall be paid on the effective date of such termination. 
 2.08 Repayment of
Loans. 
 (a) The Borrower shall repay to the Lenders on the Maturity Date the aggregate principal amount of Committed Loans
outstanding on such date. 
 (b) The Borrower shall repay each Swing Line Loan on the earlier to occur of (i) the date ten
Business Days after such Loan is made and (ii) the Maturity Date. 
 2.09 Interest. 

(a) Subject to the provisions of subsection (b) below, (i) each Eurodollar Rate Loan shall bear interest on the outstanding
principal amount thereof for each Interest Period at a rate per annum equal to the Eurodollar Rate for such Interest Period plus the Applicable Rate; (ii) each Base Rate Committed Loan shall bear interest on the outstanding principal
amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate; and (iii) each Swing Line Loan shall bear interest on the outstanding principal amount thereof from the applicable
borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate. 
 (b) (i) If any amount of principal
of any Loan is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to
the Default Rate to the fullest extent permitted by applicable Laws. 
 (ii) If any amount (other than principal
of any Loan) payable by the Borrower under any Loan Document is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, then upon the request of the Required Lenders, such amount
shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. 

  

- 43 - 

 (iii) Upon the request of the Required Lenders, while any Event of Default
exists, the Borrower shall pay interest on the principal amount of all outstanding Obligations hereunder at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. 

(iv) Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable
upon demand. 
 (c) Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto
and at such other times as may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.

 2.10 Fees. In addition to certain fees described in subsections (h) and (i) of Section 2.04:

 (a) Unused Fee. The Borrower shall pay to the Administrative Agent for the account of each Lender in accordance with
its Applicable Percentage, an unused fee equal to the Unused Fee Rate times the actual daily amount by which the Aggregate Commitments exceed the sum of (i) the Outstanding Amount of Committed Loans and (ii) the Outstanding Amount of L/C
Obligations, subject to adjustment as provided in Section 2.17. For the avoidance of doubt, the Outstanding Amount of Swing Line Loans shall not be counted towards or considered usage of the Aggregate Commitments for purposes of determining the
commitment fee. The unused fee shall accrue at all times during the Availability Period, including at any time during which one or more of the conditions in Article IV is not met, and shall be due and payable quarterly in arrears on the last
Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the last day of the Availability Period. The unused fee shall be calculated quarterly in arrears. The Unused Fee
Rate shall be equal to 0.30% if the weighted average usage during such quarter is less than or equal to 50% of the Aggregate Commitments and otherwise shall be equal to 0.25%. 
 (b) Other Fees. (i) The Borrower shall pay to the Arrangers and the Administrative Agent for their own respective accounts fees in the amounts and at the times specified in the fee letter
among Borrower, Administrative Agent and the Lenders. Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever. 
 (ii) The Borrower shall pay to the Lenders such fees as shall have been separately agreed upon in writing in the amounts and at the times so specified. Such fees shall be fully earned when paid and shall
not be refundable for any reason whatsoever. 
 2.11 Computation of Interest and Fees; Retroactive Adjustments of Applicable
Rate. (a) All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to the Eurodollar Rate) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All
other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in 

  

- 44 - 

 
more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue
on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to Section 2.13(a), bear interest for one day. Each determination
by the Administrative Agent of an interest rate or fee hereunder shall be prima facie evidence thereof. 
 (b) If, as a result
of any restatement of or other adjustment to the financial statements of the Borrower or for any other reason, the Borrower or the Lenders determine that (i) the Consolidated Leverage Ratio as calculated by the Borrower as of any applicable
date was inaccurate and (ii) a proper calculation of the Consolidated Leverage Ratio would have resulted in higher pricing for such period, the Borrower shall immediately and retroactively be obligated to pay to the Administrative Agent for the
account of the applicable Lenders or the L/C Issuer, as the case may be, promptly on demand by the Administrative Agent (or, after the occurrence of an actual or deemed entry of an order for relief with respect to the Borrower under the Bankruptcy
Code of the United States, automatically and without further action by the Administrative Agent, any Lender or the L/C Issuer), an amount equal to the excess of the amount of interest and fees that should have been paid for such period over the
amount of interest and fees actually paid for such period. This paragraph shall not limit the rights of the Administrative Agent, any Lender or the L/C Issuer, as the case may be, under Section 2.03(c)(iii), 2.03(h) or
2.09(b) or under Article VIII. The Borrower’s obligations under this paragraph shall survive the termination of the Aggregate Commitments and the repayment of all other Obligations hereunder for a period of 180 days. 

2.12 Evidence of Debt. 
 (a) The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender and by the Administrative Agent in the ordinary course of business. The
accounts or records maintained by the Administrative Agent and each Lender shall be prima facie evidence of the amount of the Credit Extensions made by the Lenders to the Borrower and the interest and payments thereon. Any failure to so record or
any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any amount owing with respect to the Obligations. In the event of any conflict between the accounts and records maintained by any
Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of demonstrable error. Upon the request of any Lender made through the
Administrative Agent, the Borrower shall execute and deliver to such Lender (through the Administrative Agent) a Note, which shall evidence such Lender’s Loans in addition to such accounts or records. Each Lender may attach schedules to its
Note and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto. 

(b) In addition to the accounts and records referred to in subsection (a), each Lender and the Administrative Agent shall maintain in
accordance with its usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit and Swing Line Loans. In the event of any conflict between the accounts and records maintained by the
Administrative Agent and the accounts and records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of demonstrable error. 

  

- 45 - 

 2.13 Payments Generally; Administrative Agent’s Clawback. 

(a) General. All payments to be made by the Borrower shall be made without condition or deduction for any counterclaim, defense,
recoupment or setoff. Except as otherwise expressly provided herein, all payments by the Borrower hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the Administrative
Agent’s Office in Dollars and in immediately available funds not later than 2:00 p.m. on the date specified herein. The Administrative Agent will promptly distribute to each Lender its Applicable Percentage (or other applicable share as
provided herein) of such payment in like funds as received by wire transfer to such Lender’s Lending Office and any payment of principal not distributed within one (1) Business Day following receipt by Administrative Agent shall bear
interest (payable by the Administrative Agent) at the Federal Funds Rate. All payments received by the Administrative Agent after 2:00 p.m. shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall
continue to accrue. If any payment to be made by the Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees,
as the case may be. 
 (b) (i) Funding by Lenders; Presumption by Administrative Agent. Unless the Administrative Agent
shall have received notice from a Lender prior to the proposed date of any Committed Borrowing of Eurodollar Rate Loans (or, in the case of any Committed Borrowing of Base Rate Loans, prior to 12:00 noon on the date of such Committed Borrowing) that
such Lender will not make available to the Administrative Agent such Lender’s share of such Committed Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with
Section 2.02 (or, in the case of a Committed Borrowing of Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by Section 2.02) and may, in reliance upon such assumption,
make available to the Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Committed Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower severally agree
to pay to the Administrative Agent forthwith on demand such corresponding amount in immediately available funds with interest thereon, for each day from and including the date such amount is made available to the Borrower to but excluding the date
of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender, the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank
compensation, plus any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by the Borrower, the interest rate applicable to the
applicable Borrowing. If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the
Borrower for such period. If such Lender pays its share of the applicable Committed Borrowing to the Administrative Agent, then the amount so paid (but not in excess of the interest rate otherwise applicable to such borrowing) shall constitute such
Lender’s Committed Loan included in such Committed Borrowing. Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.

  

- 46 - 

 (ii) Payments by Borrower; Presumptions by Administrative Agent.
Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the L/C Issuer hereunder that the Borrower will not make such
payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the L/C Issuer, as the case may be, the amount due. In
such event, if the Borrower has not in fact made such payment, then each of the Lenders or the L/C Issuer, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or the
L/C Issuer, in immediately available funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Rate
and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. 
 A
notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under this subsection (b) shall be conclusive, absent demonstrable error. 

(c) Failure to Satisfy Conditions Precedent. If any Lender makes available to the Administrative Agent funds for any Loan to be
made by such Lender as provided in the foregoing provisions of this Article II, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Credit Extension set forth in
Article IV are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest. 

(d) Obligations of Lenders Several. The obligations of the Lenders hereunder to make Committed Loans, to fund participations in
Letters of Credit and Swing Line Loans and to make payments pursuant to Section 10.04(c) are several and not joint. The failure of any Lender to make any Committed Loan, to fund any such participation or to make any payment under
Section 10.04(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Committed
Loan, to purchase its participation or to make its payment under Section 10.04(c). 
 (e) Funding Source.
Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular
place or manner. 
 2.14 Sharing of Payments by Lenders. If any Lender shall, by exercising any right of setoff or
counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of the Committed Loans made by it, or the participations in L/C Obligations or in Swing Line Loans held by it resulting in such Lender’s receiving
payment of a proportion of the 

  

- 47 - 

 
aggregate amount of such Committed Loans or participations and accrued interest thereon greater than its pro rata share thereof as provided herein, then the Lender receiving such greater
proportion shall (a) notify the Administrative Agent of such fact, and (b) purchase (for cash at face value) participations in the Committed Loans and subparticipations in L/C Obligations and Swing Line Loans of the other Lenders, or make
such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Committed Loans and other
amounts owing them, provided that: 
 (i) if any such participations or subparticipations are purchased
and all or any portion of the payment giving rise thereto is recovered, such participations or subparticipations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and 

(ii) the provisions of this Section shall not be construed to apply to (x) any payment made by or on behalf of the
Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) the application of Cash Collateral provided for in
Section 2.17, or (z) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Committed Loans or subparticipations in L/C Obligations or Swing Line Loans to any assignee or
participant, other than an assignment to the Borrower or any Subsidiary Affiliate thereof (as to which the provisions of this Section shall apply). 
 Each Loan Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may
exercise against such Loan Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Loan Party in the amount of such participation. 

2.15 Extension of Maturity Date. 
 (a) Requests for Extension. The Borrower may, up to two times, by notice to the Administrative Agent (who shall promptly notify the Lenders) not earlier than 120 days and not later than 30 days
prior to the Maturity Date then in effect hereunder (the “Existing Maturity Date”), request that the Existing Maturity Date be extended for an additional one year from the Existing Maturity Date. 

(b) Conditions to Effectiveness of Extensions. As a condition precedent to such extension, the Borrower shall pay to
Administrative Agent for the pro rata benefit of the Lenders, an extension fee equal to 0.20% (20 basis points) of the Aggregate Commitment at the time of extension and deliver to the Administrative Agent a certificate of each Loan Party dated as of
the Existing Maturity Date (in sufficient copies for each Lender) signed by a Responsible Officer of such Loan Party (i) approving or consenting to such extension (and attaching resolutions adopted by such Loan Party approving or consenting to
such extension to the extent required under such Loan Party’s Organization Documents) and (ii) in the case of the Borrower, certifying that, immediately before and after giving effect to such extension, (A) the representations and
warranties contained in Article V and the other Loan Documents are true and correct on and as 

  

- 48 - 

 
of the Existing Maturity Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they were true and correct as of such earlier
date, and except that for purposes of this Section 2.14, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to
subsections (a) and (b), respectively, of Section 6.01, (B) Borrower is in compliance with all of the financial covenants set forth in Section 7.11, and (C) no Default exists. In connection with the second extension, the
Required Lenders may elect to increase or decrease the Capitalization Rate by up to 0.50% in connection with such extension if the Required Lenders determine in good faith that such change is consistent with changes in market cap rates between the
Closing Date and the date of the second extension. If the Required Lenders elect to increase or decrease the Capitalization rate, the Administrative Agent shall notify the Borrower of the amount of such increase or decrease no later than one hundred
eighty (180) days prior the then applicable Existing Maturity Date. In such event, the certification that Borrower is in compliance with the covenants contained in Section 7.11 shall be based on calculations using the revised
Capitalization Rate. 
 2.16 Increase in Commitments. 

(a) Request for Increase. Provided there exists no Default, upon notice to the Administrative Agent (which shall promptly
notify the Lenders), the Borrower may from time to time, request an increase in the Aggregate Commitments by an amount (for all such requests) not exceeding $300,000,000; provided that any such request for an increase shall be in a minimum
amount of $25,000,000, or such other amount as may be agreed upon by Borrower and Administrative Agent. At the time of sending such notice, the Borrower (in consultation with the Administrative Agent) shall specify the time period within which each
Lender is requested to respond (which shall in no event be less than ten Business Days from the date of delivery of such notice to the Lenders) as to whether it intends to seek approval for increasing its Commitment. 

(b) Lender Elections to Increase. Each Lender shall notify the Administrative Agent within such time period whether or not
it agrees to increase its Commitment and, if so, whether by an amount equal to, greater than, or less than its Applicable Percentage of such requested increase. Any Lender not responding within such time period shall be deemed to have declined to
increase its Commitment. 
 (c) Notification by Administrative Agent; Additional Lenders. The Administrative Agent
shall notify the Borrower and each Lender of the Lenders’ responses to each request made hereunder. To achieve the full amount of a requested increase and subject to the approval of the Administrative Agent, the L/C Issuer and the Swing Line
Lender (which approvals shall not be unreasonably withheld), the Borrower may also invite additional Eligible Assignees to become Lenders pursuant to a joinder agreement in form and substance satisfactory to the Administrative Agent and its counsel.

 (d) Effective Date and Allocations. If the Aggregate Commitments are increased in accordance with this Section,
the Administrative Agent and the Borrower shall determine the effective date (the “Increase Effective Date”) and the final allocation of such increase. The Administrative Agent shall promptly notify the Borrower and the Lenders of
the final allocation of such increase and the Increase Effective Date. 

  

- 49 - 

 (e) Conditions to Effectiveness of Increase. As a condition precedent to such
increase, the Borrower shall deliver to the Administrative Agent a certificate of each Loan Party dated as of the Increase Effective Date (in sufficient copies for each Lender) signed by a Responsible Officer of such Loan Party (x) by such Loan
Party approving or consenting to such increase (and attaching resolutions adopted by such Loan Party approving or consenting to such increase to the extent required under such Loan Party’s Organization Documents), and (y) in the case of
the Borrower, certifying that, before and after giving effect to such increase, (A) the representations and warranties contained in Article V and the other Loan Documents are true and correct in all material respects on and as of the
Increase Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they were true and correct as of such earlier date, and except that for purposes of this
Section 2.16, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b),
respectively, of Section 6.01, and (B) no Default exists. The Borrower shall prepay any Committed Loans outstanding on the Increase Effective Date (and pay any additional amounts required pursuant to Section 3.05) to the
extent necessary to keep the outstanding Committed Loans ratable with any revised Applicable Percentages arising from any nonratable increase in the Commitments under this Section. 

(f) Conflicting Provisions. This Section shall supersede any provisions in Section 2.14 or 10.01 to the contrary.

 2.17 Cash Collateral. 
 (a) Certain Credit Support Events. Upon the request of the Administrative Agent or the L/C Issuer (i) if the L/C Issuer has honored any full or partial drawing request under any Letter of
Credit and such drawing has resulted in an L/C Borrowing, or (ii) if, as of the Letter of Credit Expiration Date, any L/C Obligation for any reason remains outstanding, the Borrower shall, in the case of (ii), immediately Cash Collateralize the
then Outstanding Amount of all L/C Obligations and in the case of (i), in an amount equal to the L/C Borrowing. At any time that there shall exist a Defaulting Lender, immediately upon the request of the Administrative Agent, the L/C Issuer or the
Swing Line Lender, the Borrower shall deliver to the Administrative Agent Cash Collateral in an amount sufficient to cover all Fronting Exposure (after giving effect to Section 2.18(a)(iv) and any Cash Collateral provided by the
Defaulting Lender). 
 (b) Grant of Security Interest. All Cash Collateral (other than credit support not constituting
funds subject to deposit) shall be maintained in blocked, interest bearing deposit accounts at Bank of America. The Borrower, and to the extent provided by any Lender, such Lender, hereby grants to (and subject to the control of) the Administrative
Agent, for the benefit of the Administrative Agent, the L/C Issuer and the Lenders (including the Swing Line Lender), and agrees to maintain, a first priority security interest in all such cash, deposit accounts and all balances therein, and all
other property so provided as collateral pursuant hereto, and in all proceeds of the foregoing, all as security for the obligations to which such Cash Collateral may be applied pursuant to Section 2.17(c). If at any time the
Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent as herein provided, or that the total amount of such Cash Collateral is less than the applicable Fronting
Exposure, the Borrower or the relevant Defaulting Lender will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency. 

  

- 50 - 

 (c) Application. Notwithstanding anything to the contrary contained in this
Agreement, Cash Collateral provided under any of this Section 2.17 or Sections 2.04, 2.05, 2.06, 2.18 or 8.02 in respect of Letters of Credit or Swing Line Loans shall be held and applied to the
satisfaction of the specific L/C Obligations, Swing Line Loans, obligations to fund participations therein (including, as to Cash Collateral provided by a Defaulting Lender, any interest accrued on such obligation) and other obligations for which
the Cash Collateral was so provided, prior to any other application of such property as may be provided for herein. 
 (d)
Release. Cash Collateral (or the appropriate portion thereof) provided to reduce Fronting Exposure or other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations
giving rise thereto (including by the termination of Defaulting Lender status of the applicable Lender (or, as appropriate, its assignee following compliance with Section 10.06(b)(vi))) or (ii) the Administrative Agent’s good
faith determination that there exists Cash Collateral greater than the Fronting Exposure; provided, however, (x) that Cash Collateral furnished by or on behalf of a Loan Party shall not be released during the continuance of a
Default (and following application as provided in this Section 2.17 may be otherwise applied in accordance with Section 8.03), and (y) the Person providing Cash Collateral and the L/C Issuer or Swing Line Lender, as
applicable, may agree that Cash Collateral shall not be released but instead held to support future anticipated Fronting Exposure or other obligations. 
 2.18 Defaulting Lenders. 
 (a) Adjustments. Notwithstanding anything
to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law: 

(i) Waivers and Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment, waiver or
consent with respect to this Agreement shall be restricted as set forth in the definition of “Required Lenders” and Section 10.01. 
 (ii) Defaulting Lender Waterfall. Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or
mandatory, at maturity, pursuant to Article VIII or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to Section 10.08 shall be applied at such time or times as may be determined by the Administrative Agent as
follows: first, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the L/C Issuer or Swing Line Lender
hereunder; third, to Cash Collateralize the L/C Issuer’s Fronting Exposure with respect to such Defaulting Lender in accordance with Section 2.17; fourth, as the Borrower may request (so long as no Default or Event of Default exists), to
the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrower,
to be held 

  

- 51 - 

 
in a deposit account and released pro rata in order to (x) satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Agreement and
(y) Cash Collateralize the L/C Issuer’s future Fronting Exposure with respect to such Defaulting Lender with respect to future Letters of Credit issued under this Agreement, in accordance with Section 2.16; sixth, to the payment of
any amounts owing to the Lenders, the L/C Issuer or Swing Line Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, the L/C Issuer or the Swing Line Lender against such Defaulting Lender as a result of such
Defaulting Lender’s breach of its obligations under this Agreement; seventh, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction
obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and eighth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction;
provided that if (x) such payment is a payment of the principal amount of any Loans or L/C Borrowings in respect of which such Defaulting Lender has not fully funded its appropriate share, and (y) such Loans were made or the related
Letters of Credit were issued at a time when the conditions set forth in Section 4.02 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L/C Obligations owed to, all Non-Defaulting Lenders on a pro rata
basis prior to being applied to the payment of any Loans of, or L/C Obligations owed to, such Defaulting Lender until such time as all Loans and funded and unfunded participations in L/C Obligations and Swing Line Loans are held by the Lenders pro
rata in accordance with the Commitments hereunder without giving effect to Section 2.18(a)(iv). Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting
Lender or to post Cash Collateral pursuant to this Section 2.17(a)(ii) shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto. 

(iii) Certain Fees. 
 (A) Unused Fees: No Defaulting Lender shall be entitled to receive any fee payable under Section 2.10(a) for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be
required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender). 
 (B) Each Defaulting Lender shall be entitled to receive Letter of Credit Fees for any period during which that Lender is a Defaulting Lender only to the extent allocable to its Applicable Percentage of
the stated amount of Letters of Credit for which it has provided Cash Collateral pursuant to Section 2.17. 

(C) With respect to any fee payable under Section 2.09(a) or (b) or any Letter of Credit Fee not required to be
paid to any Defaulting Lender pursuant to clause (A) or (B) above, the Borrower shall (x) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such Defaulting
Lender’s participation in L/C Obligations or Swing Line Loans that has been reallocated to such Non-Defaulting Lender pursuant to clause (iv) below, (y) pay to the L/C Issuer and Swing Line Lender, as

  

- 52 - 

 
applicable, the amount of any such fee otherwise payable to such Defaulting Lender to the extent allocable to such L/C Issuer’s or Swing Line Lender’s Fronting Exposure to such
Defaulting Lender, and (z) not be required to pay the remaining amount of any such fee. 
 (iv)
Reallocation of Applicable Percentages to Reduce Fronting Exposure. All or any part of such Defaulting Lender’s participation in L/C Obligations and Swing Line Loans shall be reallocated among the Non-Defaulting Lenders in accordance
with their respective Applicable Percentages (calculated without regard to such Defaulting Lender’s Commitment) but only to the extent that (x) the conditions set forth in Section 4.02 are satisfied at the time of such reallocation
(and, unless the Borrower shall have otherwise notified the Administrative Agent at such time, the Borrower shall be deemed to have represented and warranted that such conditions are satisfied at such time), and (y) such reallocation does not
cause the aggregate Revolving Credit Exposure of any Non-Defaulting Lender to exceed such Non-Defaulting Lender’s Commitment. No reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a
Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of such Non-Defaulting Lender’s increased exposure following such reallocation. 

(v) Cash Collateral, Repayment of Swing Line Loans. If the reallocation described in clause (a)(iv) above cannot,
or can only partially, be effected, the Borrower shall, without prejudice to any right or remedy available to it hereunder or under applicable Law, (x) first, prepay Swing Line Loans in an amount equal to the Swing Line Lenders’ Fronting
Exposure and (y) second, Cash Collateralize the L/C Issuers’ Fronting Exposure in accordance with the procedures set forth in Section 2.17. 
 (b) Defaulting Lender Cure. If the Borrower, the Administrative Agent, the Swing Line Lender and the L/C Issuer agree in writing that a Lender is no longer a Defaulting Lender, the Administrative
Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the
extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Committed Loans and funded and unfunded participations in
Letters of Credit and Swing Line Loans to be held on a pro rata basis by the Lenders in accordance with their Applicable Percentages (without giving effect to Section 2.17(a)(iv)), whereupon such Lender will cease to be a Defaulting Lender;
provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly
agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender. 

2.19 Addition and Removal of Unencumbered Properties. 
 (a) Addition of Unencumbered Properties. The Borrower may at any time and from time to time designate additional Unencumbered Properties meeting the definition of Unencumbered Properties by
providing an updated Schedule 5.19 and the appropriate Subsidiary Guarantees, at which time such additional Unencumbered Properties shall be included for purposes of determining the Borrower’s compliance with the financial covenants under
Sections 7.11(f), (g) and (h) and the amount that may be borrowed hereunder. 

  

- 53 - 

 (b) Removal of Unencumbered Properties. The Borrower may at any time and from time to
time remove Unencumbered Properties by providing an updated Schedule 5.19 reflecting which Properties will no longer constitute Unencumbered Properties; provided that in connection therewith Borrower shall demonstrate to Administrative Agent that
following removal of such Unencumbered Property that the Borrower continues to comply with Sections 7.11(f), (g) and (h) and provided Borrower complies with Section 7.11(f), (g) and
(h) and there is no Event of Default at such time, such Property shall no longer constitute an Unencumbered Property for purposes hereof. 
 ARTICLE III. TAXES, YIELD PROTECTION AND ILLEGALITY 
 3.01 Taxes.

 (a) Payments Free of Taxes; Obligation to Withhold; Payments on Account of Taxes. 

(i) Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be made
without deduction or withholding for any Taxes, except as required by applicable Laws. If any applicable Laws (as determined in the good faith discretion of the Administrative Agent) require the deduction or withholding of any Tax from any such
payment by the Administrative Agent or a Loan Party, then the Administrative Agent or such Loan Party shall be entitled to make such deduction or withholding, upon the basis of the information and documentation to be delivered pursuant to subsection
(e) below. 
 (ii) If any Loan Party or the Administrative Agent shall be required by the Code to withhold
or deduct any Taxes, including both United States Federal backup withholding and withholding taxes, from any payment, then (A) the Administrative Agent shall withhold or make such deductions as are determined by the Administrative Agent to be
required based upon the information and documentation it has received pursuant to subsection (e) below, (B) the Administrative Agent shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance
with the Code, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any required withholding or the making of
all required deductions (including deductions applicable to additional sums payable under this Section 3.01) the applicable Recipient receives an amount equal to the sum it would have received had no such withholding or deduction been made.

 (iii) If any Loan Party or the Administrative Agent shall be required by any applicable Laws other than the
Code to withhold or deduct any Taxes from any payment, then (A) such Loan Party or the Administrative Agent, as required by such Laws, shall withhold or make such deductions as are determined by it to be required based upon the information and
documentation it has received pursuant to subsection (e) below, (B) such Loan Party or the Administrative Agent, to the extent required by such Laws, shall timely 

  

- 54 - 

 
pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with such Laws, and (C) to the extent that the withholding or deduction is made on account of
Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this
Section 3.01) the applicable Recipient receives an amount equal to the sum it would have received had no such withholding or deduction been made. 
 (b) Payment of Other Taxes by the Borrower. Without limiting the provisions of subsection (a) above, the Borrower shall timely pay to the relevant Governmental Authority in accordance with
applicable law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes. 
 (c)
Tax Indemnifications. (i) The Borrower shall, and does hereby, indemnify each Recipient, and shall make payment in respect thereof within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified
Taxes imposed or asserted on or attributable to amounts payable under this Section 3.01) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient, and any penalties, interest and reasonable
expenses arising therefrom or with respect thereto (other than any such penalties, interest or expenses incurred solely as the result of the gross negligence or willful misconduct of the Administrative Agent, such Lender or the L/C Issuer), whether
or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender or the L/C Issuer (with a copy to
the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender or the L/C Issuer, shall be conclusive absent demonstrable error. The Borrower shall, and does hereby, indemnify the Administrative Agent, and shall
make payment in respect thereof within 10 days after demand therefor, for any amount which a Lender or the L/C Issuer for any reason fails to pay indefeasibly to the Administrative Agent as required pursuant to Section 3.01(c)(ii) below.

 (ii) Each Lender and the L/C Issuer shall, and does hereby, severally indemnify, and shall make payment in
respect thereof within 10 days after demand therefor, (x) the Administrative Agent against any Indemnified Taxes attributable to such Lender or the L/C Issuer (but only to the extent that the Borrower has not already indemnified the
Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (y) the Administrative Agent and the Borrower, as applicable, against any Taxes attributable to such Lender’s failure to comply
with the provisions of Section 10.06(d) relating to the maintenance of a Participant Register and (z) the Administrative Agent and the Borrower, as applicable, against any Excluded Taxes attributable to such Lender or the L/C Issuer, in
each case, that are payable or paid by the Administrative Agent or the Borrower in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed
or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent demonstrable error. Each Lender and the L/C Issuer hereby
authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender or the L/C Issuer, as the case may be, under this Agreement or any other Loan Document against any amount due to the Administrative Agent
under this clause (ii). 

  

- 55 - 

 (d) Evidence of Payments. Upon request by the Borrower or the Administrative Agent,
as the case may be, after any payment of Taxes by the Borrower or by the Administrative Agent to a Governmental Authority as provided in this Section 3.01, the Borrower shall deliver to the Administrative Agent or the Administrative Agent shall
deliver to the Borrower, as the case may be, the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of any return required by Laws to report such payment or other evidence of such payment
reasonably satisfactory to the Borrower or the Administrative Agent, as the case may be. 
 (e) Status of Lenders; Tax
Documentation. 
 (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with
respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation
reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative
Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject
to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in
Section 3.01(e)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would
materially prejudice the legal or commercial position of such Lender. 
 (ii) Without limiting the generality of
the foregoing, in the event that the Borrower is a U.S. Person, 
 (A) any Lender that is a U.S. Person shall
deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent),
executed originals of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax; 
 (B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as described below or as shall be requested by
the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is
applicable: 

  

- 56 - 

 (I) in the case of a Foreign Lender claiming the benefits of an income tax
treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, two (2) properly completed and executed originals of IRS Form W-8BEN establishing an exemption from, or reduction of, U.S.
federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN establishing an exemption from, or reduction of, U.S. federal
withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty; 
 (II) two (2) properly completed and executed originals of IRS Form W-8ECI; 
 (III) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit H-1
to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a
“controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) two (2) properly completed and executed originals of IRS Form W-8BEN; or 

(IV) to the extent a Foreign Lender is not the beneficial owner, two (2) properly completed and executed originals
of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, a U.S. Tax Compliance Certificate substantially in the form of Exhibit H-2 or Exhibit H-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as
applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate
substantially in the form of Exhibit H-4 on behalf of each such direct and indirect partner; 
 (C) any Foreign
Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender
under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction
in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made;
and 

  

- 57 - 

 if a payment made to a Lender under any Loan Document would be subject to U.S. federal
withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the
Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by
Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under
FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any
amendments made to FATCA after the date of this Agreement. 
 (iii) Each Lender agrees that if any form or
certification it previously delivered pursuant to this Section 3.01 expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of
its legal inability to do so. 
 (f) Treatment of Certain Refunds. Unless required by applicable Laws, at no time shall
the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender or the L/C Issuer, or have any obligation to pay to any Lender or the L/C Issuer, any refund of Taxes withheld or deducted from funds paid for the
account of such Lender or the L/C Issuer, as the case may be. If any Recipient determines that it has received a refund of any Taxes as to which it has been indemnified by the Borrower or with respect to which the Borrower has paid additional
amounts pursuant to this Section 3.01, it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by the Borrower under this Section 3.01 with respect to the
Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by such Recipient, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that
the Borrower, upon the request of the Recipient, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Recipient in the event the Recipient is
required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this subsection, in no event will the applicable Recipient be required to pay any amount to the Borrower pursuant to this subsection the
payment of which would place the Recipient in a less favorable net after-Tax position than such Recipient would have been in if the indemnification payments or additional amounts giving rise to such refund had never been paid. This subsection shall
not be construed to require any Recipient to make available its tax returns (or any other information relating to its taxes that it deems confidential) to the Borrower or any other Person. 

(g) Survival. Each party’s obligations under this Section 3.01 shall survive the resignation or replacement of the
Administrative Agent or any assignment of rights by, or the replacement of, a Lender or the L/C Issuer, the termination of the Commitments and the repayment, satisfaction or discharge of all other Obligations. 

  

- 58 - 

 3.02 Illegality. If any Lender reasonably determines that any Law has made it
unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable Lending Office to make, maintain or fund Loans whose interest is determined by reference to the Eurodollar Rate, or to determine or
charge interest rates based upon the Eurodollar Rate, or any Governmental Authority has imposed material restrictions on the authority of such Lender to purchase or sell, or to take deposits of, Dollars in the London interbank market, provided that
such Lender has made a similar determination with respect to similarly situated borrowers, then, on notice thereof by such Lender to the Borrower through the Administrative Agent, (i) any obligation of such Lender to make or continue Eurodollar
Rate Loans or to convert Base Rate Committed Loans to Eurodollar Rate Loans shall be suspended, and (ii) if such notice asserts the illegality of such Lender making or maintaining Base Rate Loans the interest rate on which is determined by
reference to the Eurodollar Rate component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Eurodollar Rate
component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice, (x) the Borrower shall, upon
demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all Eurodollar Rate Loans of such Lender to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid
such illegality, be determined by the Administrative Agent without reference to the Eurodollar Rate component of the Base Rate), either on the last day of the Interest Period therefor, if such Lender may lawfully continue to maintain such Eurodollar
Rate Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Eurodollar Rate Loans (in which event no amounts will be due under Section 3.05) and (y) if such notice asserts the illegality of such Lender
determining or charging interest rates based upon the Eurodollar Rate, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Eurodollar Rate component thereof
until the Administrative is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon the Eurodollar Rate. Upon any such prepayment or conversion, the Borrower shall also pay
accrued interest on the amount so prepaid or converted. 
 3.03 Inability to Determine Rates. If the Required Lenders
reasonably determine that for any reason in connection with any request for a Eurodollar Rate Loan or a conversion to or continuation thereof and each Lender comprising the Required Lenders has made a similar determination with respect to other
similarly situated borrowers that (a) Dollar deposits are not being offered to banks in the London interbank eurodollar market for the applicable amount and Interest Period of such Eurodollar Rate Loan, (b) adequate and reasonable means do
not exist for determining the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan or in connection with an existing or proposed Base Rate Loan, or (c) the Eurodollar Rate for any requested Interest
Period with respect to a proposed Eurodollar Rate Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, the Administrative Agent will promptly so notify the Borrower and each Lender. Thereafter, (x) the
obligation of the Lenders to make or maintain Eurodollar Rate Loans shall be suspended, and (y) in the event of a determination described in the preceding sentence with respect to the Eurodollar Rate component of the Base Rate, the utilization
of the Eurodollar Rate component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (upon the instruction of the Required Lenders) revokes such notice. Upon receipt of such notice, the 

  

- 59 - 

 
Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of Eurodollar Rate Loans or, failing that, will be deemed to have converted such request into a request
for a Committed Borrowing of Base Rate Loans in the amount specified therein. 
 3.04 Increased Costs; Reserves on Eurodollar
Rate Loans. 
 (a) Increased Costs Generally. If any Change in Law shall: 

(i) impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar
requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement contemplated by Section 3.04(e); 

(ii) subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses
(b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital
attributable thereto; or 
 (iii) impose on any Lender or the L/C Issuer or the London interbank market any other
condition, cost or expense affecting this Agreement or Eurodollar Rate Loans made by such Lender or any Letter of Credit or participation therein; 
 and the result of any of the foregoing shall be to increase the cost to such Lender of making or maintaining any Loan the interest on which is determined by reference to the Eurodollar Rate (or of
maintaining its obligation to make any such Loan), or to increase the cost to such Lender or the L/C Issuer of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter
of Credit), or to reduce the amount of any sum received or receivable by such Lender or the L/C Issuer hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or the L/C Issuer, the Borrower will pay to such
Lender or the L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L/C Issuer, as the case may be, for such additional costs incurred or reduction suffered; provided, however, that such
Lender’s or the LC Issuer’s determination of any such amounts assessed against the Borrower shall be consistent with the determination of amounts assessed against other (but not necessarily all) borrowers that are similarly situated to the
Borrower. 
 (b) Capital Requirements. If any Lender or the L/C Issuer determines that any Change in Law affecting such
Lender or the L/C Issuer or any Lending Office of such Lender or such Lender’s or the L/C Issuer’s holding company, if any, regarding capital requirements has or would have the effect of reducing the rate of return on such Lender’s or
the L/C Issuer’s capital or on the capital of such Lender’s or the L/C Issuer’s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by, or participations in Letters of Credit
held by, such Lender, or the Letters of Credit issued by the L/C Issuer, to a level below that which such Lender or the L/C Issuer or such Lender’s or the L/C Issuer’s holding company could have achieved but for such Change in Law (taking
into consideration such Lender’s or the L/C Issuer’s policies and the policies of such Lender’s or the L/C Issuer’s holding company with respect to capital adequacy), then from time to time the Borrower will pay

  

- 60 - 

 
to such Lender or the L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or the L/C Issuer or such Lender’s or the L/C Issuer’s holding
company for any such reduction suffered. The L/C Issuer and each Lender agrees that, in the event that it submits any demand for payment under this Section 3.04(b) it shall, as part of making such demand, have made a good faith determination
(which determination shall be conclusive) that it is concurrently making similar demands of other (but not necessarily all) customers similarly situated. 
 (c) Certificates for Reimbursement. A certificate of a Lender or the L/C Issuer setting forth the amount or amounts necessary to compensate such Lender or the L/C Issuer or its holding company, as
the case may be, as specified in subsection (a) or (b) of this Section and delivered to the Borrower shall be conclusive absent demonstrable error. Subject to Section 3.04(d) below, the Borrower shall pay such Lender or the L/C
Issuer, as the case may be, the amount shown as due on any such certificate within 10 days after receipt thereof. 
 (d)
Delay in Requests. Failure or delay on the part of any Lender or the L/C Issuer to demand compensation pursuant to the foregoing provisions of this Section shall not constitute a waiver of such Lender’s or the L/C Issuer’s right to
demand such compensation, provided that the Borrower shall not be required to compensate a Lender or the L/C Issuer pursuant to the foregoing provisions of this Section for any increased costs incurred or reductions suffered more than six
months prior to the date that such Lender or the L/C Issuer, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s or the L/C Issuer’s intention to claim
compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the six-month period referred to above shall be extended to include the period of retroactive effect thereof).

 (e) Reserves on Eurodollar Rate Loans. The Borrower shall pay to each Lender, as long as such Lender shall be required
to maintain reserves with respect to liabilities or assets consisting of or including Eurocurrency funds or deposits (currently known as “Eurocurrency liabilities”), additional interest on the unpaid principal amount of each Eurodollar
Rate Loan equal to the actual costs of such reserves allocated to such Loan by such Lender (as determined by such Lender in good faith, which determination shall be binding absent demonstrable error), which shall be due and payable on each date on
which interest is payable on such Loan, provided the Borrower shall have received at least 10 days’ prior notice (with a copy to the Administrative Agent) of such additional interest from such Lender. If a Lender fails to give notice 10 days
prior to the relevant Interest Payment Date, such additional interest shall be due and payable 10 days from receipt of such notice, provided the period for which such interest is due shall not be more than ninety days prior to such notice.

 3.05 Compensation for Losses. Upon demand of any Lender (with a copy to the Administrative Agent) from time to time,
the Borrower shall promptly compensate such Lender for and hold such Lender harmless from any out-of-pocket loss, cost or expense incurred by it as a result of: 
 (a) any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory,
automatic, by reason of acceleration, or otherwise); 

  

- 61 - 

 (b) any failure by the Borrower (for a reason other than the failure of such Lender to make
a Loan) to prepay, borrow, continue or convert any Loan other than a Base Rate Loan on the date or in the amount notified by the Borrower; or 
 (c) any assignment of a Eurodollar Rate Loan on a day other than the last day of the Interest Period therefor as a result of a request by the Borrower pursuant to Section 10.13; 

including any loss or expense arising from the liquidation or reemployment of funds obtained by it to maintain such Loan or from fees payable to
terminate the deposits from which such funds were obtained but excluding any loss of anticipated profits. The Borrower shall also pay any customary administrative fees charged by such Lender in connection with the foregoing. 

For purposes of calculating amounts payable by the Borrower to the Lenders under this Section 3.05, each Lender shall be deemed to have
funded each Eurodollar Rate Loan made by it at the Eurodollar Rate for such Loan by a matching deposit or other borrowing in the London interbank eurodollar market for a comparable amount and for a comparable period, whether or not such Eurodollar
Rate Loan was in fact so funded. 
 3.06 Mitigation Obligations; Replacement of Lenders. 

(a) Designation of a Different Lending Office. If any Lender requests compensation under Section 3.04, or the Borrower
is required to pay any additional amount to any Lender, the L/C Issuer, or any Governmental Authority for the account of any Lender or the L/C Issuer pursuant to Section 3.01, or if any Lender gives a notice pursuant to
Section 3.02, then such Lender or the L/C Issuer shall, as applicable, use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another
of its offices, branches or affiliates, if, in the reasonable judgment of such Lender or the L/C Issuer, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 3.01 or 3.04, as the
case may be, in the future, or eliminate the need for the notice pursuant to Section 3.02, as applicable, and (ii) in each case, would not subject such Lender or the L/C Issuer, as the case may be, to any unreimbursed cost or
expense and would not otherwise be disadvantageous to such Lender or the L/C Issuer, as the case may be. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender or the L/C Issuer in connection with any such
designation or assignment. 
 (b) Replacement of Lenders. If any Lender requests compensation under
Section 3.04, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, the Borrower may replace such Lender in accordance
with Section 10.13. 
 3.07 Survival. All of the Borrower’s obligations under this Article III
shall survive termination of the Aggregate Commitments, repayment of all other Obligations hereunder, and resignation of the Administrative Agent. 
 ARTICLE IV. CONDITIONS PRECEDENT TO CREDIT EXTENSIONS 
 4.01 Conditions
of Initial Credit Extension. The obligation of the L/C Issuer and each Lender to make its initial Credit Extension hereunder is subject to satisfaction of the following conditions precedent: 

  

- 62 - 

 (a) The Administrative Agent’s receipt of the following, each of which shall be
originals or pdf copies (followed promptly by originals) unless otherwise specified, each properly executed by a Responsible Officer of the signing Loan Party, each dated the Closing Date (or, in the case of certificates of governmental officials, a
recent date before the Closing Date) and each in form and substance reasonably satisfactory to the Administrative Agent: 
 (i) executed counterparts of this Agreement and the Guaranty, sufficient in number for distribution to the Administrative Agent, each Lender and the Borrower; 

(ii) a Note executed by the Borrower in favor of each Lender requesting a Note; 

(iii) such certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible
Officers of each Loan Party as the Administrative Agent may reasonably require evidencing the identity, authority and capacity of each Responsible Officer thereof authorized to act as a Responsible Officer in connection with this Agreement and the
other Loan Documents to which such Loan Party is a party; 
 (iv) such documents and certifications as the
Administrative Agent may reasonably require to evidence that each Loan Party is duly organized or formed, and that each of the Borrower and the Trust is validly existing, in good standing and qualified to engage in business in its jurisdiction of
organization; 
 (v) a favorable opinion of counsel to the Loan Parties, addressed to the Administrative Agent
and each Lender, as to the matters set forth in Exhibit H and such other matters concerning the Loan Parties and the Loan Documents as the Required Lenders may reasonably request; 

(vi) a certificate of a Responsible Officer of each Loan Party either (A) attaching copies of all consents, licenses
and approvals required in connection with the execution, delivery and performance by such Loan Party and the validity against such Loan Party of the Loan Documents to which it is a party, and such consents, licenses and approvals shall be in full
force and effect, or (B) stating that no such consents, licenses or approvals are so required; 
 (vii) a
certificate signed by a Responsible Officer of the Borrower certifying (A) that the conditions specified in Sections 4.02(a) and (b) have been satisfied, (B) that there has been no event or circumstance since the date of
the Audited Financial Statements that has had or would be reasonably expected to have, either individually or in the aggregate, a Material Adverse Effect and (C) a calculation of the Consolidated Leverage Ratio as of the last day of the fiscal
quarter of the Borrower most recently ended prior to the Closing Date; 
 (viii) a duly completed Compliance
Certificate as of the last day of the fiscal quarter of the Borrower ended on June 30, 2012, signed by a Responsible Officer of the Borrower; 
 (ix) evidence that the Existing Credit Agreement has been or concurrently with the Closing Date is being terminated; and 

  

- 63 - 

 (x) such other assurances, certificates, documents, consents or opinions as
the Administrative Agent, the L/C Issuer, the Swing Line Lender or the Required Lenders reasonably may reasonably require. 

(b) Any fees required to be paid to the Administrative Agent or any Lender in connection with this Agreement on or before the Closing
Date shall have been paid. 
 (c) Unless waived by the Administrative Agent, the Borrower shall have paid all reasonable and
documented fees, charges and disbursements of counsel to the Administrative Agent (directly to such counsel if requested by the Administrative Agent) to the extent invoiced prior to or on the date that is three Business Days prior to the Closing
Date, plus such additional amounts of such fees, charges and disbursements as shall constitute its reasonable estimate of such fees, charges and disbursements incurred or to be incurred by it through the closing proceedings (provided that
such estimate shall not thereafter preclude a final settling of accounts between the Borrower and the Administrative Agent). 

Without limiting the generality of the provisions of the last paragraph of Section 9.03, for purposes of determining
compliance with the conditions specified in this Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required
thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto. 

4.02 Conditions to all Credit Extensions. The obligation of each Lender to honor any Request for Credit Extension (other than a
Committed Loan Notice requesting only a conversion of Committed Loans to the other Type, or a continuation of Eurodollar Rate Loans) is subject to the following conditions precedent: 

(a) The representations and warranties of the Borrower and each other Loan Party contained in Article V or any other Loan Document,
or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects on and as of the date of such Credit Extension, except to the extent that such
representations and warranties specifically refer to an earlier date, in which case they shall have been true and correct in all material respects as of such earlier date, and except that for purposes of this Section 4.02, the
representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of
Section 6.01. 
 (b) No Default shall exist, or would result from such proposed Credit Extension or from the
application of the proceeds thereof. 
 (c) The Administrative Agent and, if applicable, the L/C Issuer or the Swing Line Lender
shall have received a Request for Credit Extension in accordance with the requirements hereof. 
 Each Request for Credit
Extension (other than a Committed Loan Notice requesting only a conversion of Committed Loans to the other Type or a continuation of Eurodollar Rate Loans) submitted by the Borrower shall be deemed to be a representation and warranty that the
conditions specified in Sections 4.02(a) and (b) have been satisfied on and as of the date of the applicable Credit Extension. 

  

- 64 - 

 ARTICLE V. REPRESENTATIONS AND WARRANTIES 

The Borrower represents and warrants to the Administrative Agent and the Lenders that: 

5.01 Existence, Qualification and Power. Each Loan Party (a) is duly organized or formed, validly existing and, as
applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own or
lease its assets and carry on its business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party, and (c) is duly qualified and is licensed and, as applicable, in good standing under the Laws
of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license; except in each case referred to in clause (b)(i) or (c), to the extent that failure to do so would not
reasonably be expected to have a Material Adverse Effect. 
 5.02 Authorization; No Contravention. The execution,
delivery and performance by each Loan Party of each Loan Document to which such Person is party, have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of
such Person’s Organization Documents; (b) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (i) any Contractual Obligation to which such Person is a
party or affecting such Person or the properties of such Person or any of its Subsidiaries or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject, the
conflict or breach of which under the foregoing clauses (i) and/or (ii) would reasonably be expected to have a Material Adverse Effect; or (c) violate any Law. 
 5.03 Governmental Authorization; Other Consents. No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is
necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document, except with respect to notices which have already been given or where the
failure to obtain any of the foregoing would not have a Material Adverse Effect. 
 5.04 Binding Effect. This Agreement
has been, and each other Loan Document, when delivered hereunder, will have been, duly executed and delivered by each Loan Party that is party thereto. This Agreement constitutes, and each other Loan Document when so delivered will constitute, a
legal, valid and binding obligation of such Loan Party, enforceable against each Loan Party that is party thereto in accordance with its terms. 
 5.05 Financial Statements; No Material Adverse Effect. 
 (a) The Audited
Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; and (ii) fairly present, in all material respects, the financial
condition of the Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly
noted therein. 

  

- 65 - 

 (b) The unaudited consolidated balance sheets of the Trust and its Subsidiaries dated
June 30, 2012, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for the fiscal quarter ended on that date (i) were prepared in accordance with GAAP consistently applied throughout
the period covered thereby, except as otherwise expressly noted therein, and (ii) fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of operations for
the period covered thereby, subject, in the case of clauses (i) and (ii), to the absence of footnotes and to normal year-end audit adjustments. 
 (c) Since the date of the Audited Financial Statements, there has been no event or circumstance, either individually or in the aggregate, that has had a Material Adverse Effect. 

5.06 Litigation. There are no actions, suits, proceedings, claims or disputes pending or, to the knowledge of the Borrower after
due and diligent investigation, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against the Borrower or any of its Subsidiaries or against any of their properties or revenues that
(a) purport to affect or pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby, or (b) except as specifically disclosed in Schedule 5.06, either individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect. 
 5.07 No Default. Neither any Loan Party nor any Subsidiary
thereof is in default under or with respect to any Contractual Obligation that would, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No Default has occurred and is continuing or would result from
the consummation of the transactions contemplated by this Agreement or any other Loan Document. 
 5.08 Ownership of
Property; Liens. Each of the Borrower and each Subsidiary has good record and marketable title in fee simple to, or valid leasehold interests in, all real property material to its business, except for such defects in title as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No Unencumbered Property is subject to any Liens, other than Liens permitted by Section 7.01. 

5.09 Environmental Compliance. The Borrower and its Subsidiaries normally conduct, prior to the acquisition of any Property, a
customary review of the effect of existing Environmental Laws and claims alleging potential liability or responsibility for violation of any Environmental Law on such Property, and as a result thereof the Borrower has reasonably concluded that such
Environmental Laws and claims would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 5.10 Taxes. The Borrower and its Subsidiaries have filed all Federal, state and other material tax returns and reports required to be filed, and have paid all Federal, state and other material
taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except (a) those which are being contested in good faith by appropriate proceedings diligently
conducted and for which adequate reserves have been provided in accordance with GAAP, or (b) to the extent that the failure to do so would not reasonably be expected to result in a Material Adverse Effect. 

  

- 66 - 

 5.11 ERISA Compliance. 

(a) Except as would not reasonably be expected to result in a Material Adverse Effect, (i) each Pension Plan is in compliance in all
material respects with the applicable provisions of ERISA, the Code and other Federal or state laws and (ii) each Pension Plan that is intended to be a qualified plan under Section 401(a) of the Code has received a favorable determination,
opinion or advisory letter from the Internal Revenue Service to the effect that the form of such Pension Plan is qualified under Section 401(a) of the Code and the trust related thereto has been determined by the Internal Revenue Service to be
exempt from federal income tax under Section 501(a) of the Code, or an application for such a letter is currently being processed by, or shall be timely submitted to, the Internal Revenue Service, and, to the best knowledge of the Borrower,
nothing has occurred that would prevent or cause the loss of such tax-qualified status. 
 (b) There are no pending or, to the
knowledge of the Borrower, threatened claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Pension Plan that would reasonably be expected to have a Material Adverse Effect. There has been no prohibited
transaction or violation of the fiduciary responsibility rules with respect to any Pension Plan that has resulted or would reasonably be expected to result in a Material Adverse Effect. 

(c) Except as would not be reasonably by expected to result in a Material Adverse Effect, (i) no ERISA Event has occurred, and
neither the Borrower nor any ERISA Affiliate is aware of any fact, event or circumstance that would reasonably be expected to constitute or result in an ERISA Event with respect to any Pension Plan; (ii) the Borrower and each ERISA Affiliate
has met all applicable requirements under the Pension Funding Rules in respect of each Pension Plan, and no waiver of the minimum funding standards under the Pension Funding Rules has been applied for or obtained; (iii) as of the most recent
valuation date for any Pension Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is 60% or higher and neither the Borrower nor any ERISA Affiliate knows of any facts or circumstances that could
reasonably be expected to cause the funding target attainment percentage for any such plan to drop below 60% as of the most recent valuation date; (iv) neither the Borrower nor any ERISA Affiliate has incurred any liability to the PBGC other
than for the payment of premiums, and there are no premium payments which have become due that are unpaid; (v) neither the Borrower nor any ERISA Affiliate has engaged in a transaction that could be subject to Section 4069 or
Section 4212(c) of ERISA; and (vi) no Pension Plan has been terminated by the plan administrator thereof nor by the PBGC, and no event or circumstance has occurred or exists that would reasonably be expected to cause the PBGC to institute
proceedings under Title IV of ERISA to terminate any Pension Plan. 
 5.12 Subsidiaries; Equity Interests. As of the
Closing Date, Schedule 5.12 sets forth the owners of outstanding Equity Interests in each Subsidiary Guarantor and such Equity Interests have been validly issued, are fully paid and nonassessable and are owned by such Subsidiary Guarantor free and
clear of all Liens, other than Permitted Liens. A majority of the Equity Interests in Borrower are owned by the Trust. 

  

- 67 - 

 5.13 Margin Regulations; Investment Company Act. 

(a) The Borrower is not engaged and will not engage, principally or as one of its important activities, in the business of purchasing or
carrying margin stock (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock. Following the application of the proceeds of each Borrowing or drawing under each Letter of
Credit, not more than 25% of the value of the assets (either of the Borrower only or of the Borrower and its Subsidiaries on a consolidated basis) subject to the provisions of Section 7.01 or subject to any restriction contained in any
agreement or instrument between the Borrower and any Lender or any Affiliate of any Lender relating to Indebtedness and within the scope of Section 8.01(e) will be margin stock. 

(b) None of the Borrower, any Person Controlling the Borrower, or any Subsidiary is or is required to be registered as an
“investment company” under the Investment Company Act of 1940. 
 5.14 Disclosure. The Borrower has disclosed
to the Administrative Agent and the Lenders all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, individually or in the aggregate, would
reasonably be expected to result in a Material Adverse Effect. The reports, financial statements, certificates and other information furnished in writing by or on behalf of any Loan Party to the Administrative Agent or any Lender in connection with
the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or under any other Loan Document (in each case, as modified or supplemented by other information so furnished), taken as a whole, do not contain any
material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial
information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being recognized by the Administrative Agent and the Lenders that actual results during the
period or periods covered by any such projections and forecasts may differ from the projected or forecasted results and the differences may be material). 
 5.15 Compliance with Laws. Each Loan Party and each Subsidiary thereof is in compliance in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees
applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure
to comply therewith, either individually or in the aggregate, with respect to all such non-compliance by all such Subsidiaries would not reasonably be expected to have a Material Adverse Effect. 

5.16 Taxpayer Identification Number. The Borrower’s true and correct U.S. taxpayer identification number is set forth on
Schedule 10.02. 
 5.17 Intellectual Property; Licenses, Etc. The Borrower and its Subsidiaries own, or are
licensed to use, all of the trademarks, service marks, trade names, copyrights, patents, patent rights, franchises, licenses and other intellectual property rights (collectively, “IP Rights”) that are material to their respective
businesses, except where the failure would not reasonably be 

  

- 68 - 

 
expected to have a Material Adverse Effect. To the best knowledge of the Borrower, no slogan or other advertising device, product, process, method, substance, part or other material now employed,
or now contemplated to be employed, by the Borrower or any Subsidiary infringes upon any rights held by any other Person, except for any infringement that individually or in the aggregate would not reasonably be expected to result in a Material
Adverse Effect. 
 5.18 REIT Status. The Trust is qualified to elect or has elected status as a real estate investment
trust under Section 856 of the Code and currently is in compliance in all material respects with all provisions of the Code applicable to the qualification of the Trust as a real estate investment trust. 

5.19 Unencumbered Properties. Schedule 5.19 hereto contains a complete and accurate description of Unencumbered Properties
designated by the Borrower to constitute Unencumbered Properties hereunder as of the Closing Date and as supplemented from time to time in connection with the delivery of a Compliance Certificate pursuant to Section 6.01(c) hereof or as set
forth in Section 2.19 and upon the inclusion or removal of a Property as an Unencumbered Property for purposes of the financial covenants contained in Section 7.11, including the entity that owns each Unencumbered Property. With respect to
each Property identified from time to time as an Unencumbered Property, Borrower hereby represents and warrants as follows except to the extent disclosed in writing to the Lenders and approved by the Required Lenders (which approval shall not be
unreasonably withheld): 
 (a) No portion of any improvement on the Unencumbered Property is located in an area identified by the
Secretary of Housing and Urban Development or any successor thereto as an area having special flood hazards pursuant to the National Flood Insurance Act of 1968 or the Flood Disaster Protection Act of 1973, as amended, or any successor law, or, if
located within any such area, Borrower or the applicable Subsidiary, to the extent the same is available on commercially reasonable terms, has obtained and will maintain insurance coverage for flood and other water damage in the amount of the
replacement cost of the improvements at the Unencumbered Property. 
 (b) To the Borrower’s knowledge, the Unencumbered
Property and the present use and occupancy thereof are in material compliance with all applicable zoning ordinances (without reliance upon adjoining or other properties), building codes, land use and Environmental Laws (“Applicable Laws”).

 (c) The Unencumbered Property is served by all utilities required for the current use thereof. All utility service is provided
by public utilities and the Unencumbered Property has accepted or is equipped to accept such utility service. 
 (d) Except with
respect to Assets Under Development, all public roads and streets necessary for service of and access to the Unencumbered Property for the current use thereof have been completed, are serviceable and all-weather and are physically and legally open
for use by the public. 
 (e) The Unencumbered Property is served by public water and sewer systems or, if the Unencumbered
Property is not serviced by a public water and sewer system, such alternate systems are adequate and meet, in all material respects, all requirements and regulations of, and otherwise complies in all material respects with, all Applicable Laws with
respect to such alternate systems. 

  

- 69 - 

 (f) Borrower is not aware of any material latent or patent structural defect in the
Unencumbered Property. The Unencumbered Property is free of damage and waste that would materially and adversely affect the value of the Unencumbered Property (other than any casualty loss being handled in accordance with the Loan Documents or
condemnation proceedings being handled in accordance with Loan Documents) and is in adequate repair for its intended use. The Unencumbered Property is free from material damage caused by fire or other casualty (other than any casualty loss being
handled in accordance with the Loan Documents). There is no pending or, to the actual knowledge of Borrower, threatened condemnation proceedings affecting the Unencumbered Property, or any material part thereof. 

(g) To Borrower’s knowledge, all liquid and solid waste disposal, septic and sewer systems located on the Unencumbered Property are
in a condition and repair adequate for its intended use and, to Borrower’s knowledge, in material compliance with all Applicable Laws with respect to such systems. 
 (h) All improvements on the Unencumbered Property lie within the boundaries and building restrictions of the legal description of record of the Unencumbered Property other than encroachments that do not
materially adversely affect the use or occupancy of the Unencumbered Property, no such improvements encroach upon easements benefiting the Unencumbered Property other than encroachments that do not materially adversely affect the use or occupancy of
the Unencumbered Property and no improvements on adjoining properties encroach upon the Unencumbered Property or easements benefiting the Unencumbered Property other than encroachments that do not materially adversely affect the use or occupancy of
the Unencumbered Property. All access routes that materially benefit the Unencumbered Property are available to Borrower or the applicable Subsidiary of the Borrower, constitute permanent easements that benefit all or part of the Unencumbered
Property or are public property, and the Unencumbered Property, by virtue of such easements or otherwise, is contiguous to a physically open, dedicated all weather public street, and has any necessary permits for ingress and egress. 

(i) There are no material delinquent taxes, ground rents, water charges, sewer rents, assessments, insurance premiums, leasehold payments,
or other outstanding charges affecting the Unencumbered Property except to the extent such items are being contested in good faith and as to which adequate reserves have been provided. 

(j) Each Unencumbered Property satisfies each of the requirements set forth in the definition of “Unencumbered Property”.

 A breach of any of the representations and warranties contained in this Section 5.19 with respect to a Property shall
disqualify such Property from being an Unencumbered Property for so long as such breach continues (unless otherwise approved by the Required Lenders) but shall not constitute a Default (unless the elimination of such Property as an Unencumbered
Property results in a Default under one of the other provisions of this Agreement). 

  

- 70 - 

 ARTICLE VI. AFFIRMATIVE COVENANTS 

So long as any Lender shall have any Commitment hereunder, any Loan or other Obligation (other than unasserted contingent indemnification
obligations) hereunder shall remain unpaid or unsatisfied, or any Letter of Credit shall remain outstanding, the Borrower shall, and shall (except in the case of the covenants set forth in Sections 6.01, 6.02, and 6.03) cause
each Subsidiary to: 
 6.01 Financial Statements and Other Information. The Borrower will furnish to the Administrative
Agent and each Lender: 
 (a) As soon as available, but in any event not later than 120 days after the close of each fiscal year,
for the Consolidated Group, audited financial statements, including a consolidated balance sheet as at the end of such year and the related consolidated statements of income and retained earnings and of cash flows for such year, setting forth in
each case in comparative form the figures for the previous year, without a “going concern” or like qualification or exception, or qualification arising out of the scope of the audit, prepared by KPMG LLC or other independent certified
public accountants of nationally recognized standing; 
 (b) As soon as available, but in any event not later than 60 days after
the close of each of the first three fiscal quarters and not later than 90 days after the close of the last fiscal quarter of any fiscal year, for the Consolidated Group, an unaudited internally prepared consolidated balance sheet as of the close of
each such period and the related unaudited internally prepared consolidated statements of income and retained earnings and of cash flows of the Consolidated Group for such period and the portion of the fiscal year through the end of such period,
setting forth in each case in comparative form the figures for the previous year, all certified by the Borrower’s chief financial officer or chief accounting officer; 
 (c) concurrently with any delivery of financial statements under clause (a) or (b) above, a Compliance Certificate (i) certifying as to whether a Default has occurred and, if a Default has
occurred, specifying the details thereof and any action taken or proposed to be taken with respect thereto, (ii) setting forth reasonably detailed calculations demonstrating whether the Borrower is in compliance with Sections 7.06 and 7.11,
including an update of Schedule 5.19 listing all of the Unencumbered Properties as of such date, and (iii) stating whether any material change in GAAP or in the application thereof has occurred since the date of the audited financial statements
referred to in Section 5.05 and, if any such change has occurred, specifying the effect of such change on the financial statements accompanying such certificate; 
 (d) concurrently with the quarterly financial statements required under (b) above, a schedule of the Unencumbered Properties comprising the Total Unencumbered Property Pool Value, summarizing total
revenues, expenses, and Unencumbered Property NOI. 
 (e) promptly following any request thereafter, copies of all periodic and
regular reports, registration statements (without exhibits unless expressly requested by Administrative Agent) and prospectuses and all amendments thereto filed by the Trust, the Borrower or any Subsidiary with the SEC, or any Governmental Authority
succeeding to any or all of the functions of the SEC, or with any national securities exchange, or distributed by the Trust to its shareholders generally, as the case may be; and 

  

- 71 - 

 (f) promptly following any request therefor, such other information regarding the
operations, business affairs and financial condition of the Trust, the Borrower or any Subsidiary, or compliance with the terms of this Agreement, pursuant to a reasonable and customary request from the Administrative Agent or any Lender.

 The Borrower may, in its sole discretion, satisfy its obligations under Sections 6.01(a) and (b) by filing with the SEC
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and such other reports on other forms as may be appropriate at such times and in accordance with the SEC’s rules and the instructions accompanying such forms. 

Documents required to be delivered pursuant to Section 6.01(a) or (b) or Section 6.01(e) (to the
extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Borrower posts such documents, or
provides a link thereto on the Borrower’s website on the Internet at the website address listed on Schedule 10.02; or (ii) on which such documents are posted on the Borrower’s behalf on an Internet or intranet website, if any,
to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent); provided that: (i) the Borrower shall deliver paper copies of such documents to
the Administrative Agent or any Lender upon its request to the Borrower to deliver such paper copies until a written request to cease delivering paper copies is given by the Administrative Agent or such Lender and (ii) the Borrower shall notify
the Administrative Agent and each Lender (by telecopier or electronic mail) of the posting of any such documents and provide to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents. The
Administrative Agent shall have no obligation to request the delivery of or to maintain paper copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower with any such request by a
Lender for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents. 
 6.02 Notices. Promptly notify the Administrative Agent and each Lender: 

(a) of the occurrence of any Default; 
 (b) of any matter that has resulted in a Material Adverse Effect, including (i) breach or non-performance of, or any default under, a Contractual Obligation of the Borrower or any Subsidiary;
(ii) any dispute, litigation, investigation, proceeding or suspension between the Borrower or any Subsidiary and any Governmental Authority; or (iii) the commencement of, or any material development in, any litigation or proceeding
affecting the Borrower or any Subsidiary, including pursuant to any applicable Environmental Laws; 
 (c) of the occurrence of
any ERISA Event that would reasonably be expected to result in a Material Adverse Effect; and 
 (d) of any material change in
accounting policies or financial reporting practices by the Borrower or any Subsidiary. 

  

- 72 - 

 Each notice pursuant to this Section 6.02 shall be accompanied by a statement of
a Responsible Officer of the Borrower setting forth details of the occurrence referred to therein and stating what action the Borrower has taken and proposes to take with respect thereto. Each notice pursuant to Section 6.02(a) shall
describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached. 

6.03 Payment of Taxes. Pay and discharge as the same shall become due and payable all tax liabilities, assessments and
governmental charges or levies upon it or its properties or assets, unless (a) the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the
Borrower or such Subsidiary or (b) the failure to do so would not have a Material Adverse Effect. 
 6.04 Preservation
of Existence, Etc. (a) Preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its organization except in a transaction permitted by Section 7.04;
(b) take all reasonable action to maintain all rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that failure to do so would not reasonably be expected to
have a Material Adverse Effect; and (c) preserve or renew all of its registered patents, trademarks, trade names and service marks, the non-preservation of which would reasonably be expected to have a Material Adverse Effect. 

6.05 Maintenance of Properties. Maintain, preserve and protect all of its material properties and equipment necessary in the
operation of its business in good working order and condition, ordinary wear and tear excepted; provided that this Section shall not prevent the Borrower or any Subsidiary from discontinuing the operation and the maintenance of any of its properties
if such discontinuance is desirable in the conduct of its business and the Borrower has concluded that such discontinuance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

6.06 Maintenance of Insurance. Maintain with insurance companies not Affiliates of the Borrower that the Borrower reasonably
believes to be financially sound and reputable, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such
amounts as are customarily carried under similar circumstances by such other Persons. 
 6.07 Compliance with Laws.
Comply in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which (a) such requirement of Law or order, writ,
injunction or decree is being contested in good faith by appropriate proceedings diligently conducted; or (b) the failure to comply therewith would not reasonably be expected to have a Material Adverse Effect. 

6.08 Books and Records. Maintain proper books of record and account, in which full, true and correct entries in conformity with
GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of the Borrower or such Subsidiary, as the case may be. 

  

- 73 - 

 6.09 Inspection Rights. Permit representatives and independent contractors of the
Administrative Agent and each Lender to visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its
directors, officers, and independent public accountants (provided the Borrower is given the opportunity to be present for such discussions), all at such reasonable times during normal business hours and as often as may be reasonably desired, upon
reasonable advance notice to the Borrower; provided, however, that unless an Event of Default exists the Borrower shall not be required to pay for such inspection. 

6.10 Use of Proceeds and Letters of Credit. The Letters of Credit and the proceeds of the Loans will be used only for general
business purposes of the Borrower (including, but not limited to debt refinancing, property acquisitions, new construction, renovations, expansions, tenant improvement, refinancing of existing lines, financing acquisition of Permitted Investments,
and closing costs and equity investments primarily associated with commercial real estate property acquisitions or refinancings). No part of the proceeds of any Loan will be used, whether directly or indirectly, for any purpose that entails a
violation of any of the Regulations of the FRB, including Regulations T, U and X. 
 6.11 REIT Status. The Trust will at
all times comply with all applicable provisions of the Code necessary to allow the Trust to qualify for status as a real estate investment trust. 
 6.12 Subsidiary Guarantees. The Borrower shall cause each of its Subsidiaries that owns a Property that is included as an Unencumbered Property and so designated by Borrower for purposes of
determining Borrower’s compliance with the financial covenants contained in this Agreement to execute and deliver to the Administrative Agent the Subsidiary Guaranty as required under Article IV above. No Subsidiary Guarantor may be a guarantor
of the KeyBank Line of Credit. For any Property added to the pool of Unencumbered Properties after the date hereof, Borrower shall cause the Subsidiary owning such Unencumbered Property to execute and deliver to the Administrative Agent, on or prior
to the date that such Property is included as an Unencumbered Property for purposes of determining Borrower’s compliance with the financial covenants contained in this Agreement, a joinder in the Subsidiary Guaranty, together with supporting
organizational and authority documents and opinions similar to those provided with respect to the Borrower and the initial Subsidiary Guarantors under Section 4.01. 
 A Subsidiary shall be automatically released from its obligations under the Subsidiary Guaranty if (i) there is no Event of Default (or event which, upon expiration of an applicable cure period, will
become an Event of Default), and (ii) Borrower delivers an updated Compliance Certificate to Administrative Agent demonstrating compliance with all financial covenants contained in Section 7.11(f), (g) and (h) of this Agreement
without such Subsidiary being included as the owner of an Unencumbered Property in the calculation of Borrower’s compliance with any of the foregoing covenants pertaining to Unencumbered Properties, and representing and warranting that based on
the information as of the end or the prior quarter, but without counting the Unencumbered Property owned by the Subsidiary Guarantor being released as an Unencumbered Property, Borrower will continue to comply with all of the financial covenants in
this Agreement upon release of such Subsidiary Guarantor. Subject to the foregoing, the Administrative Agent shall, from time to time, upon request from the Borrower, execute and deliver to the Borrower a written acknowledgement that a Subsidiary
has been released from its obligations under the Subsidiary Guaranty and the Lenders and the L/C Issuer hereby authorize the Administrative Agent to deliver such acknowledgement. 

  

- 74 - 

 ARTICLE VII. NEGATIVE COVENANTS 

So long as any Lender shall have any Commitment hereunder, any Loan or other Obligation (other than unasserted contingent indemnification
obligations) hereunder shall remain unpaid or unsatisfied, or any Letter of Credit shall remain outstanding, the Borrower shall not, nor shall it permit the Trust or any Subsidiary to, directly or indirectly: 

7.01 Liens. Create, incur, assume or suffer to exist any Lien upon any Unencumbered Property, whether now owned or hereafter
acquired, other than Permitted Encumbrances. 
 7.02 Investments. Make any Investments other than industrial Properties
and Cash and Cash Equivalents and deposit accounts and securities accounts maintained in the ordinary course of business, except that an aggregate 30% of Total Asset Value, subject to individual limits set forth below, may be invested in the
following categories of assets: 
 (a) Ownership of unimproved land on which no material improvements have been commenced up to
5% of Total Asset Value 
 (b) Investments in Unconsolidated Affiliates (including real estate funds or privately held companies)
up to 20% of total Asset Value which may be increased to 25% of Total Asset Value with approval of the Required Lenders; 
 (c)
Ownership of non-industrial Properties up to 10% of Total Asset Value 
 (d) Debt Investments (including mezzanine debt and
mortgage notes) up to 5% of Total Asset Value; and 
 (e) Ownership of Assets Under Development (which for this purpose shall be
the book value plus the budgeted cost to complete) up to 10% of Total Asset Value. 
 In the event that any Investments exceed the maximum
amounts set forth above, such excess Investments shall not constitute an Event of Default but shall be excluded from the calculation of the financial covenants in Section 7.11. 

7.03 INTENTIONALLY DELETED. 
 7.04 Fundamental Changes. Merge, dissolve, liquidate, consolidate with or into another Person, or Dispose of (whether in one transaction or in a series of transactions) all or substantially all of
its assets (whether now owned or hereafter acquired) to or in favor of any Person, except that, so long as no Default exists or would result therefrom: 
 (a) any Person may merge or consolidate with or into (i) the Borrower or the Trust, provided that the Borrower or the Trust, as applicable, shall be the continuing or surviving Person and
there is no Change of Control, or (ii) any one or more other Subsidiaries, including newly formed Subsidiaries, provided that when any Subsidiary Guarantor is merging or consolidating with or into another Subsidiary that is not a
Subsidiary Guarantor, the Subsidiary Guarantor shall be the continuing or surviving Person; 

  

- 75 - 

 (b) any Subsidiary may dissolve or liquidate, or Dispose of any, all or substantially all of
its assets (upon voluntary liquidation or otherwise), and Borrower may Dispose of any or all of its Equity Interests in any Subsidiary, provided that if such Subsidiary owns a Property that had been included as an Unencumbered Property, and the
Property Value of such Property together with the Property Value of any other Unencumbered Properties being sold in the same or related transactions is $50,000,000 or more, Borrower must provide an updated Compliance Certificate as a condition to
the dissolution, liquidation, or Disposition being permitted hereby, demonstrating that Borrower is in compliance with all of its covenants without including such Property as an Unencumbered Property; and 

(c) Borrower or Trust may enter into a merger in which such entity is the survivor. 

7.05 INTENTIONALLY DELETED. 
 7.06 Restricted Payments. Make any Restricted Payments without the consent of the Required Lenders at any time during which an Event of Default (other than an Event of Default under clause
(c) of Section 8.01) is continuing, except to the extent necessary for the Trust to maintain its status as a real estate investment trust. 
 7.07 Change in Nature of Business. Engage to any material extent in any business if, as a result, the general nature of the business in which the Borrower and its Subsidiaries, taken as a whole,
would then be engaged would be substantially changed from the general nature of the business in which the Borrower and its Subsidiaries, taken as a whole, are engaged on the date of this Agreement. 

7.08 Transactions with Affiliates. Sell, lease or otherwise transfer any property or assets to, or purchase, lease or otherwise
acquire any property or assets from, or otherwise engage in any other transactions with, any of its Affiliates, except (a) in the ordinary course of business at prices and on terms and conditions not less favorable to the Borrower or such
Subsidiary than could be obtained on an arm’s-length basis from unrelated third parties, (b) transactions between or among the Borrower and its Subsidiaries not involving any other Affiliate and (c) Restricted Payments permitted by
Section 7.06 and (d) pursuant to each of the agreements listed on Schedule 7.08 attached hereto together with any amendment, modification, renewal, replacement or similar agreement entered into on terms which are not materially less
favorable (taken as a whole) to the Borrower or the Trust than the agreements set forth on Schedule 7.08. 
 7.09
INTENTIONALLY DELETED. 
 7.10 Use of Proceeds. Use the proceeds of any Credit Extension, whether directly or
indirectly, and whether immediately, incidentally or ultimately, to purchase or carry margin stock (within the meaning of Regulation U of the FRB) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund
indebtedness originally incurred for such purpose. 

  

- 76 - 

 7.11 Financial Covenants. 

(a) Consolidated Tangible Net Worth. Permit Consolidated Tangible Net Worth on the date of determination to be less than
$621,576,000 plus seventy percent (70%) of the aggregate proceeds received by the Borrower or the Trust (net of reasonable related fees and expenses) in connection with any offering of stock or other equity after June 30, 2012. 

(b) Consolidated Fixed Charge Coverage Ratio. Permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.5 at any date
of determination, determined based on information for the most recent quarter annualized. 
 (c) Consolidated Leverage
Ratio. Permit Consolidated Leverage Ratio to be more than sixty percent (60%) at any date of determination, provided that the Consolidated Leverage Ratio may increase to up to 65% for up to four (4) consecutive quarters after a
Material Acquisition. 
 (d) Secured Indebtedness. Permit Total Secured Indebtedness to exceed fifty-five percent
(55%) of Total Asset Value at any date of determination during the first Loan Year, fifty percent (50%) of Total Asset Value at any date of determination during the second Loan Year, or forty-five percent (45%) thereafter provided
that for four quarters immediately following a Material Acquisition that is financed by secured debt, the preceding maximum percentages shall increase to sixty percent (60%), fifty-five percent (55%) and fifty percent (50%) respectively.

 (e) Secured Recourse Indebtedness. Permit Total Secured Recourse Indebtedness to exceed ten percent (10%) of
Total Asset Value on the date of determination, excluding recourse associated with interest rate hedges. 
 (f) Unencumbered
Debt Yield. Permit the Unencumbered Debt Yield to be less than 11% at any date of determination. 
 (g) Maximum
Unencumbered Asset Pool Leverage Ratio. Permit the Unencumbered Asset Pool Leverage Ratio on the date of determination to be more than sixty percent (60%) which maximum percentage shall be increased to 65% for up to four consecutive
quarters after a Material Acquisition. 
 (h) Unencumbered Property Pool Criteria. Borrower shall comply with the
following requirements regarding Unencumbered Properties: 
 (i) There must be a minimum of $100,000,000 in Total
Unencumbered Property Pool Value at all times; 
 (ii) There must be at least ten (10) Unencumbered
Properties; 
 (iii) No single Unencumbered Property shall account for more than twenty-five percent
(25%) of Total Unencumbered Property Pool Value and any amount in excess of twenty-five percent (25%) shall be disregarded for purposes of determining Total Unencumbered Property Pool Value and Unencumbered Property NOI, but shall not
constitute a Default hereunder; 

  

- 77 - 

 (iv) The percentage of Total Unencumbered Property Pool Value attributable
to Unencumbered Property NOI from a single tenant shall not exceed twenty-five percent (25%) if the tenant has an Investment Grade Rating (or another comparable tenant reasonably approved by the Required Lenders for treatment as an investment grade
tenant for the purpose of this provision) and twenty percent (20%) for all other tenants and any amount in excess of twenty-five percent (25%) (or 20%, as applicable) shall be disregarded for purposes of determining Total Unencumbered
Property Pool Value and Unencumbered Property NOI, but shall not constitute a Default hereunder. 
 (v) No single
metropolitan statistical area shall compromise more than twenty-five percent (25%) of the aggregate Unencumbered Property NOI for all Unencumbered Properties and any amount in excess of twenty-five percent (25%) shall be disregarded for
purposes of determining Total Unencumbered Property Pool Value and Unencumbered Property NOI, but shall not constitute a Default hereunder. 
 7.12 KeyBank Line of Credit. Borrower shall not increase the maximum amount of the KeyBank Line of Credit to an amount greater than $40,000,000 or extend the maturity date thereof beyond
June 8, 2013, without the consent of all Lenders. Borrower shall not refinance or replace the KeyBank Line of Credit with a similar type credit collateralized in a similar manner while any Obligations are outstanding. 

ARTICLE VIII. EVENTS OF DEFAULT AND REMEDIES 
 8.01 Events of Default. Any of the following shall constitute an Event of Default: 
 (a) Non-Payment. The Borrower or any other Loan Party fails to pay (i) when and as required to be paid herein, any amount of principal of any Loan or any L/C Obligation, or (ii) within
five (5) Business Days after the same becomes due, any interest on any Loan or on any L/C Obligation, or any fee due hereunder, or (iii) within five days after written notice of such failure, any other amount payable hereunder or under any
other Loan Document; or 
 (b) Specific Covenants. The Borrower fails to perform or observe any term, covenant or
agreement contained in any of Section 6.04 (with respect to the Borrower’s existence), 6.10, 7.02, 7.04, 7.06, or 7.07, or the Borrower fails to perform or observe any term, covenant or agreement
contained in any of Section 7.01 or 7.08 and such failure continues for 15 days after Borrower’s knowledge of such failure. 
 (c) Other Defaults. Any Loan Party fails to perform or observe any other covenant or agreement (not specified in subsection (a) or (b) above) contained in any Loan Document on its part to
be performed or observed and such failure continues for 30 days after written notice from the Administrative Agent provided that such period shall be extended for up to an additional 30 days so long as such breach is reasonably susceptible of cure
within such additional period and the Borrower diligently and in good faith continues to attempt to cure such breach; or 
 (d)
Representations and Warranties. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Borrower or any other Loan Party herein, in any other Loan Document, or in any document delivered by
or on behalf of the Borrower or any other Loan Party pursuant to the requirements contained herein shall be materially incorrect or materially misleading when made or deemed made; or 

  

- 78 - 

 (e) Cross-Default. Any event or condition occurs that results in any Material
Indebtedness becoming due prior to its scheduled maturity or an event or condition has occurred at the time of the determination of default under this clause (e) that enables or permits (with or without the giving of notice, the lapse of time
or both) the holder or holders of any Material Indebtedness or any trustee or agent on its or their behalf to cause any Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its
scheduled maturity; provided that this clause (e) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Indebtedness; or 

(f) Insolvency Proceedings, Etc. Any Loan Party institutes or consents to the institution of any proceeding under any Debtor Relief
Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its
property; or any such receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for 90 calendar days;
or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undismissed or unstayed for 90 calendar days, or an order for
relief is entered in any such proceeding; or 
 (g) Inability to Pay Debts; Attachment. (i) The Borrower or any Loan
Party becomes unable or admits in writing its inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of
the property of any such Person and is not released, vacated or fully bonded within 30 days after its issue or levy; or 
 (h)
Judgments. There is entered against the Borrower or any Loan Party (i) one or more final judgments or orders for the payment of money in an aggregate amount (as to all such judgments or orders) exceeding $25,000,000 (to the extent not
covered by independent third-party insurance as to which the insurer does not dispute coverage), or (ii) any one or more non-monetary final judgments that have, or would reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect and, in either case, (A) enforcement proceedings are commenced by any creditor upon such judgment or order, or (B) there is a period of 60 consecutive days during which a stay of enforcement of such judgment, by
reason of a pending appeal or otherwise, is not in effect but only if, Borrower or the applicable party has not paid such judgment or otherwise set aside such judgment within 30 days after the commencement of enforcement proceedings; or 

(i) ERISA. (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which when taken together with all
other ERISA Events that have occurred has resulted or would reasonably be expected to result in a Material Adverse Effect, or (ii) the Borrower or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period,
any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount in excess of $25,000,000; or 

  

- 79 - 

 (j) Invalidity of Loan Documents. Any Loan Document, at any time after its execution
and delivery and for any reason other than as expressly permitted hereunder or 
 thereunder or satisfaction in full of all the Obligations,
ceases to be in full force and effect; or any Loan Party or any other Person contests in any manner the validity or enforceability of any Loan Document; or any Loan Party denies that it has any or further liability or obligation under any Loan
Document, or purports to revoke, terminate or rescind any Loan Document; or 
 (k) Change of Control. There occurs any
Change of Control. 
 8.02 Remedies Upon Event of Default. If any Event of Default occurs and is continuing, the
Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions: 
 (a) declare the commitment of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions to be terminated, whereupon such commitments and obligation shall be terminated;

 (b) declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other
amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Borrower; 

(c) require that the Borrower Cash Collateralize the L/C Obligations (in an amount equal to the then Outstanding Amount thereof); and

 (d) exercise on behalf of itself, the Lenders and the L/C Issuer all rights and remedies available to it, the Lenders and the
L/C Issuer under the Loan Documents; 
 provided, however, that upon the occurrence of an actual or deemed entry of an order for
relief with respect to the Borrower under the Bankruptcy Code of the United States, the obligation of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions shall automatically terminate, the unpaid principal
amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Borrower to Cash Collateralize the L/C Obligations as aforesaid shall automatically become
effective, in each case without further act of the Administrative Agent or any Lender. 
 8.03 Application of Funds.
After the exercise of remedies provided for in Section 8.02 (or after the Loans have automatically become immediately due and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in the
proviso to Section 8.02), any amounts received on account of the Obligations shall, subject to the provisions of Sections 2.17 and 2.18, be applied by the Administrative Agent in the following order: 

First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including fees,
charges and disbursements of counsel to the Administrative Agent and amounts payable under Article III) then due and payable to the Administrative Agent in its capacity as such; 

  

- 80 - 

 Second, to payment of that portion of the Obligations constituting fees, indemnities
and other amounts (other than principal, interest and Letter of Credit Fees) then due and payable to the Lenders and the L/C Issuer (including fees, charges and disbursements of counsel to the respective Lenders and the L/C Issuer (including fees
and time charges for attorneys who may be employees of any Lender or the L/C Issuer) and amounts payable under Article III), ratably among them in proportion to the respective amounts described in this clause Second payable to them;

 Third, to payment of that portion of the Obligations constituting accrued and unpaid Letter of Credit Fees and interest
on the Loans, L/C Borrowings and other Obligations then due and payable, ratably among the Lenders and the L/C Issuer in proportion to the respective amounts described in this clause Third payable to them; 

Fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans and L/C Borrowings, ratably among
the Lenders and the L/C Issuer in proportion to the respective amounts described in this clause Fourth held by them; 

Fifth, to the Administrative Agent for the account of the L/C Issuer, to Cash Collateralize that portion of L/C Obligations
comprised of the aggregate undrawn amount of Letters of Credit to the extent not otherwise Cash Collateralized by the Borrower pursuant to Sections 2.04 and 2.17; and 

Last, the balance, if any, after all of the Obligations then due and payable have been indefeasibly paid in full, to the Borrower
or as otherwise required by Law. 
 Subject to Sections 2.04(c) and 2.17, amounts used to Cash Collateralize the aggregate undrawn
amount of Letters of Credit pursuant to clause Fifth above shall be applied to satisfy drawings under such Letters of Credit as they occur. If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully
drawn or expired, such remaining amount shall be applied to the other Obligations, if any, in the order set forth above. 

ARTICLE IX. ADMINISTRATIVE AGENT 
 9.01 Appointment and Authority. Each of the Lenders and the L/C Issuer hereby irrevocably appoints Bank of America to act on its behalf as the Administrative Agent hereunder and under the other
Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are
reasonably incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuer, and neither the Borrower nor any other Loan Party shall have rights as a third party beneficiary of
any of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or
other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.

 9.02 Rights as a Lender. The Person serving as the Administrative Agent hereunder shall have the same rights and
powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context
otherwise requires, 

  

- 81 - 

 
include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor
or in any other advisory capacity for and generally engage in any kind of business with the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor
to the Lenders. 
 9.03 Exculpatory Provisions. The Administrative Agent shall not have any duties or obligations except
those expressly set forth herein and in the other Loan Documents and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent: 

(a) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;

 (b) may, but shall not have any duty to take any discretionary action or exercise any discretionary powers, except
discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as
shall be expressly provided for herein or in the other Loan Documents), provided that the Administrative Agent shall not be required to take any action that, in its reasonable opinion or the reasonable opinion of its counsel, may expose the
Administrative Agent to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture,
modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and 
 (c) shall not,
except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or
obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity. 
 The Administrative Agent
shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in
good faith shall be necessary, under the circumstances as provided in Sections 10.01 and 8.02) or (ii) in the absence of its own bad faith, gross negligence or willful misconduct. The Administrative Agent shall be deemed not to
have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent by the Borrower, a Lender or the L/C Issuer. 
 The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any
other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other
terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or
(v) the satisfaction of any condition set forth in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent. 

  

- 82 - 

 9.04 Reliance by Administrative Agent. The Administrative Agent shall be entitled to
rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution)
believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the
proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by its terms must be
fulfilled to the satisfaction of a Lender or the L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or the L/C Issuer unless the Administrative Agent shall have received notice to the contrary from
such Lender or the L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts
selected by it, and shall not be liable for any action taken or not taken by it in accordance with the written advice of any such counsel, accountants or experts. 
 9.05 Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more
sub agents appointed by the Administrative Agent. The Administrative Agent and any such sub agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of
this Article shall apply to any such sub agent and to the Related Parties of the Administrative Agent and any such sub agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for
herein as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non
appealable judgment that the Administrative Agent acted with bad faith, gross negligence or willful misconduct in the selection of such sub-agents. 
 9.06 Resignation of Administrative Agent. 
 (a) The Administrative Agent may
at any time give notice of its resignation to the Lenders, the L/C Issuer and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, with the reasonable consent of the Borrower so long as no Event of
Default has occurred and is continuing, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so appointed by the
Required Lenders and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the “Resignation Effective
Date”), then the retiring Administrative Agent may (but shall not be obligated to) on behalf of the Lenders and the L/C Issuer, appoint a successor Administrative Agent meeting the qualifications set forth above. Whether or not a successor has
been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date. If the initial Administrative Agent at any time is no longer a Lender 

  

- 83 - 

 
then the Administrative Agent will upon the request of the Borrower, which Borrower may make so long as no Event of Default exists and is continuing, resign as Administrative Agent in which event
a new Administrative Agent shall be appointed in accordance with the terms hereof. 
 (b) If the Person serving as
Administrative Agent is a Defaulting Lender pursuant to clause (d) of the definition thereof, the Required Lenders may, to the extent permitted by applicable law, by notice in writing to the Borrower and such Person remove such Person as
Administrative Agent and, with the reasonable consent of the Borrower so long as no Event of Default has occurred and is continuing, appoint a successor. If no such successor shall have been so appointed by the Required Lenders and shall have
accepted such appointment within 30 days (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”), then such removal shall nonetheless become effective in accordance with such notice on the Removal
Effective Date. 
 (c) With effect from the Resignation Effective Date or the Removal Effective Date (as applicable)
(1) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents arising from and after such date (except that in the case of any collateral security held by the
Administrative Agent on behalf of the Lenders or the L/C Issuer under any of the Loan Documents, the retiring or removed Administrative Agent shall continue to hold such collateral security until such time as a successor Administrative Agent is
appointed) and (2) except for any indemnity payments or other amounts then owed to the retiring or removed Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent
shall instead be made by or to each Lender and the L/C Issuer directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above. Upon the acceptance of a successor’s appointment as
Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or removed) Administrative Agent (other than as provided in Section 3.01(g) and other than
any rights to indemnity payments or other amounts owed to the retiring or removed Administrative Agent as of the Resignation Effective Date or the Removal Effective Date, as applicable), and the retiring or removed Administrative Agent shall be
discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section) . The fees payable by the Borrower to a successor Administrative Agent shall be the
same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring or removed Administrative Agent’s resignation or removal hereunder and under the other Loan Documents, the provisions
of this Article and Section 10.04 shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of
them while the retiring or removed Administrative Agent was acting as Administrative Agent. 
 (d) Any resignation by Bank of
America as Administrative Agent pursuant to this Section shall also constitute its resignation as L/C Issuer and Swing Line Lender. If Bank of America resigns as an L/C Issuer, it shall retain all the rights, powers, privileges and duties of the L/C
Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as L/C Issuer and all L/C Obligations with respect thereto, including the right to require the Lenders to make Base Rate Loans or fund
risk participations in Unreimbursed Amounts pursuant to Section 2.03(c). If Bank of America resigns as Swing Line Lender, it shall 

  

- 84 - 

 
retain all the rights of the Swing Line Lender provided for hereunder with respect to Swing Line Loans made by it and outstanding as of the effective date of such resignation, including the right
to require the Lenders to make Base Rate Loans or fund risk participations in outstanding Swing Line Loans pursuant to Section 2.04(c). Upon the appointment by the Borrower of a successor L/C Issuer or Swing Line Lender hereunder (which
successor shall in all cases be a Lender other than a Defaulting Lender), (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer or Swing Line Lender, as
applicable, (b) the retiring L/C Issuer and Swing Line Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Loan Documents, and (c) the successor L/C Issuer shall issue letters of
credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of
Credit. 
 9.07 Non-Reliance on Administrative Agent and Other Lenders. Each Lender and the L/C Issuer acknowledges that
it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter
into this Agreement. Each Lender and the L/C Issuer also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as
it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.

 9.08 No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of the Bookrunners, Arrangers, or
Syndication Agent listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, a Lender or the L/C
Issuer hereunder. 
 9.09 Administrative Agent May File Proofs of Claim. In case of the pendency of any proceeding under
any Debtor Relief Law or any other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan or L/C Obligation shall then be due and payable as herein expressed or by declaration or
otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise 

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations
and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuer and the Administrative Agent (including any claim for the reasonable
compensation, expenses, disbursements and advances of the Lenders, the L/C Issuer and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuer and the Administrative Agent under
Sections 2.04(i) and (j), 2.10 and 10.04) allowed in such judicial proceeding; and 

  

- 85 - 

 (b) to collect and receive any monies or other property payable or deliverable on any such
claims and to distribute the same; 
 and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any
such judicial proceeding is hereby authorized by each Lender and the L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders
and the L/C Issuer, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent
under Sections 2.10 and 10.04. 
 Nothing contained herein shall be deemed to authorize the Administrative Agent
to authorize or consent to or accept or adopt on behalf of any Lender or the L/C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or the L/C Issuer to authorize the
Administrative Agent to vote in respect of the claim of any Lender or the L/C Issuer in any such proceeding. 
 9.10 Lender
Reply Period. All communications from Administrative Agent to Lenders requesting Lenders’ determination, consent or approval (i) shall be given in the form of a written notice to each Lender, (ii) shall be accompanied by a
description of the matter as to which such determination, consent or approval is requested, (iii) shall include a legend substantially as follows, printed in capital letters or boldface type: 

“THIS COMMUNICATION REQUIRES IMMEDIATE RESPONSE. FAILURE TO RESPOND WITHIN TEN (10) BUSINESS DAYS AFTER THE DELIVERY OF THIS
COMMUNICATION SHALL CONSTITUTE A DEEMED APPROVAL BY THE ADDRESSEE OF THE MATTER DESCRIBED ABOVE.” 
 and (iv) shall include
Administrative Agent’s recommended course of action or determination in respect thereof. Each Lender shall reply promptly to any such request, but in any event within ten (10) Business Days after the delivery of such request by
Administrative Agent (the “Lender Reply Period”). Unless a Lender shall give written notice to Administrative Agent that it objects to the recommendation or determination of Administrative Agent (together with a written explanation of the
reasons behind such objection) within the Lender Reply Period, such Lender shall be deemed to have approved of or consented to such recommendation or determination. With respect to decisions requiring the approval of the Required Lenders or all
Lenders, Administrative Agent shall timely submit any required written notices to all Lenders and upon receiving the required approval or consent shall follow the course of action or determination recommended by Administrative Agent or such other
course of action recommended by the Required Lenders or all of the Lenders, as the case may be, and each non-responding Lender shall be deemed to have concurred with such recommended course of action. Nothing in this Section 9.10 shall restrict
the Administrative Agent from requesting a reply to a request for an approval in less than ten Business Days but the deemed approval provided in this Section 9.6 shall not apply until the expiration of a ten Business Day period. 

  

- 86 - 

 ARTICLE X. MISCELLANEOUS 

10.01 Amendments, Etc. No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any
departure by the Borrower or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders and the Borrower or the applicable Loan Party, as the case may be, and acknowledged by the Administrative Agent, and
each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no such amendment, waiver or consent shall: 

(a) waive any condition set forth in Section 4.01(a) without the written consent of each Lender; 

(b) extend or increase the Commitment of any Lender (or reinstate any Commitment terminated pursuant to Section 8.02) without
the written consent of such Lender; 
 (c) postpone any date fixed by this Agreement or any other Loan Document for any payment
hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; 
 (d) reduce
the principal of, or the rate of interest specified herein on, any Loan or L/C Borrowing, or any fees or other amounts payable hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby;
provided, however, that only the consent of the Required Lenders shall be necessary (i) to amend the definition of “Default Rate” or to waive any obligation of the Borrower to pay interest or Letter of Credit Fees at the
Default Rate or (ii) to amend or waive any financial covenant hereunder (or any defined term used therein) even if the effect of such amendment would be to reduce the rate of interest on any Loan or L/C Borrowing or to reduce any fee payable
hereunder; 
 (e) change Section 2.14 or 8.03 in a manner that would alter the pro rata sharing of payments required
thereby without the written consent of each Lender, subject to the proviso below; 
 (f) change the definition of
“Applicable Percentage”; 
 (g) change any provision of this Section or the definition of “Required Lenders”
or any other provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder, without the written consent of each Lender;

 (h) release the Trust as a Guarantor or, except as permitted by Section 6.12, release all or substantially all of the
Subsidiary Guarantors; 
 (i) amend or waive the provision in Section 6.12 which prohibits a Subsidiary Guarantor from being
a guarantor of the KeyBank Line of Credit without the written consent of each Lender; 

  

- 87 - 

 and, provided further, that (i) no amendment, waiver or consent shall, unless in writing and
signed by the L/C Issuer in addition to the Lenders required above, affect the rights or duties of the L/C Issuer under this Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by it; (ii) no amendment,
waiver or consent shall, unless in writing and signed by the Swing Line Lender in addition to the Lenders required above, affect the rights or duties of the Swing Line Lender under this Agreement; (iii) no amendment, waiver or consent shall,
unless in writing and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; and (iv) notwithstanding anything in
this Agreement to the contrary, any amendment that would extend the Maturity Date with respect to Loans or Commitments, provide for any increased pricing (including fees) for any Lenders agreeing to extend their Loans or Commitments pursuant to the
terms of such amendment and any corresponding modifications under this Agreement related thereto may be effected pursuant to an agreement or agreements in writing entered into by the Borrower, the Administrative Agent, and the extending Lenders.
Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all
Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such
Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such
Defaulting Lender. 
 10.02 Notices; Effectiveness; Electronic Communication. 

(a) Notices Generally. Except in the case of notices and other communications expressly permitted to be given by telephone (and
except as provided in subsection (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by telecopier
as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows: 

(i) if to the Borrower, the Administrative Agent, the L/C Issuer or the Swing Line Lender, to the address, telecopier
number, electronic mail address or telephone number specified for such Person on Schedule 10.02; and 

(ii) if to any other Lender, to the address, telecopier number, electronic mail address or telephone number specified in
its Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire then in effect for the delivery of notices that may contain material non-public
information relating to the Borrower). 
 Notices and other communications sent by hand or overnight courier service, or mailed by certified or
registered mail, shall be deemed to have been given when received; notices and other communications sent by telecopier shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be
deemed to have been given at the opening of business on the next Business Day for the recipient). Notices and other communications delivered through electronic communications to the extent provided in subsection (b) below, shall be effective as
provided in such subsection (b). 

  

- 88 - 

 (b) Electronic Communications. Notices and other communications to the Lenders and
the L/C Issuer hereunder may be delivered or furnished by electronic communication (including e mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not apply
to notices to any Lender or the L/C Issuer pursuant to Article II if such Lender or the L/C Issuer, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication.
The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures
may be limited to particular notices or communications. 
 Unless the Administrative Agent otherwise prescribes,
(i) notices and other communications sent to an e-mail address shall be deemed received upon actual receipt or the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested”
function, as available, return e-mail or other written acknowledgement), provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have
been sent at the opening of business on the next Business Day for the recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its
e-mail address as described in the foregoing clause (i) of notification from Administrative Agent that such notice or communication is available and identifying the website address therefor. 

(c) The Platform. The Borrower hereby acknowledges that (a) the Administrative Agent and/or Arranger may, but shall not be
obligated to, make available to the Lenders and L/C Issuer materials and/or information provided by or on behalf of the Borrower hereunder (collectively, “Borrower Materials”) by posting the borrower materials on IntraLinks or another
similar electronic system (the “Platform”). THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY
OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties
(collectively, the “Agent Parties”) have any liability to the Borrower, any Lender, the L/C Issuer or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising
out of the Borrower’s or the Administrative Agent’s transmission of Borrower Materials through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent
jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event shall any Agent Party have any liability to the Borrower, any
Lender, the L/C Issuer or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages). 

  

- 89 - 

 (d) Change of Address, Etc. Each of the Borrower, the Administrative Agent, the L/C
Issuer and the Swing Line Lender may change its address, telecopier or telephone number for notices and other communications hereunder by notice to the other parties hereto. Each other Lender may change its address, telecopier or telephone number
for notices and other communications hereunder by notice to the Borrower, the Administrative Agent, the L/C Issuer and the Swing Line Lender. In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the
Administrative Agent has on record (i) an effective address, contact name, telephone number, telecopier number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such
Lender. 
 (e) Reliance by Administrative Agent, L/C Issuer and Lenders. The Administrative Agent, the L/C Issuer and the
Lenders shall be entitled to rely and act upon any notices (including telephonic Committed Loan Notices and Swing Line Loan Notices) purportedly given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified
herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify the
Administrative Agent, the L/C Issuer, each Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower
and reasonably relied on by such Person. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.

 10.03 No Waiver; Cumulative Remedies; Enforcement. No failure by any Lender, the L/C Issuer or the Administrative
Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude
any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges
provided by law. 
 Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to
enforce rights and remedies hereunder and under the other Loan Documents against the Loan Parties or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and
maintained exclusively by, the Administrative Agent in accordance with Section 8.02 for the benefit of all the Lenders and the L/C Issuer; provided, however, that the foregoing shall not prohibit (a) the Administrative
Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) the L/C Issuer or the Swing Line Lender from exercising
the rights and remedies that inure to its benefit (solely in its capacity as L/C Issuer or Swing Line Lender, as the case may be) hereunder and under the other Loan Documents, (c) any Lender from exercising setoff rights in accordance with
Section 10.08 (subject to the terms of Section 2.14), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to any Loan Party under
any Debtor Relief Law; and provided, further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise
ascribed to the Administrative Agent pursuant to Section 8.02 and (ii) in addition to the matters set forth in clauses (b), (c) and (d) of the preceding proviso and subject to Section 2.14, any Lender may, with
the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders. 

  

- 90 - 

 10.04 Expenses; Indemnity; Damage Waiver. 

(a) Costs and Expenses. The Borrower shall pay all reasonable and documented out of pocket expenses (i) incurred by the
Administrative Agent and its Affiliates (including the reasonable and documented out of pocket fees, charges and disbursements of counsel for the Administrative Agent), in connection with the syndication of the credit facilities provided for herein,
the preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby
or thereby shall be consummated), (ii) customarily incurred by the L/C Issuer in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder, provided that such expenses are
customarily charged in connection with the issuance of the Letters of Credit and (iii) incurred by the Administrative Agent, any Lender or the L/C Issuer (including the fees, charges and disbursements of any counsel for the Administrative
Agent, any Lender or the L/C Issuer), and shall pay all reasonable and documented fees and time charges for attorneys who may be employees of the Administrative Agent, any Lender or the L/C Issuer, in connection with the enforcement or protection of
its rights (A) in connection with this Agreement and the other Loan Documents, including its rights under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such out of pocket
expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit. 
 (b)
Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and the L/C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an
“Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the reasonable and documented fees, charges and disbursements of any counsel for any
Indemnitee), and shall indemnify and hold harmless each Indemnitee from all fees and time charges and disbursements for attorneys who may be employees of any Indemnitee, incurred by any Indemnitee or asserted against any Indemnitee by any third
party or by the Borrower or any other Loan Party arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the
performance by the parties hereto of their respective obligations hereunder or thereunder, the consummation of the transactions contemplated hereby or thereby, or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related
Parties only, the administration of this Agreement and the other Loan Documents (including in respect of any matters addressed in Section 3.01), (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom
(including any refusal by the L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or
alleged presence or release of Hazardous Materials on or from any property owned or operated by the Borrower or any of its Subsidiaries, or any Environmental Liability related in any way to the Borrower or any of its Subsidiaries, or (iv) any
actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, 

  

- 91 - 

 
whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower or any other Loan Party, and regardless of whether any Indemnitee is a party thereto, IN
ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY OR SOLE NEGLIGENCE OF THE INDEMNITEE; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such
losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or
(y) result from a claim brought by the Borrower or any other Loan Party against an Indemnitee for breach in bad faith of such Indemnitee’s obligations hereunder or under any other Loan Document, if the Borrower or such other Loan Party has
obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction. 

(c) Reimbursement by Lenders. To the extent that the Borrower for any reason fails to indefeasibly pay any amount required under
subsection (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the L/C Issuer or any Related Party of any of the foregoing, and without limiting Borrower’s obligation to do so, each
Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the L/C Issuer or such Related Party, as the case may be, such Lender’s Applicable Percentage (determined as of the time that the applicable unreimbursed
expense or indemnity payment is sought) of such unpaid amount, provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative
Agent (or any such sub-agent) or the L/C Issuer in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) or L/C Issuer in connection with such capacity. The obligations
of the Lenders under this subsection (c) are subject to the provisions of Section 2.13(d). 
 (d) Waiver of
Consequential Damages, Etc. To the fullest extent permitted by applicable law, the Borrower shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive
damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any
Loan or Letter of Credit or the use of the proceeds thereof. No Indemnitee referred to in subsection (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed to
such unintended recipients by such Indemnitee through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby other
than for direct or actual damages resulting from the gross negligence or willful misconduct of such Indemnitee as determined by a final and nonappealable judgment of a court of competent jurisdiction. 

(e) Payments. All amounts due under this Section shall be payable not later than ten Business Days after demand therefor.

 (f) Survival. The agreements in this Section and the indemnity provisions of Section 10.02(e) shall
survive the resignation of the Administrative Agent, the L/C Issuer and the Swing Line Lender, the replacement of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other Obligations.

  

- 92 - 

 10.05 Payments Set Aside. To the extent that any payment by or on behalf of the
Borrower is made to the Administrative Agent, the L/C Issuer or any Lender, or the Administrative Agent, the L/C Issuer or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently
invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, the L/C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any
other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender and the L/C Issuer severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so
recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders
and the L/C Issuer under clause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement. 
 10.06 Successors and Assigns. 
 (a) Successors and Assigns
Generally. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that neither the Borrower nor any other Loan Party may assign
or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except
(i) to an assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (d) of this Section, or (iii) by way of pledge or
assignment of a security interest subject to the restrictions of subsection (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall
be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated
hereby, the Related Parties of each of the Administrative Agent, the L/C Issuer and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. 

(b) Assignments by Lenders. Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and
obligations under this Agreement (including all or a portion of its Commitment and the Loans (including for purposes of this subsection (b), participations in L/C Obligations and in Swing Line Loans) at the time owing to it); provided that
any such assignment shall be subject to the following conditions: 
 (i) Minimum Amounts. 

(A) in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment and the Loans at
the time owing to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and 

  

- 93 - 

 (B) in any case not described in subsection (b)(i)(A) of this Section, the
aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such assignment,
determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less
than $5,000,000 (and in integral multiples of $1,000,000 in excess thereof) unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be
unreasonably withheld or delayed); provided, however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single Eligible Assignee will be treated as a single
assignment for purposes of determining whether such minimum amount has been met. 
 (ii) Proportionate
Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with respect to the Loans or the Commitment assigned, except that this clause
(ii) shall not apply to rights in respect of the Swing Line Lender’s rights and obligations in respect of Swing Line Loans; 
 (iii) Required Consents. No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition: 

(A) the consent of the Borrower (such consent not to be unreasonably withheld) shall be required unless (1) an Event
of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; provided that the Borrower shall be deemed to have consented to any such
assignment unless it shall object thereto by written notice to the Administrative Agent within ten (10) Business Days after having received notice thereof; 
 (B) the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required if such assignment is to a Person that is not a Lender, an Affiliate of such Lender
or an Approved Fund with respect to such Lender; 
 (C) the consent of the L/C Issuer (such consent not to be
unreasonably withheld or delayed) shall be required for any assignment that increases the obligation of the assignee to participate in exposure under one or more Letters of Credit (whether or not then outstanding); and 

(D) the consent of the Swing Line Lender (such consent not to be unreasonably withheld or delayed) shall be required for
any assignment. 
 (iv) Assignment and Assumption. The parties to each assignment shall execute and
deliver to the Administrative Agent an Assignment and Assumption, together 

  

- 94 - 

 
with a processing and recordation fee in the amount of $3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and
recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. 
 (v) No Assignment to Certain Persons. No such assignment shall be made (A) to the Borrower or any of the Borrower’s Affiliates or Subsidiaries, (B) a direct competitor of Borrower,
the Guarantors or any Affiliates of any thereof, unless an Event of Default has occurred and is continuing at the time of such assignment, or (C) to any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender
hereunder, would constitute any of the foregoing Persons described in this clause (C), or (D) to a natural person. 
 (vi) Certain Additional Payments. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition
to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright
payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested
but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent
or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit and Swing Line Loans in accordance with its Applicable Percentage.
Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of
such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs. 
 Subject to
acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement
and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and
Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party
hereto) but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05, and 10.04 with respect to facts and circumstances occurring prior to the effective date of such assignment, notwithstanding notice to
the contrary. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. No Person that acquires any interest in any rights or
obligations of any Lender under this Agreement pursuant to this Section 10.6(b) shall be entitled to receive, absent a Change in Law occurring after the date such Person acquires such interest, any greater payments or greater benefits under
Section 3.01 with respect to such interest than were available 

  

- 95 - 

 
on the date of assignment to the assigning or transferring Lender from whom such Person acquired such interest. Upon request, the Borrower (at its expense) shall execute and deliver a Note to the
assignee Lender. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such
rights and obligations in accordance with subsection (d) of this Section. 
 (c) Register. The Administrative Agent,
acting solely for this purpose as an agent of the Borrower (and such agency being solely for tax purposes), shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it and a register for the
recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts of the Loans and L/C Obligations owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries
in the Register shall be conclusive, and the Borrower, the Administrative Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement,
notwithstanding notice to the contrary. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available
for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. 
 (d)
Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural person, a Defaulting Lender or the Borrower or any of the
Borrower’s Affiliates or Subsidiaries, or any direct competitor of Borrower, Guarantors or any Affiliates of any thereof unless an Event of Default has occurred and is continuing) (each, a “Participant”) in all or a portion of
such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans (including such Lender’s participations in L/C Obligations and/or Swing Line Loans) owing to it); provided
that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the
Administrative Agent, the Lenders and the L/C Issuer shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement. For the avoidance of doubt, each Lender shall be
responsible for the indemnity under Section 10.04(c) without regard to the existence of any participation. 
 Any agreement
or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement;
provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification described in the first proviso to Section 10.01 that affects such
Participant. The Borrower agrees that each Participant shall be entitled to the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b) of this
Section (it being understood that the documentation required under Section 3.01(e) shall be delivered to the Lender who sells the participation) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to
paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions of Sections 3.06 and 10.13 as if it were an assignee 

  

- 96 - 

 
under paragraph (b) of this Section and (B) shall not be entitled to receive any greater payment under Sections 3.01 or 3.04, with respect to any participation, than the Lender from
whom it acquired the applicable participation would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable
participation. Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Section 3.06 with respect to any Participant. To
the extent permitted by law, each Participant also shall be entitled to the benefits of Section 10.08 as though it were a Lender; provided that such Participant agrees to be subject to Section 2.13 as though it were a Lender. Each Lender
that sells a participation shall, acting solely for this purpose as an agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s
interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any
Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish
that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent demonstrable error,
and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the
Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register. 
 (e) Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note, if any) to secure
obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such
pledgee or assignee for such Lender as a party hereto. 
 (f) Resignation as L/C Issuer or Swing Line Lender after
Assignment. Notwithstanding anything to the contrary contained herein, if at any time Bank of America assigns all of its Commitment and Loans pursuant to subsection (b) above, Bank of America may, (i) upon 30 days’ notice to the
Borrower and the Lenders, resign as L/C Issuer and/or (ii) upon 30 days’ notice to the Borrower, resign as Swing Line Lender. In the event of any such resignation as L/C Issuer or Swing Line Lender, the Borrower shall be entitled to
appoint from among the Lenders a successor L/C Issuer or Swing Line Lender hereunder; provided, however, that no failure by the Borrower to appoint any such successor shall affect the resignation of Bank of America as L/C Issuer or
Swing Line Lender, as the case may be. If Bank of America resigns as L/C Issuer, it shall retain all the rights, powers, privileges and duties of the L/C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of
its resignation as L/C Issuer and all L/C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Committed Loans or fund risk participations in Unreimbursed Amounts pursuant to Section 2.04(c)). If
Bank of America resigns as Swing Line Lender, it shall retain all the rights of the Swing Line Lender provided for hereunder with respect to Swing Line Loans made by it and outstanding as of the effective date of such resignation, 

  

- 97 - 

 
including the right to require the Lenders to make Base Rate Committed Loans or fund risk participations in outstanding Swing Line Loans pursuant to Section 2.05(c). Upon the
appointment of a successor L/C Issuer and/or Swing Line Lender, (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer or Swing Line Lender, as the case may be, and
(b) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the
obligations of Bank of America with respect to such Letters of Credit. 
 10.07 Treatment of Certain Information;
Confidentiality. Each of the Administrative Agent, the Lenders and the L/C Issuer agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and
its Affiliates’ respective partners, directors, officers, employees, agents, trustees, advisors and representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such
Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of
Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) to the extent necessary in connection with the exercise of any
remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions
substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or any Eligible Assignee invited to be a Lender
pursuant to Section 2.16(c) or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (g) with the consent of the Borrower or (h) to the
extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender, the L/C Issuer or any of their respective Affiliates on a
nonconfidential basis from a source other than the Borrower. For purposes of this Section, “Information” means all information received from the Borrower or any Subsidiary relating to the Borrower or any Subsidiary or any of their
respective businesses, other than any such information that is available to the Administrative Agent, any Lender or the L/C Issuer on a nonconfidential basis prior to disclosure by the Borrower or any Subsidiary, provided that, in the case of
information received from the Borrower or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this
Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

 Each of the Administrative Agent, the Lenders and the L/C Issuer acknowledges that (a) the Information may include
material non-public information concerning the Borrower or a Subsidiary, as the case may be, (b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public
information in accordance with applicable Law, including United States Federal and state securities Laws. 

  

- 98 - 

 10.08 Right of Setoff. If an Event of Default shall have occurred and be continuing,
each Lender, the L/C Issuer and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and all deposits (general or special, time or
demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender, the L/C Issuer or any such Affiliate to or for the credit or the account of the Borrower or any other
Loan Party against any and all of the obligations of the Borrower or such Loan Party now or hereafter existing under this Agreement or any other Loan Document to such Lender or the L/C Issuer, irrespective of whether or not such Lender or the L/C
Issuer shall have made any demand under this Agreement or any other Loan Document and although such obligations of the Borrower or such Loan Party may be unmatured or are owed to a branch or office of such Lender or the L/C Issuer different from the
branch or office holding such deposit or obligated on such indebtedness; provided, that in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the
Administrative Agent for further application in accordance with the provisions of Section 2.18 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the
Administrative Agent and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such
right of setoff. The rights of each Lender, the L/C Issuer and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender, the L/C Issuer or their respective
Affiliates may have. Each Lender and the L/C Issuer agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application, provided that the failure to give such notice shall not affect the validity of such
setoff and application. 
 10.09 Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Loan
Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”). If the Administrative Agent or any Lender shall
receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for,
charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than
interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.

 10.10 Counterparts; Integration; Effectiveness. This Agreement may be executed in counterparts (and by different
parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement, and the other Loan Documents constitute the entire contract among the
parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in Section 4.01, this Agreement shall become
effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. Delivery of an
executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement. 

  

- 99 - 

 10.11 Survival of Representations and Warranties. All representations and warranties
made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or
will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or
knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder (other than unasserted contingent obligations) shall remain unpaid or unsatisfied or any
Letter of Credit shall remain outstanding. 
 10.12 Severability. If any provision of this Agreement or the other Loan
Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the
parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.
The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. Without limiting the foregoing provisions of this Section 10.12, if and to the extent that
the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, the L/C Issuer or the Swing Line Lender, as applicable, then such
provisions shall be deemed to be in effect only to the extent not so limited. 
 10.13 Replacement of Lenders. If any
Lender requests compensation under Section 3.04, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, or if a single Lender has
given notice pursuant to Section 3.02 or is unable to determine or provide the Eurodollar Rate under Section 3.03, as applicable (it being agreed that if multiple Lenders have given that notice or are unable to determine or provide the
Eurodollar Rate then the right to replace for that reason shall not apply), or if any Lender is a Defaulting Lender or in connection with any proposed amendment, modification, termination, waiver or consent with respect to any of the provisions
hereof as contemplated by Section 10.01, the consent of the Required Lenders (or the requisite other percentage of Lenders under Section 10.01) shall have been obtained but the consent of one or more of such other Lenders whose consent is
required shall not have been obtained, then the Borrower may, at its sole expense and effort, upon notice to such Lender (for greater clarity, a Lender whose consent was not obtained, in the case of any proposed amendment, modification, termination,
waiver or consent) and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 10.06), all of its interests,
rights and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment), provided that: 

(a) the Borrower shall have paid to the Administrative Agent the assignment fee specified in Section 10.06(b); 

  

- 100 - 

 (b) such Lender shall have received payment of an amount equal to 100% of the outstanding
principal of its Loans and L/C Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Sections 3.04 and 3.05) from the assignee (to
the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); 

(c) in the case of any such assignment resulting from a claim for compensation under Section 3.04 or payments required to be
made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments thereafter; and 
 (d) such assignment does not conflict with applicable Laws. 
 A Lender shall not
be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply for reasons other than
that such Lender is not owed any compensation under Section 3.04 because Borrower has paid it, or Borrower is no longer required to pay any additional amount to such Lender or any Governmental Authority for the account of such Lender pursuant
to Section 3.01 because all such amounts have been paid by Borrower. 
 10.14 Governing Law; Jurisdiction; Etc.

 (a) GOVERNING LAW. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION
(WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT (EXCEPT, AS TO ANY OTHER LOAN DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) AND THE TRANSACTIONS CONTEMPLATED HEREBY AND
THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 
 (b) SUBMISSION TO
JURISDICTION. THE BORROWER IRREVOCABLY AND UNCONDITIONALLY AGREES THAT IT WILL NOT COMMENCE ANY ACTION, LITIGATION OR PROCEEDING OF ANY KIND OR DESCRIPTION, WHETHER IN LAW OR EQUITY, WHETHER IN CONTRACT OR IN TORT OR OTHERWISE, AGAINST THE
ADMINISTRATIVE AGENT, ANY LENDER, THE L/C ISSUER, OR ANY RELATED PARTY OF THE FOREGOING IN ANY WAY RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS RELATING HERETO OR THERETO, IN ANY FORUM OTHER THAN THE COURTS OF THE STATE
OF NEW YORK SITTING IN NEW YORK COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK, AND ANY APPELLATE COURT FROM ANY THEREOF, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE JURISDICTION
OF SUCH COURTS AND AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION, LITIGATION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE 

  

- 101 - 

 
COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION, LITIGATION OR PROCEEDING SHALL BE
CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, ANY LENDER OR THE L/C
ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST THE BORROWER OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. 

(c) WAIVER OF VENUE. THE BORROWER IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN PARAGRAPH (B) OF THIS SECTION. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. 

(d) SERVICE OF PROCESS. EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION
10.02. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW. 
 10.15 Waiver of Jury Trial. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY
OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES
HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 
 10.16 No Advisory or Fiduciary Responsibility. In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification
hereof or of any other Loan Document), the Borrower acknowledges and agrees, and acknowledges its Affiliates’ understanding, that: (i) (A) the arranging and other services regarding this Agreement provided by the Administrative Agent
are arm’s-length commercial transactions between the Borrower and its and Affiliates, on the one hand, and the 

  

- 102 - 

 
Administrative Agent the Arrangers, on the other hand, (B) the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and
(C) the Borrower is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (ii) (A) the Administrative Agent, and the Arranger each
is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower, or any of its Affiliates, or any other
Person and (B) neither the Administrative Agent nor the Arrangers has any obligation to the Borrower, any other Loan Party or any of their respective Affiliates with respect to the transactions contemplated hereby except those obligations
expressly set forth herein and in the other Loan Documents; and (iii) the Administrative Agent and the Arrangers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
the Borrower, the other Loan Parties and their respective Affiliates, and neither the Administrative Agent nor the Arrangers has any obligation to disclose any of such interests to the Borrower, any other Loan Party or any of their respective
Affiliates. To the fullest extent permitted by law, the Borrower hereby waives and releases any claims that it may have against the Administrative Agent and the Arrangers with respect to any breach or alleged breach of agency or fiduciary duty in
connection with any aspect of any transaction contemplated hereby. 
 10.17 Electronic Execution of Assignments and Certain
Other Documents. The words “execution,” “signed,” “signature,” and words of like import in any Assignment and Assumption or in any amendment or other modification hereof (including waivers and consents) shall be
deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as
the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws
based on the Uniform Electronic Transactions Act. 
 10.18 USA PATRIOT Act. Each Lender that is subject to the Act (as
hereinafter defined) and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26,
2001)) (the “Act”), it is required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender or the
Administrative Agent, as applicable, to identify the Borrower in accordance with the Act. The Borrower shall, promptly following a request by the Administrative Agent or any Lender, provide all documentation and other information that the
Administrative Agent or such Lender requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Act. 

10.19 Time of the Essence. Time is of the essence of the Loan Documents. 

10.20 ENTIRE AGREEMENT. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENT AMONG THE PARTIES AND MAY NOT BE
CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES. 
 [Remainder of Page Intentionally Left Blank] 

  

- 103 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed
as of the date first above written. 
  

			
	 INDUSTRIAL INCOME OPERATING
 PARTNERSHIP LP, a Delaware limited
 partnership

		
	By:	 	Industrial Income Trust Inc., its sole general partner
		
		 	 By: /s/    Thomas G. McGonagle        

Name:    Thomas G. McGonagle        

Title:
CFO                                         
     

  
 S-1

 BANK OF AMERICA, N.A., as 

Administrative Agent 
 By:     /s/    Kurt Mathison                    

 Name: Kurt Mathison 

Title: Senior Vice President 

  
 S-2

 BANK OF AMERICA, N.A., as a Lender, L/C 

Issuer and Swing Line Lender 
 By:     /s/    Kurt Mathison                    

 Name: Kurt Mathison 

Title: Senior Vice President 

  
 S-3

 KEYBANK NATIONAL ASSOCIATION, as 

Syndication Agent and as a Lender 

By:     /s/    Christopher T.
Neil                     
 Name: Christopher T. Neil 
 Title: Senior Vice President

  
 S-4

 WELLS FARGO BANK, NATIONAL 

ASSOCIATION, as Co-Documentation Agent and 

as a Lender 
 By:     /s/    Carl H. Skanderup                    

 Name: Carl H. Skanderup 

Title: Vice President 

  
 S-5

 REGIONS BANK, as Co-Documentation Agent 

and as a Lender 
 By:     /s/    Rob MacGregor                    

 Name: Rob MacGregor 

Title: Senior Vice President 

  
 S-6

 JPMORGAN CHASE BANK, N.A., as Co- 

Documentation Agent and as a Lender 

By:     /s/ Amber
Coffey             
 Name:
    AMBER COFFEY             
 Title:     CREDIT BANKER             

  
 S-7

 U.S. BANK NATIONAL ASSOCIATION, as a 

Lender 
 By:     /s/    James Jennings Payne                    

 Name: James Jennings Payne 

Title: Vice President 

  
 S-8

 RBS CITIZENS, N.A., as a Lender 

By:     /s/    Samuel
Bluso                     
 Name: Samuel Bluso 
 Title: Senior Vice President 

  
 S-9Third Amended and Restated Investor Rights Agreement

 Exhibit 4.4 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 THIS THIRD AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of October 19, 2007, by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) all holders of
the Company’s common stock listed on Exhibit A (referred to herein individually as a “Founder” and collectively as the “Founders”), (iii) the Series C Investors listed on Exhibit B (the
“Series C Investors”), (iv) the Series D Investors listed on Exhibit C (the “Series D Investors”), (v) the Series F Investors listed on Exhibit D (the “Series F Investors”)
and (vi) the Series H Investors listed on Exhibit E (the “Series H Investors,” together with the Series C Investors, Series D Investors and Series F Investors, the “Investors”). The Founders and the
Investors may be referred to herein individually as a “Stockholder,” and collectively as “Stockholders.” This Agreement amends and restates the Investor Rights Agreement dated as of April 28, 2000, as such
Investor Rights Agreement was amended and restated as of September 20, 2001 and June 2, 2004, respectively. 

WHEREAS, the Company, the Founders, the Series C Investors, the Series D Investors and the Series F Investors are each party to that
certain Second Amended and Restated Investor Rights Agreement, dated June 2, 2004 (the “Second Amended and Restated IRA”) in connection with the issuance by the Company (a) to the Series C Investors of 5,100,500 shares of
the Company’s Series C Convertible Preferred Stock, $.001 par value per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series C Stock”), (b) to the Series D Investors of
6,390,866 shares of the Company’s Series D Convertible Preferred Stock, par value $.001 per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series D Stock”) and (c) to the
Series F Investors of 925,412 shares of the Company’s Series F Convertible Preferred Stock, par value $.001 per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series F Stock”)
and warrants to purchase an additional 441,826 shares of Series F Stock (the “Warrant Shares”); 
 WHEREAS, the
Series H Investors have purchased shares (the “Series H Stock”) of the Company’s Series H Convertible Preferred Stock, $.001 par value per share, convertible into shares of the Company’s common stock, $.001 par value per
share, pursuant to the terms of that certain Securities Purchase Agreement, dated October 10, 2007, by and among the Series H Investors and the Company (the “Securities Purchase Agreement”) (the Series C Stock, Series D Stock,
Series F Stock and the Series H Stock may be referred to herein collectively as the “Investor Preferred Stock”); 
 WHEREAS, Series C Investors, Series D Investors and Series F Investors party hereto, holding in the aggregate a sufficient number of shares of Series C Stock, Series D Stock and Series F Stock necessary
to amend the Second Amended and Restated IRA in accordance with the provisions of Section 8.3 thereof, desire, as hereinafter provided, to amend and restate the Second Amended and Restated IRA in order to add the Series H Investors as parties
thereto; and 
 WHEREAS, the Board of Directors of the Company has determined that it is in the best interests of the Company
that the Company enter into this Agreement. 

 NOW, THEREFORE, in consideration of the covenants and agreements set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereto covenant and agree as follows: 
  

	1.	GENERAL PROVISIONS 

 1.1 Amendment and
Restatement of Second Amended and Restated IRA. The Second Amended and Restated IRA is hereby amended and restated and superceded and replaced in its entirety by this Agreement. 
 1.2 Shares Subject to this Agreement. The Stockholders expressly agree that the terms and restrictions of this Agreement shall apply to all shares of the Company’s capital stock which any of
them now owns or hereafter acquires by any means, including, without limitation, by purchase, assignment or operation of law, or as a result of any stock dividend, stock split, reorganization, reclassification, whether voluntary or involuntary, or
other similar transaction, and to any shares of capital stock of any successor in interest of the Company, whether by sale, merger, consolidation or other similar transaction, or by purchase, assignment or operation of law (the
“Shares”). 
 1.3 No Partnership Relationship. Notwithstanding, but not in limitation of, any other provision of this
Agreement, the parties understand and agree that the creation, management and operation of the Company shall not create or imply a general partnership between or among the Investors and shall not make any Investor the agent or partner of any other
Investor for any purpose. 
 1.4 Certain Definitions. As used in this Agreement, the following terms shall have the following respective
meanings: 
 “Affiliate” has the meaning ascribed to that term in Rule 12b-2 under the Exchange Act, or any
successor rule. 
 “Commission” shall mean the United States Securities and Exchange Commission and any
successor agency of the Federal government administering the Securities Act and the Exchange Act. 
 “Common
Stock” shall mean (i) the common stock, par value $.001 per share, of the Company, (ii) any other capital stock of the Company, however designated, authorized on or after the date hereof, which shall neither be limited to a fixed
sum or percentage of par value in respect of the rights of the holders thereof to participate in dividends nor entitled to a preference in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the
Company, and (iii) any other securities into which or for which any of the securities described in (i) or (ii) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, consolidation, sale of assets
or other similar transaction. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and
any similar or successor Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 

  
 2 

 “Initial Public Offering” shall mean the first underwritten public offering
of Common Stock of the Company at a price per share no less than $6.14 (subject to appropriate adjustment for stock splits, reverse stock splits, stock dividends, combinations and other similar recapitalization events), offered on a firm commitment
basis pursuant to a registration statement filed with the Commission under the Securities Act on Form S-1 or its then equivalent, in which the aggregate gross proceeds to the Company equals or exceeds $40,000,000. 

“Person” means an individual, corporation, partnership, joint venture, trust or unincorporated organization, or a
government or any agency or political subdivision thereof. 
 The terms “register”,
“registered” and “registration” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the
declaration or ordering of the effectiveness of such registration statement under the Securities Act, or, as the context may require, under the Exchange Act or applicable state securities laws. 

“Registrable Securities” shall mean (i) shares of Common Stock or other securities issued or issuable pursuant to
the conversion of the Investor Preferred Stock (including the Warrant Shares); and (ii) any shares of Common Stock or other securities issued or issuable pursuant to the conversion of the Investor Preferred Stock upon any stock split, stock
dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event, excluding in any event securities which have been (a) registered under the Securities Act pursuant to an effective registration statement filed
thereunder and disposed of in accordance with the registration statement covering them or (b) publicly sold pursuant to Rule 144 under the Securities Act; provided that, with respect to any holder (other than Persons who are
Affiliates of the Company), shares of Common Stock or other securities held by such holder shall cease to be Registrable Securities at such time when such holder can sell such shares of Common Stock or other securities pursuant to Rule 144(k) under
the Securities Act. Wherever reference is made in this Agreement to a request or consent of holders of a certain percentage of Registrable Securities, the determination of such percentage shall be calculated on the basis of shares of Common Stock
issued or issuable upon conversion of the Investor Preferred Stock even if such conversion has not been effected. 

“Registration Expenses” shall mean the expenses so described in Section 4.7(a). 

“Securities Act” shall mean the Securities Act of 1933, as amended, and any similar or successor Federal statute, and
the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 

“Selling Expenses” shall mean the expenses so described in Section 4.7(a). 

“Series H Original Issue Date” shall mean the date on which shares of Series H Stock were first issued. 

“Subsidiary” or “Subsidiaries” shall mean any corporation, partnership, trust or other entity of
which the Company and/or any of its other Subsidiaries directly or indirectly owns at the time a majority of the outstanding shares of any class of equity security of such corporation, partnership, trust or other entity. 

  
 3 

	2.	PREEMPTIVE RIGHTS 

 2.1 Notice of New
Issuance. Except with respect to “Exempt Issuances” as defined in Section 2.3, in the event that the Company plans to issue any (i) shares of Common Stock, (ii) warrants, options or other rights to purchase Common Stock
(collectively, “Rights”), or (iii) any debentures or other securities (including capital stock) convertible into or exchangeable for shares of Common Stock (collectively, “Convertible Securities”), the Company
will deliver to the Investors a notice (the “Offer Notice”), promptly upon the completion of such issuance (the “New Issuance”), stating the price and other terms and conditions thereof. 

2.2 Right to Purchase Shares, Rights or Convertible Securities. In the event of a New Issuance (other than an Exempt Issuance), the Investors
shall have the right to purchase such number of shares of Common Stock, Rights or Convertible Securities at the price and on the terms upon which such New Issuance was made, such that, after giving effect to the issuance to the Investors and the
conversion, exercise and exchange into or for (whether directly or indirectly) shares of Common Stock of all such Rights and Convertible Securities, each Investor who exercises such right will continue to maintain his, her or its same proportionate
ownership of Common Stock as of the date immediately preceding the New Issuance, treating each Investor, for the purpose of such computation, as the holder of the number of shares of Common Stock which would be issuable to him, her or it, as the
case may be, upon conversion, exercise and exchange of all Rights and Convertible Securities held by him, her or it on the date immediately preceding the New Issuance and assuming the like conversion, exercise and exchange of all such securities
held by other Persons. The rights set forth in this Article 2 shall be exercised by the Investors, if at all, by written notice to the Company delivered not later than thirty (30) days after the receipt by the Investors of the Offer Notice in
accordance with the terms and conditions stated therein and such right shall expire at the end of the thirtieth day after the day of the receipt by the Investors of the Offer Notice. 
 2.3 Exempt Issuances. The issuances referred to in Section 2.1 which will not give the Investors the rights described in Section 2.2 (the “Exempt Issuances”) are
issuances in which shares of Common Stock or Rights or Convertible Securities of the Company are issued or deemed issued (i) as a dividend or distribution payable pro rata to all holders of Common Stock or other securities of the Company;
(ii) in connection with Rights to purchase up to six million (6,000,000) shares of Common Stock (which amount shall be subject to equitable adjustment whenever there shall occur a stock dividend, stock split, combination of shares,
reclassification or other similar event with respect to the Common Stock) issued or issuable to employees, consultants, officers and directors of the Company pursuant to the Company’s 1996 Employee, Director and Consultant Stock Plan, 2005
Employee, Director and Consultant Stock Plan or any other equity plan or arrangement approved by the Company’s Board of Directors in accordance with Section 6.2(d) unless a higher number of Rights is approved by holders of at least fifty
percent (50%) of the Investor Preferred Stock, voting together as a single class on an as-converted basis; (iii) in connection with the exercise of any preemptive or percentage maintenance rights outstanding on the date hereof;
(iv) in connection with the conversion or exercise of any Rights or Convertible Securities outstanding on the date hereof; (v) in connection with an acquisition by the Company of stock or assets of another Person, provided that the Company
acquires at least fifty percent (50%) of the voting power of the other Person, and the acquisition has been approved in accordance with Section 6.2(f); (vi) in connection with 

  
 4 

 
commercial or equipment financing not to exceed an amount equal to four percent (4%) of the fully-diluted equity of the Company immediately after the final closing of the Series H Stock
transaction; or (vii) in connection with the Company’s Initial Public Offering. 
 2.4 Termination. The respective rights and
obligations of the parties under this Article 2 shall terminate upon to the consummation of the Company’s Initial Public Offering. 
  

	3.	RESTRICTIONS ON TRANSFER; INVESTOR PARTICIPATION IN SALES 

 3.1 Restrictions on Transfer by Stockholders. The Stockholders hereby agree to the provisions set forth in this Article 3 with respect to any sale, transfer or other disposition of Shares, in the
event such sale, transfer or disposition is allowed pursuant to Section 4.2 hereof. 
 3.2 Non-Complying Transfers Prohibited. Each
Stockholder understands that he may not sell, assign, transfer, exchange, gift, devise, pledge, hypothecate, encumber or otherwise alienate or dispose of any Shares, or any right or interest therein, whether voluntarily or involuntarily, by
operation of law or otherwise, except in accordance with this Agreement. Any such purported transfer in violation of any provision of this Agreement and all actions by the purported transferor and transferee in connection therewith shall be of no
force or effect. The Company shall not recognize such purported transfer for any purpose, including, without limitation, for the purposes of dividend and voting rights. If any transfer of Shares is made or attempted contrary to the provisions of
this Agreement or if any Shares are not offered as required by this Agreement, the Company or the other holders of Shares of the Company shall have the right to purchase such Shares from each such transferring Stockholder or each such transferee at
any time before or after each such purported transfer, as hereinafter provided. In addition to any other legal or equitable remedies the Company or such other holders may have, the Company and such other holders may enforce this right by actions for
specific performance, to the extent permitted by law. 
 3.3 Rights of First Refusal on Voluntary Transfers. 

(a) Right of First Refusal of the Company. Except as otherwise provided herein, any Stockholder who intends to sell, assign,
transfer or otherwise voluntarily alienate or dispose of any Shares in one transaction or a series of related transactions (the “Selling Stockholder”) shall, prior to any such transfer, give written notice (the “Selling
Stockholder’s Notice”) of such intention to the Company and to the Investors. The Selling Stockholder’s Notice shall include the name of the proposed transferee, the proposed purchase price per Share, the terms of payment of such
purchase price and all other matters relating to such sale and shall be accompanied by a copy of a binding written agreement of the proposed transferee to purchase such Shares from the Selling Stockholder. The Selling Stockholder’s Notice shall
constitute a binding offer by the Selling Stockholder to sell to the Company or its designee all or any part of such number of Shares (the “Offered Shares”) then owned by the Selling Stockholder as are proposed to be sold in the
Selling Stockholder’s Notice at the monetary price per Share designated in the Selling Stockholder’s Notice, payable as provided in Section 3.3(c). Not later than twenty (20) days after receipt of the Selling Stockholder’s
Notice, the Company shall deliver written notice to the Selling Stockholder stating whether the Company has accepted the offer stated in the Selling Stockholder’s Notice (in whole or in part); provided, however, that the

  
 5 

 
Company shall not accept such offer without the prior approval of Company’s Board of Directors (including each of the Series H Directors (as hereinafter defined)). The closing of any
purchase of the Offered Shares by the Company shall take place on the later of (i) fifteen (15) days after the end of the twenty (20) day period set forth above and (ii) the date on which the Investors consummate any purchase of
Offered Shares pursuant to Section 3.3(b) below. Notwithstanding anything to the contrary contained herein, the Company may accept the offer stated in the Selling Stockholder’s Notice without the prior approval of the Company’s Board
of Directors as required by this Section 3.3(a) in the event that the Company has not purchased in excess of fifty thousand (50,000) Shares pursuant to this Section 3.3(a) (subject to appropriate adjustment for stock splits, stock
dividends, combinations and similar recapitalization events) during any twelve (12) month period. 
 (b) Right of First
Refusal of the Investors. If the Company does not accept the offer to purchase all of the Offered Shares within the twenty (20) day period provided in Section 3.3(a), no later than the end of such twenty (20) day period the
Company shall give notice (the “Company Notice”) of that fact to each Investor and each Investor shall have the right to purchase all or any part of its Proportionate Percentage (as defined below) of the Offered Shares not purchased
by the Company or its designee (the “Remaining Shares”), at the monetary price per Share designated in the Selling Stockholder’s Notice, payable as provided in Section 3.3(c). Not later than fifteen (15) days after
delivery of the Company Notice, each Investor shall deliver to the Company, the other Investors and the Selling Stockholder a written notice stating whether such Investor has accepted the offer stated in the Selling Stockholder’s Notice with
respect to its Proportionate Percentage of the Remaining Shares. If one (1) or more of the Investors elects not to purchase all of the Remaining Shares which it is entitled to purchase pursuant to this Section 3.3(b), the other Investors,
by written notice to the Company and the Selling Stockholder within five (5) days after the end of the fifteen (15) day period set forth above, may elect to purchase all or a part of such unpurchased Remaining Shares without the consent of
any non-purchasing Investors, pro rata between or among them or in such other manner as they may agree. The closing of any purchase of the Remaining Shares by the Investors shall take place no later than fifteen (15) days after the end of the
fifteen (15) day period set forth above. As used in this Section 3.3(b), “Proportionate Percentage” shall mean with respect to each Investor a fraction, the numerator of which is the number of Shares owned by such Investor
(calculated on a fully diluted basis), and the denominator of which is the total number of Shares owned by all Investors (calculated on a fully diluted basis). 
 (c) Closing. The place for the closing of any purchase and sale described in Section 3.3(a) or Section 3.3(b) shall be the principal office of the Company or at such other place as the
parties shall agree. At the closing, the Selling Stockholder shall accept payment on the terms (including price) offered by the proposed transferee named in the Selling Stockholder’s Notice, provided, however, that the Company and
the Investors shall not be required to meet any non-monetary terms of the proposed transfer, including, without limitation, delivery of consideration in the form of other securities in exchange for the Shares proposed to be sold. At the closing, the
Selling Stockholder shall deliver to the Company or the Investors, as the case may be, in exchange for Shares purchased and sold at the closing, certificates for the number of Shares stated in the Selling Stockholder’s Notice, accompanied by
duly executed instruments of transfer. 

  
 6 

 (d) Transfers to Third Parties. If the Company and the Investors in the aggregate
fail to accept the offer stated in the Selling Stockholder’s Notice with respect to all of the Offered Shares, then the Selling Stockholder shall be free to sell any of the remaining shares of the Offered Shares not purchased by the Company and
the Investors at a price and on terms no less favorable to the Selling Stockholder than described in the Selling Stockholder’s Notice, provided, however, that such sale is consummated within ninety (90) days after the giving
of the Selling Stockholder’s Notice pursuant to Section 3.3(a). As a condition precedent to the effectiveness of a transfer pursuant to this Section 3.3(d), the proposed transferee(s) shall agree in writing prior to such transfer to
become a party to this Agreement and shall thereafter be permitted to transfer Shares only in accordance with this Agreement. 
 3.4
Participation in Sales. 
 (a) Take-Along Right. In the event that a Stockholder (the
“Offeree”) receives a bona fide offer from a third party or parties, other than from a Permitted Transferee (as defined below) or any other Stockholder (the “Offeror”), to acquire any of his, her or its Shares (the
“Take-Along Shares”) for a specified price payable in cash or otherwise and on specified terms and conditions (the “Offer”), and the Offeree proposes to sell or otherwise transfer the Take-Along Shares to the
Offeror pursuant to the Offer, the Offeree shall not effect such sale or transfer unless each Investor is first given the right to sell to the Offeror, at the same price per Share and on the same terms and conditions as stated in the Offer, the same
proportion of shares of Common Stock (or shares of Investor Preferred Stock then convertible into such number of shares of Common Stock) then owned by such Investor, as the proportion that the number of the Take-Along Shares bears to the total
number of shares of Common Stock held by the Offeree and all Investors on the date of the Company Notice. 
 (b) Notices of
Offer and Intent to Participate. If an Investor wishes to participate in any sale pursuant to Section 3.4(a) it shall notify the Offeree in writing of such intention and the number of Shares it wishes to sell pursuant to this
Section 3.4(b) not later than fifteen (15) days after delivery of the Company Notice (as described in Section 3.3(b) above). If the Offeree does not receive such notice from an Investor within such fifteen (15) day period, the
Offeree shall be free to consummate the proposed transaction without any obligation to include such Investor’s Shares in such transaction. 
 (c) Sale of Take-Along Shares. The Offeree and each Investor who has provided timely notice in accordance with Section 3.4(b) above shall sell to the Offeror all, or at the option of the
Offeror, any part of the Shares proposed to be sold by them at not less than the price and upon other terms and conditions, if any, not more favorable to the Offeror than those stated in the Offer, provided, however, that any purchase
of less than all of such Shares by the Offeror shall be made from the Offeree and each such Investor pro rata based upon the relative amount of the Shares that the Offeree and such Investor is entitled to sell pursuant to Section 3.4.

 3.5 Drag Along Obligation. If at any time after the fourth anniversary of the Series H Original Issue Date, holders representing at
least sixty-six and two-thirds percent (66-2/3%) of the Investor Preferred Stock then outstanding (the “Selling Investors”) shall approve (a) a proposal from a Person for the transfer, directly or indirectly, of a majority of
the Company’s stock to such Person (a “Stock Sale”), (b) the merger or consolidation of the Company with or 

  
 7 

 
into another Person in which the Company’s stockholders will receive cash or securities of any other Person for their shares or (c) the sale by the Company or its Subsidiaries of all or
substantially all of their assets to a Person, in each of the above cases for a specified price payable in cash or otherwise and on specified terms and conditions (a “Sale Proposal”), then the Company shall deliver a written notice
(a “Required Sale Notice”) with respect to such Sale Proposal to each Stockholder stating that the Selling Investors have approved a Sale Proposal and proposes to effect the Sale Proposal and providing the identity of the Persons
involved in such Sale Proposal and the terms thereof. Each such Stockholder, upon receipt of a Required Sale Notice, shall be obligated, which obligation shall be enforceable by the Selling Investors and the Company, to participate in the
transaction (a “Required Sale”) contemplated by the Sale Proposal, and agrees as follows: 
 (a) if such
transaction requires stockholder approval, with respect to all Shares that such Stockholder owns or over which such Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares
in favor of, and adopt, such Sale Proposal (together with any related amendment to the Company’s Certificate of Incorporation required in order to implement such Sale Proposal) and to vote in opposition to any and all other proposals that could
reasonably be expected to delay or impair the ability of the Company to consummate such Sale Proposal; 
 (b) if such
transaction is a Stock Sale, to sell the same proportion of Shares beneficially held by such Stockholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their Shares on the same terms and
conditions as the Selling Investors; 
 (c) to execute and deliver all related documentation and take such other action in
support of the Sale Proposal as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 3.5, including, without limitation, executing and delivering instruments of
conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and
encumbrances) and any similar or related documents; 
 (d) not to deposit, and to cause their Affiliates not to deposit, except
as provided in this Agreement, any Shares owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquiror in
connection with the Sale Proposal; and 
 (e) if the consideration to be paid in exchange for the Shares pursuant to this
Section 3.5 includes any securities and due receipt thereof by any Stockholder would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such
securities or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated
under the Securities Act, the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Stockholder, an amount in cash equal to the fair value (as determined in
good faith by the Company’s Board of Directors) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such securities in exchange for the Shares. 

  
 8 

 Any Required Sale Notice may be rescinded by the Company upon the request of the Selling Investors by
delivering written notice thereof to all of the Stockholders. 
 3.6 Transfers to Permitted Transferees. The provisions contained in this
Article 3 shall not apply to (a) transfers by a Stockholder to an Affiliate of such Stockholder, (b) if such Stockholder is a corporation, transfers to the stockholders of such corporation pursuant to a duly declared dividend,
(c) transfers to any nominee of such Stockholder made solely for bona fide internal administrative purposes, (d) transfers by a Stockholder to such Stockholder’s spouse, children or other member of such Stockholder’s immediate
family, or to a trust for the benefit of such persons, (e) transfers by a Stockholder to the trustee or trustees of a trust revocable solely by such Stockholder, (f) transfers by a Stockholder to such Stockholder’s guardian or
conservator, (g) transfers by a Stockholder, in the event of such Stockholder’s death, to such Stockholder’s executor(s) or administrator(s) or to trustee(s) under such Stockholder’s will or (h) transfers of (1) an
aggregate of 770,000 shares of Series C Stock by Schweizerhall Holding AG to Omega Fund III, L.P., (2) an aggregate of 65,732 shares of Series F Stock by Schweizerhall Holding AG to Omega Fund III, L.P. and (3) warrants for the purchase of
an aggregate of 16,433 shares of Series F stock by Schweizerhall Holding AG to Omega Fund III, L.P. (collectively, “Permitted Transferees”); provided, however, that in any such event the Shares so transferred in the
hands of each such Permitted Transferee shall remain subject to the provisions of this Article 3, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. 

3.7 Waiver. From time to time the Company and/or each of the Stockholders may waive their rights hereunder either generally or with respect to one
or more specified transfers which have been proposed, attempted or made. 
 3.8 Termination. The respective rights and obligations of the
parties under this Article 3 shall terminate upon the consummation of the Company’s Initial Public Offering or a merger, acquisition or other form of corporate reorganization in which outstanding shares of the Company are exchanged for
securities or other consideration issued, or caused to be issued, by the acquiring corporation or its subsidiary (other than a mere reincorporation transaction) and pursuant to which the holders of the outstanding voting securities of the Company
immediately prior to such consolidation, merger or other transaction fail to hold (in substantially the same percentages) equity securities representing a majority of the voting power of the Company or surviving entity immediately following such
consolidation, merger or other transaction (excluding voting securities of the acquiring corporation held by such holders prior to such transaction), or the sale of all or substantially all of the assets of the Company. 

  
 9 

	4.	TRANSFER OF REGISTRABLE SECURITIES; REGISTRATION 

 4.1 Restrictive Legend. Each certificate representing Registrable Securities shall, except as otherwise provided in this Section 4.1 or in Section 4.2, be stamped or otherwise imprinted
with a legend substantially in the following form (in addition to any legend required under applicable state securities laws): 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY OTHER SECURITIES
LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933 AND ANY OTHER APPLICABLE SECURITIES LAWS, UNLESS THE HOLDER SHALL HAVE OBTAINED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION
IS NOT REQUIRED OR THE TRANSFEREE IS AN AFFILIATE OF THE HOLDER; PROVIDED THAT THE CORPORATION SHALL NOT REQUIRE SUCH OPINION OF COUNSEL WITH RESPECT TO TRANSFERS MADE PURSUANT TO RULE 144 OR REGULATIONS UNDER THE SECURITIES ACT.” 

In addition to the foregoing, each certificate representing Registrable Shares held by a Founder shall also be stamped or otherwise imprinted with a
legend substantially in the following form: 
 “THE SHARES REPRESENTED HEREBY ARE ALSO SUBJECT TO RESTRICTIONS ON TRANSFER
CONTAINED IN A CERTAIN STOCK SUBSCRIPTION AND RIGHT OF FIRST REFUSAL AGREEMENT, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT COMPLIANCE WITH THE TERMS THEREOF. THE COMPANY WILL FURNISH A COPY OF THE FULL TEXT OF SUCH RESTRICTIONS TO
THE HOLDER OF THIS CERTIFICATE UPON WRITTEN REQUEST AND WITHOUT CHARGE.” 
 4.2 Notice of Proposed Transfer. Subject to the
provisions of Article 3, prior to any proposed sale, pledge, hypothecation or other transfer of any Registrable Securities (other than under the circumstances described in Section 4.3, 4.4 or 4.5), the holder thereof shall give written notice
to the Company of its intention to effect such sale, pledge, hypothecation or other transfer. Each such notice shall describe the manner of the proposed sale, pledge, hypothecation or other transfer and, if requested by the Company shall be
accompanied by either (i) an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed sale, pledge, hypothecation or other transfer may be effected without registration under the Securities Act or (ii) a
“no action” letter from the Commission to the effect that the distribution of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the
holder of such stock shall be entitled to transfer such stock in accordance with the terms of its notice; provided, however, that no such opinion of counsel or “no-action” letter shall be required by the Company (A) for
a distribution to one or more partners of the transferor (in the case of a transferor that is a partnership) or to a stockholder (in the case of a transferor that is a corporation) in each case in respect of the beneficial interest of such partner
or stockholder, or to an affiliate of such transferor, or (B) in the case of a transfer made in accordance with the provisions of Rule 144 or Regulation S under 

  
 10 

 
the Securities Act, although such opinion of counsel may be required by an independent transfer agent of the Company after the Initial Public Offering. Each certificate for Registrable Securities
transferred as above provided shall bear the appropriate restrictive legend or legends, as the case may be, set forth in Section 4.1, except that such certificate shall not bear the first such legend if (i) such transfer is in accordance
with the provisions of Rule 144 (or any other rule permitting public sale without registration under the Securities Act) or (ii) the opinion of counsel or “no-action” letter referred to above is to the further effect that the
transferee and any subsequent transferee (other than an affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act or that the first such legend is not required to establish
compliance with any provisions of the Securities Act. Notwithstanding any other provision hereof, the restrictions provided for in this Section 4.2 shall not apply to securities that are not required to bear the legends prescribed by
Section 4.1 in accordance with the provisions of that Section. 
 4.3 Required Registration. 

(a) At any time after the earlier of (i) 180 days after the effective date of the registration statement covering the first
underwritten public offering of Common Stock of the Company (an “IPO”) and (ii) the third anniversary of the Series H Original Issue Date, holders of at least forty percent (40%) of the Investor Preferred Stock (including
Common Stock issuable upon conversion thereof), together as a single class, on three occasions only may request the Company to register for sale under the Securities Act all or any portion of the shares of Registrable Securities held by such
requesting holder or holders for sale in the manner specified in such notice; provided, however, that in the event of any such request, the aggregate offering price of shares of Registrable Securities to be registered on any such
registration statement, net of underwriting discounts and commissions, is at least Five Million Dollars ($5,000,000). Notwithstanding anything to the contrary contained herein, the Company shall not be required to effect a registration pursuant to
this Section 4.3 during the period commencing sixty (60) days prior to the estimated filing date of, and ending on the date which is one hundred eighty (180) days after the closing date of, a registration statement filed by the
Company covering an underwritten public offering of the Common Stock under the Securities Act, provided the Company is actively employing in good faith reasonable efforts to cause such registration statement to become effective and such estimate of
the filing date is made in good faith. If the Company shall furnish to the holders of Registrable Securities a certificate signed by its President stating that in the good faith judgment of its Board of Directors it would be seriously detrimental to
the Company or its stockholders for a registration statement to be filed at such time, then the Company’s efforts to cause a registration statement to be filed shall be deferred for a period not to exceed four (4) months in any twelve
(12) month period, provided that in such event, if the Company does not effect a registration requested pursuant to this Section 4.3, such request shall not be counted for purposes of the limitations on registrations set forth above and in
Section 4.3(b). 
 (b) Following receipt of any notice under this Section 4.3, the Company shall immediately notify
all holders of Registrable Securities from whom notice has not been received and such holders shall then be entitled within thirty (30) days after receipt of such notice from the Company to request the Company to include in the requested
registration all or any portion of their shares of Registrable Securities. The Company shall use reasonable best efforts to register 

  
 11 

 
under the Securities Act, for public sale in accordance with the method of disposition specified in the notice from requesting holders described in paragraph (a) above, the number of shares
of Registrable Securities specified in such notice (and in all notices received by the Company from other holders within thirty (30) days after the receipt of such notice by such holders). The Company shall be obligated to register the
Registrable Securities pursuant to this Section 4.3 on three (3) occasions only if requested by holders of at least forty percent (40%) of the Investor Preferred Stock, including, in each case Common Stock issuable upon conversion
thereof, provided, further, that such obligation shall be deemed satisfied only when a registration statement covering all shares of Registrable Securities specified in notices received as aforesaid, for sale in accordance with the
method of disposition specified by the requesting holders, shall have become effective and, if such method of disposition is a firm commitment underwritten public offering, sixty-six and two-thirds percent (66-2/3%) or more of such shares shall have
been sold pursuant thereto. The Company shall not be obligated to register, pursuant to this Section 4.3, the Registrable Securities of any holder who fails to provide promptly to the Company such information as the Company may reasonably
request at any time to enable the Company to comply with any applicable law or regulation or to facilitate preparation of the registration statement. 
 (c) If the holders requesting such registration intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall (i) so advise the Company as a part of
their request made pursuant to this Section 4.3 and the Company shall include such information in the written notice referred to in paragraph (b) above and (ii) designate the managing underwriter of such offering, which managing
underwriter shall be reasonably acceptable to the Company. The right of any holder to registration pursuant to this Section 4.3 shall be conditioned upon such holder’s agreeing to participate in such underwriting and to permit inclusion of
such holder’s Registrable Securities in the underwriting. A holder may elect to include in such underwriting all or a part of the Registrable Securities it holds. 
 (d) A registration statement filed pursuant to this Section 4.3 may, subject to the following provisions, include (i) shares of Common Stock for sale by the Company for its own account,
(ii) shares of Common Stock held by officers or directors of the Company and (iii) shares of Common Stock held by persons entitled to include such shares in such registration pursuant to “incidental” or “piggyback”
registration rights granted to such persons in accordance with Section 4.14 (the “Other Shareholders”), in each case for sale in accordance with the method of disposition specified by the requesting holders. If such
registration shall be underwritten, the Company, such officers and directors and Other Shareholders proposing to distribute their shares through such underwriting shall enter into an underwriting agreement in customary form with the representative
of the underwriter or underwriters selected for such underwriting on terms no less favorable to such officers, directors or Other Shareholders than the terms afforded the holders of Registrable Securities. If and to the extent that the managing
underwriter determines that marketing factors require a limitation on the number of shares to be included in such registration, then the shares of Common Stock held by officers or directors or by Other Shareholders (other than Registrable
Securities) and shares of Common Stock to be sold by the Company for its own account shall be excluded from such registration to the extent so required by such managing underwriter, and unless the holders of such shares and the Company have
otherwise agreed in writing, such exclusion shall be applied first to the shares held by the directors and officers of the Company and the Other Shareholders to the extent 

  
 12 

 
required by the managing underwriter, then to the shares of Common Stock of the Company to be included for its own account to the extent required by the managing underwriter. If the managing
underwriter determines that marketing factors require a limitation of the number of Registrable Securities to be registered under this Section 4.3, then Registrable Securities shall be excluded in such manner that the securities to be sold
shall be allocated pro rata among the selling holders based on their ownership of Registrable Securities. If, in such event, the managing underwriter reduces the number of shares of Registrable Securities to be registered under this Section 4.3
to an amount which is less than fifty percent (50%) of the number of shares specified in notices received under this Section 4.3, then such registration shall not be counted for purposes of the limitations on registrations set forth in
Section 4.3(b). In any event, all securities to be sold other than Registrable Securities will be excluded prior to any exclusion of Registrable Securities. No Registrable Securities or any other security excluded from the underwriting by
reason of the underwriter’s marketing limitation shall be included in such registration. If any holder of Registrable Securities, officer, director or Other Shareholder who has requested inclusion in such registration as provided above,
disapproves of the terms of the underwriting, such holder of securities may elect to withdraw therefrom by written notice to the Company and the managing underwriter. The securities so withdrawn shall also be withdrawn from registration. 

4.4 Incidental Registration. Except for the IPO, if the Company at any time (other than pursuant to Section 4.3 or 4.5) proposes to register
any of its securities under the Securities Act for sale to the public, whether for its own account or for the account of other security holders or both (except with respect to registration statements on Forms S-4, S-8 or any successor to such forms
or another form not available for registering the Registrable Securities for sale to the public), each such time it will promptly give written notice to all holders of the Registrable Securities of its intention so to do. Upon the written request of
any such holder, received by the Company within thirty (30) days after the giving of any such notice by the Company, to register any or all of its Registrable Securities, the Company will use reasonable best efforts to cause the Registrable
Securities as to which registration shall have been so requested to be included in the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent requisite to permit the sale or other disposition by
the holder (in accordance with its written request) of such Registrable Securities so registered. If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the
holders of Registrable Securities as a part of the written notice given pursuant to this Section 4.4. In such event the right of any holder of Registrable Securities to registration pursuant to this Section 4.4 shall be conditioned upon
such holder’s participation in such underwriting to the extent provided herein. All holders of Registrable Securities proposing to distribute their securities through such underwriting shall (together with the Company and the Other Shareholders
distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for underwriting by the Company. Notwithstanding any other provision of this
Section 4.4, if the managing underwriter determines that marketing factors require a limitation on the number of shares to be underwritten, the Company shall so advise all holders of securities requesting registration of any limitations on the
number of shares to be underwritten, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated (i) first to the Company with respect to shares of Common Stock being sold for
its own account, (ii) second, to holders of Registrable Securities requesting registration in proportion, as 

  
 13 

 
nearly as practicable, to the respective amounts of securities owned by them and (iii) third, to Other Shareholders requesting registration in proportion, as nearly as practicable, to the
respective amounts of securities owned by them; provided that, with respect to any registration statement declared effective during the first six months following the IPO, at least twenty-five percent (25%) of the securities included in
such registration statement will be Registrable Securities. Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this Section 4.4 without thereby incurring any liability to the holders of
Registrable Securities. If any holder of Registrable Securities disapproves of the terms of any such underwriting, it may elect to withdraw therefrom by written notice to the Company and the underwriter. Any Registrable Securities or other
securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. 
 4.5 Registration on Form S-3. In
addition to the rights provided in Sections 4.3 and 4.4, subject to a limit of one (1) registration hereunder in any six-month period, if at any time (i) any holder or holders of the Registrable Securities request that the Company file a
registration statement on Form S-3 or any comparable or successor form thereto for a public offering of all or any portion of the shares of Registrable Securities held by such requesting holder or holders, the reasonably anticipated aggregate price
to the public of which would be at least One Million Dollars ($1,000,000), and (ii) the Company is a registrant entitled to use Form S-3 or any comparable or successor form thereto to register such shares, then the Company shall use its
reasonable best efforts to register under the Securities Act on Form S-3 or any comparable or successor form thereto, for public sale in accordance with the method of disposition specified in such notice, the number of shares of Registrable
Securities specified in such notice. Whenever the Company is required by this Section 4.5 to use its reasonable best efforts to effect the registration of Registrable Securities, each of the procedures and requirements of Section 4.3,
including, but not limited to, the requirement that the Company notify all holders of Registrable Securities from whom notice has not been received and provide them with the opportunity to participate in the offering, shall apply to such
registration. If the holders requesting such registration notify the Company that they intend to distribute the Registrable Securities covered by their request by means of an underwriting, and if the managing underwriter in connection with such
underwriting determines that marketing factors require a limitation on the number of shares to be underwritten, then notwithstanding any other provision of this Section 4.5, such limitation will be imposed pro rata with respect to all
Registrable Securities whose holders have requested inclusion in such registration pursuant to this Section 4.5 provided that, in any event, all securities to be sold other than Registrable Securities will be excluded prior to any
exclusion of Registrable Securities. 
 4.6 Registration Procedures. If and whenever the Company is required by the provisions of
Section 4.3, 4.4 or 4.5 to use reasonable best efforts to effect the registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 

(a) prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering pursuant to
Section 4.3, shall be on Form S-1 or other form of general applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities including executing an undertaking to file post-effective amendments
and use reasonable best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated thereby; 

  
 14 

 (b) prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified herein and comply with the provisions of the Securities Act with respect to the
disposition of all Registrable Securities covered by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period; 

(c) furnish to each seller of Registrable Securities and to each underwriter such number of copies of the registration statement and each
such amendment and supplement thereto (in each case including all exhibits) and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or other
disposition of the Registrable Securities covered by such registration statement; 
 (d) use reasonable best efforts to register
or qualify the Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the sellers of Registrable Securities or, in the case of an underwritten public offering, the
managing underwriter reasonably shall request, provided, however, that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so
qualified or to consent to general service of process in any such jurisdiction, unless the Company is already subject to service in such jurisdiction; 
 (e) use reasonable best efforts to list the Registrable Securities covered by such registration statement with any securities exchange on which the Common Stock of the Company is then listed; 

(f) comply with all applicable rules and regulations under the Securities Act and Exchange Act; 

(g) immediately notify each seller of Registrable Securities and each underwriter under such registration statement, at any time when a
prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and promptly prepare and furnish
to such seller a reasonable number of copies of a prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 
 (h) if the offering is underwritten and at the request of any seller of Registrable Securities, use reasonable best efforts to furnish on the date that Registrable Securities are delivered to the
underwriters for sale pursuant to such registration: (i) an opinion dated such date of counsel representing the Company for the purposes of such registration, addressed to the underwriters to such effects as reasonably may be requested by
counsel for the underwriters, and (ii) a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters stating that they are independent public accountants within the

  
 15 

 
meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or
supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the period ending no
more than five (5) business days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request; 
 (i) make available for inspection by each seller of Registrable Securities, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other
agent retained by such seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and properties of the Company, as such parties may reasonably request, and cause the Company’s officers, directors
and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement; 
 (j) cooperate with the selling holders of Registrable Securities and the managing underwriter, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities
to be sold, such certificates to be in such denominations and registered in such names as such holders or the managing underwriter may request at least two (2) business days prior to any sale of Registrable Securities; and 

(k) permit any holder of Registrable Securities which holder, in the sole and exclusive judgment, exercised in good faith, of such
holder, might be deemed to be a controlling person of the Company, to participate in good faith in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing,
which in the reasonable judgment of such holder and its counsel should be included. 
 For purposes of this Agreement, the
period of distribution of Registrable Securities in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of
Registrable Securities in any other registration shall be deemed to extend until the earlier of the sale of all Registrable Securities covered thereby or one hundred and eighty (180) days after the effective date thereof, provided,
however, in the case of any registration of Registrable Securities on Form S-3 or a comparable or successor form which are intended to be offered on a continuous or delayed basis, such 180-day period shall be extended, if necessary, to keep
the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided
further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment, permit, in lieu of filing a post-effective amendment which (y) includes any prospectus required by Section 10(a)(3)
of the Securities Act or (z) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in
(y) and (z) above contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement. 

  
 16 

 In connection with each registration hereunder, the sellers of Registrable Securities will
furnish to the Company in writing such information requested by the Company with respect to themselves and the proposed distribution by them as shall be reasonably necessary in order to assure compliance with Federal and applicable state securities
laws. 
 4.7 Expenses. 
 (a) All expenses incurred by the Company in complying with Sections 4.3, 4.4, 4.5 and 4.6 including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of
counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or “blue sky” laws, fees of the National Association of Securities Dealers,
Inc., transfer taxes, fees of transfer agents and registrars, costs of any insurance which might be obtained by the Company with respect to the offering by the Company, and reasonable fees and disbursements (not to exceed Thirty Thousand Dollars
($30,000)) of one counsel selected by a majority in interest of the sellers of Registrable Securities, but excluding any Selling Expenses (defined below), are called “Registration Expenses”. All underwriting discounts, underwriting
selling commissions and brokerage commissions applicable to the sale of Registrable Securities are called “Selling Expenses”. 
 (b) The Company will pay all Registration Expenses in connection with each registration statement under Section 4.3, 4.4 or 4.5. All Selling Expenses in connection with each registration statement
under Section 4.3, 4.4 or 4.5 shall be borne by the participating sellers in proportion to the number of shares registered by each, or by such participating sellers other than the Company (except to the extent the Company shall be a seller) as
they may agree. 
 4.8 Indemnification and Contribution. 
 (a) In the event of a registration of any of the Registrable Securities under the Securities Act pursuant to Section 4.3, 4.4 or 4.5, the Company will indemnify and hold harmless each holder of
Registrable Securities, its officers, directors, partners and employees, each underwriter of such Registrable Securities thereunder and each other person, if any, who controls such holder or underwriter within the meaning of the Securities Act,
against any losses, claims, damages or liabilities, joint or several, to which such holder, officer, director, partner, employee, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any prospectus, offering circular or other document incident to
such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to Section 4.3, 4.4 or 4.5, any preliminary prospectus or final prospectus
contained therein, or any amendment or supplement thereof), (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or
other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application”), (iii) any omission or
alleged omission to state in any such registration statement, prospectus, amendment or supplement or in any Blue Sky Applications executed or filed by the 

  
 17 

 
Company, a material fact required to be stated therein or necessary to make the statements therein not misleading, (iv) any violation by the Company or its agents of the Securities Act or
any rule or regulation promulgated under the Securities Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration, or (v) any failure to register or qualify the
Registrable Securities in any state where the Company or its agents has affirmatively undertaken or agreed in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company) will undertake such
registration or qualification (provided that in such instance the Company shall not be so liable if it has used reasonable best efforts to so register or qualify the Registrable Securities) and will reimburse each such seller, and such
officer, director, partner and employee, each such underwriter and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or
action, promptly after being so incurred, provided, however, that the Company will not be liable in any such case (i) if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission so made in conformity with written information furnished by any such holder, any such underwriter or any such controlling person in writing specifically for use in such
registration statement or prospectus, or (ii) in the case of a sale directly by such holder of Registrable Securities (including a sale of such Registrable Securities through any underwriter retained by such holder of Registrable Securities to
engage in a distribution solely on behalf of such holder of Registrable Securities), such untrue statement or alleged untrue statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final or amended
prospectus, and such holder of Registrable Securities failed to deliver a copy of the final or amended prospectus at or prior to the confirmation of the sale of Registrable Securities to the person asserting any such loss, claim, damage or liability
in any case where such delivery is required by the Securities Act or any state securities laws. 
 (b) In the event of a
registration of any of the Registrable Securities under the Securities Act pursuant to Section 4.3, 4.4 or 4.5, each seller of such Registrable Securities thereunder, severally and not jointly, will indemnify and hold harmless the Company, each
person, if any, who controls the Company within the meaning of the Securities Act, each officer of the Company who signs the registration statement, each director of the Company, each other seller of Registrable Securities, each underwriter and each
person who controls any underwriter within the meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director, other seller, underwriter or controlling person may
become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact
contained in any prospectus offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to
Section 4.3, 4.4 or 4.5, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), or any Blue Sky Application or arise out of or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, other seller, underwriter and controlling person for any legal or other
expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, promptly after being 

  
 18 

 
so incurred, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that any such loss, claim, damage or liability arises out of or
is based upon an untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading made in reliance upon
and in conformity with information pertaining to such seller, as such, furnished in writing to the Company by such seller specifically for use in such registration statement or prospectus; provided, however, that in no event shall any
indemnity hereinunder exceed the net proceeds from the offering received by such seller. Not in limitation of the foregoing, it is understood and agreed that the indemnification obligations of any seller hereunder pursuant to any underwriting
agreement entered into in connection herewith shall be limited to the obligations contained in this subparagraph (b). 
 (c)
Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party
in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 4.8 and shall only relieve it from any liability which it
may have to such indemnified party under this Section 4.8 if and to the extent the indemnifying party is substantially prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the
indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after
notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 4.8 for any legal expenses
subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided, however, that, if the defendants in any such action
include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the
indemnifying party or that the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal
defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the indemnifying party as incurred. No indemnifying party,
in the defense of any such claim or action, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect to such claim or action. Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying party may reasonably request
in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 

(d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which either
(i) any holder of Registrable Securities exercising rights under this Agreement, or any controlling person of any such holder, makes a claim for indemnification pursuant to this Section 4.8 but it is judicially determined (by the entry of
a final 

  
 19 

 
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 4.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in circumstances
for which indemnification is provided under this Section 4.8; then, and in each such case the Company and such holder will contribute to such aggregate losses, claims, damages or liabilities (i) in such proportion as is appropriate to
reflect the relative fault of the Company on the one hand and of such holder on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative fault referred to in clause (i) above but also reflective
of the relative benefits received by the Company on the one hand and by such holder on the other, provided, however, that, in any such case, no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The relative benefits received by the Company on the one hand and such holder on the other shall be deemed to be in the
same respective proportion as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company and such holder. The relative fault of the Company on the one hand and of such
holder on the other shall be determined by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or alleged omission relates to information supplied by the Company or such holder
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 (e) The indemnities and obligations provided in this Section 4.8 shall survive the transfer of any Registrable Securities by such holder. 
 4.9 Changes in Common Stock. If, and as often as, there is any change in the Common Stock by way of a stock split, stock dividend, combination or reclassification, or through a merger,
consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall continue with respect to the Common Stock as so changed.

 4.10 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at
any time permit the sale of the Registrable Securities to the public without registration, except as provided in paragraph (c) below, at all times after ninety (90) days after any registration statement covering a public offering of
securities of the Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) make and keep
public information available, as those terms are understood and defined in Rule 144 under the Securities Act (or any successor rule); 
 (b) use reasonable best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 

  
 20 

 (c) furnish to each holder of Registrable Securities forthwith upon request a written
statement by the Company as to its compliance with the reporting requirements of such Rule 144 (or any successor rule) and, at any time after it has become subject to such reporting requirements, of the Securities Act and the Exchange Act, a copy of
the most recent annual or quarterly report of the Company, and such other reports and documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder to sell
any Registrable Securities without registration. 
 4.11 “Market Stand-Off” Agreement. Each holder of Registrable Securities
agrees, if requested by the Company and an underwriter of Common Stock (or other securities) of the Company, (i) not to lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether such shares or
any such securities are then owned by such holder or are thereafter acquired), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, whether in privately negotiated or open market transactions, during the one
hundred and eighty (180) day period following the effective date of a registration statement of the Company filed under the Securities Act with respect to the Initial Public Offering, provided that all Other Shareholders, all officers
and directors of the Company, all Founders, all persons including shares in such offering and all holders of one percent (1%) or more of the outstanding shares of all classes of capital stock of the Company enter into similar agreements for
periods of equal or greater length. The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of said period. 

4.12 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Article 4 may be
assigned (but only with all related obligations) by a holder of Registrable Securities to a transferee or assignee of such securities (y) who is not an operating company engaged in a business activity directly competitive with the Company (as
reasonably determined by the Company’s Board of Directors) and who after such assignment or transfer, holds at least 50,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and
similar recapitalization events); provided, however, no Investor shall be deemed to be engaged in a business activity directly competitive with the Company, or (z) who is an Affiliate or a constituent partner of such holder;
provided the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned;
and provided, further, that such assignment shall be effective only if (i) immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and
(ii) the transferee or assignee shall acknowledge in writing that the transferred or assigned Registrable Securities shall remain subject to this Agreement. For the purposes of determining the number of shares of Registrable Securities held by
a transferee or assignee, the holdings of transferees and assignees of a partnership who are partners or retired partners of such partnership (including spouses and ancestors, lineal descendants and siblings of such partners or

  
 21 

 
spouses who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership; provided that all assignees and transferees who
would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under this Article 4. 

4.13 Conditions to Registration Obligations. The Company shall not be obligated to effect the registration of Registrable Securities pursuant to
Sections 4.3, 4.4 and 4.5 unless all holders of shares being registered consent to reasonable conditions imposed by the Company as the Company shall determine with the advice of counsel to be required by law including, without limitation:

 (a) conditions requiring such holder to comply with all prospectus delivery requirements of the Securities Act and with all
anti-stabilization, anti-manipulation and similar provisions of Section 10 of the Exchange Act and any rules issued thereunder by the Commission, and to furnish to the Company information about sales made in such public offering; and

 (b) conditions requiring the holders of Registrable Securities to enter into an underwriting agreement in form and substance
reasonably satisfactory to the Company and the holders of Registrable Securities. 
 4.14 Limitation on Subsequent Registration Rights.
The Company shall not grant to any Person any registration rights that in any way conflict with those contained herein, so long as any of the registration rights under this Agreement remains in effect, provided, in any event, (i) any
grant of demand, required or Form S-3 registration rights shall provide that the holders of Registrable Securities hereunder have incidental or “piggyback” registration rights with respect thereto in accordance with the provisions of
Section 4.4 hereof; (ii) such demand, required or Form S-3 registration rights shall not become effective prior to the rights of the holders of Registrable Securities hereunder, and (iii) any grant of incidental or
“piggyback” registration rights shall be junior in right of priority with the “piggyback” registration rights of holders of Registrable Securities hereunder. 
 4.15 No Conflict of Rights. The Company represents and warrants to each holder of Registrable Securities that other than the registration rights granted to the holders of the Company’s Series
A Convertible Preferred Stock., $.001 par value per share, the holders of the Company’s Series B Convertible Preferred Stock, $.001 par value per share, certain covenants by and between the Company and Tufts University
(“Tufts”) and Massachusetts Biotechnology Research Institute (“MBRI”), each pursuant to a certain Stock Subscription and Right of First Refusal Agreement dated March 31, 1997 by and between the Company and
Tufts and MBRI, respectively, and the registration rights granted hereby, there are no other registration rights granted by the Company. 
  

	5.	BOARD OF DIRECTORS 

 5.1 Election of
Directors. Each Stockholder shall take or cause to be taken such actions as may be required from time to time to establish and maintain the number of persons comprising 

  
 22 

 
the Board of Directors of the Company at nine (9) or at such other number (not to exceed ten (10)) as the Board of Directors (including at least one (1) Series H Director (as
defined below)) may determine from time to time, and to elect as directors (i) two (2) representatives of the Series C Stock, (A) one (1) of whom to be designated by Nomura International plc, and (B) one (1) of whom to
be elected by a majority of the holders of Series C Stock issued and outstanding (together with the representative designated under clause (A), the “Series C Directors”), (ii) two (2) representatives of the Series H Stock,
(A) one (1) of whom to be designated by Aisling Capital II, LP (initially Anthony Sun), and (B) one (1) of whom to be elected by a majority of the holders of Series H Stock issued and outstanding, (together with the
representative designated under clause (A), the “Series H Directors”), (iii) Walter Gilbert, Ph.D. or his designee, (iv) Stuart B. Levy, M.D. or his designee, (v) the Company’s Chief Executive Officer (who
currently is Thomas J. Bigger), and (vi) two (2) outside independent directors designated by Walter Gilbert, Ph.D., Stuart B. Levy, M.D. (or their respective designees) and the Company’s Chief Executive Officer (who currently are
Kenneth J. Novack and Pieter Strijkert, Ph.D., the “Outside Directors”); provided, however, in the event that the Series H Directors request in good faith that the size of the Board of Directors of the Company be
reduced to eight (8) for more efficient operation of such Board of Directors, such action will be taken as determined in good faith by, and with the approval of, the Company’s Chief Executive Officer, the Chairman of the Company’s
Board of Directors and the Series H Directors. Without limiting the generality of the foregoing, at each annual meeting of the stockholders, and at each special meeting of the stockholders called for the purpose of electing directors of the Company,
and at any time at which the stockholders have the right to, or shall, elect directors of the Company, then, and in each event, the Stockholders shall vote all Shares owned by them (or shall consent in writing in lieu of a meeting of stockholders,
as the case may be) to set the number of, and to elect persons as, directors of the Company in accordance with the preceding sentence. Notwithstanding anything contained herein or in that certain Securities Purchase Agreement, dated June 2,
2004, by and among the Series F Investors and the Company to the contrary, subject to applicable law, Nomura International plc’s director nominee shall be permitted to disclose to Nomura International plc all information and materials furnished
to directors at meetings or otherwise. 
 5.2 Removal of Directors; Filling of Vacancies. Notwithstanding anything to the contrary
contained herein, in the event that the size of the Board of Directors of the Company is reduced to eight (8) directors pursuant to Section 5.1 hereof, such reduction shall be effected by eliminating an Outside Director. Each Stockholder
shall take all action necessary to remove forthwith any director when such removal is requested for any reason, with or without cause, by the Persons that designated such director for election. In the case of the death, resignation or removal as
herein provided of a director, each Stockholder shall vote all Shares owned by him, her or it to elect another person designated by the Persons that designated the deceased, resigning or removed director if, at the time such vacancy occurs, such
Persons shall have the right to have a person designated by them elected as a director pursuant to Section 5.1. If any Person that is entitled to designate or elect, as the case may be, a director pursuant to Section 5.1 fails to designate
or elect a sufficient number of directors to fill all directorships for which they are entitled to designate or elect pursuant to Section 5.1, then any directorship not so filled shall remain vacant until such time as such Person designates or
elects an individual to fill such directorship; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to designate or elect a person to fill such directorship.
At any meeting held for the purpose of electing a director, the presence in 

  
 23 

 
person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such
director. Except as otherwise provided in this Section 5.2, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series
or by any remaining director or directors elected by the holders of such class or series pursuant to this Section 5.2. 
 5.3 Company
Committees; Directors of Subsidiaries. The Company’s Board of Directors shall establish a Compensation Committee (the “Compensation Committee”) consisting of the Chairman of the Board, one Board member elected by the
holders of the Series C Stock and one other Board member that is not an executive officer or otherwise affiliated with an executive officer of the Company. The Compensation Committee will be authorized by the Board of Directors (i) to establish
compensation for senior management of the Company, (ii) to grant shares of Common Stock, Rights or Convertible Securities and other forms of compensation under the Company’s option plans or other equity arrangements and (iii) to make
recommendations to the Board of Directors regarding the recruitment and termination of senior management. Notwithstanding anything contained herein to the contrary, each Series H Director shall be entitled to become a member of any committee of the
Board of Directors of the Company, including, but not limited to, the Compensation Committee, as well as a member of the Board of Directors of any Subsidiary of the Company. 
 5.4 Board Observer Rights. The holders of a majority of outstanding shares of Series D Stock and, as long as Aisling Capital II, LP owns not less than ten percent (10%) of the Series H Stock
it purchased pursuant to the Securities Purchase Agreement, Aisling Capital II, LP shall each have the right to designate one representative, reasonably acceptable to the Company, who shall be entitled to attend all meetings of the Company’s
Board of Directors in a non-voting observer capacity, and to receive copies of all materials that the Company provides to its directors, provided that such representatives shall maintain the confidentiality of all information provided
to them in such materials and in the course of their attendance at meetings of the Company’s Board of Directors, and provided further that such representatives may be excluded from any “executive session” of the Board of
Directors at which, in the opinion of the Chairman of the Board of Directors exercised in good faith, such exclusion is necessary to preserve or protect the exercise of the Board of Directors’ fiduciary duties, to preserve the attorney-client
privilege, to protect confidential information or to avoid a conflict of interest. The representative of Aisling Capital II, LP entitled to the rights set forth in this Section 5.4 shall initially be Dov Goldstein. 

5.5 Contingent Expansion of the Board. If, at any time after the fourth anniversary of the Series H Original Issue Date, a Triggering Event (as
hereinafter defined) occurs, the number of persons then comprising the Board of Directors of the Company shall be increased automatically from nine (9) to fifteen (15) and the Board of Directors shall be reconstituted (the
“Reconstituted Board of Directors”) such that there shall be (i) two (2) Series C Directors, two (2) Series H Directors and two (2) Outside Directors, in each case as required by Section 5.1 hereof,
(ii) three (3) directors, other than the Outside Directors, elected by the holders of Common Stock and of any other class or series of voting stock (including the Series C Stock and Series H Stock), voting together as a separate class, who
shall be Walter Gilbert, Ph.D. or his designee, Stuart B. Levy, M.D. or his designee, and the Company’s Chief Executive Officer, and 

  
 24 

 
(iii) six (6) directors elected by the Selling Investors identified in Section 3.5 hereof, voting together as a single class; provided, however, if the number of persons
comprising the Board of Directors of the Company at the time of the Triggering Event is eight (8), as permitted by Section 5.1 hereof, then the number of Outside Directors shall be one (1) and the total number of directors elected pursuant
to clause (iii) above shall be five (5); provided, further, if the number of persons comprising the Board of Directors of the Company at the time of the Triggering Event is ten (10), as permitted by Section 5.1 hereof, then
the total number of directors elected pursuant to clause (iii) above shall be seven (7). For the purposes hereof, a “Triggering Event” shall occur when both of the following events take place: (a) the Selling Investors
identified in Section 3.5 hereof approve the merger or consolidation of the Company with or into another Person in which the Company’s stockholders will receive cash or securities of any other Person for their shares, thereby causing the
Stockholders to be obligated to participate in such transaction pursuant to Section 3.5 hereof (a “Merger”), and (b) the Board of Directors of the Company, after receipt of a bona fide offer regarding the Merger (in
the form of a term sheet or otherwise), elects not to approve the Merger at a duly called meeting or via written consent. Notwithstanding anything contained herein to the contrary, the Board of Directors of the Company shall only be expanded to
become the Reconstituted Board of Directors pursuant to this Section 5.5 solely for the purpose of obtaining approval by the Reconstituted Board of Directors of the Merger and the actions directly related thereto that are the subject of a
Triggering Event. In the event that the consummation of such Merger fails to occur for any reason within the time period set forth in any bona fide term sheet or other writing related to the Merger, in each case as may be amended or extended from
time to time, or in the event that any action unrelated to such Merger is required to be voted on, the composition of the Board of Directors of the Company shall automatically revert back to the composition in effect immediately prior to the
Reconstituted Board of Directors becoming effective. The rights and obligations contained in this Section 5.5 relating to the Merger that is the subject of a Triggering Event may be waived only by the Selling Investors identified in
Section 3.5 hereof, voting together as a single class. 
 5.6 Reimbursement of Expenses. The Company shall promptly reimburse
members of its Board of Directors and any observer permitted by Section 5.4 for reasonable travel and other out-of-pocket expenses incurred by them in connection with their attendance at meetings of the Company’s Board of Directors or
committees thereof. If requested by the Company, such directors and observers shall provide the Company with documentation supporting any such expenses. 
 5.7 Termination of Article. The provisions of this Article 5 shall be of no further force or effect upon the consummation of the Company’s Initial Public Offering. 

 

	6.	NEGATIVE COVENANTS OF THE COMPANY. 

6.1 The Company covenants and agrees that it will not, without first having obtained the affirmative vote or written consent of the holders of at
least sixty-six and two-thirds percent (66-2/3%) of the outstanding shares of Series C Stock, take any of the actions set forth in the following covenants and provisions: 
 (a) Amendments to the Charter and By-Laws. The Company will not amend the Certificate of Incorporation or By-Laws of the Company in any way which adversely affects the rights of the holders of the
Series C Stock. 

  
 25 

 (b) Reclassification of Capital Stock. The Company will not reclassify any other
class of capital stock into shares having any preference or priority as to assets superior to that of the Series C Stock. 
 (c)
Authorization of Capital Stock. The Company will not authorize or issue any shares of capital stock having any preferences or priority as to dividends or assets upon liquidation superior to that of the Series C Stock. 

6.2 The Company covenants and agrees that it will not, without first having obtained the affirmative vote or written consent of the holders of at
least sixty-six and two-thirds percent (66-2/3%) of the outstanding shares of the Series C Stock, the Series D Stock, the Series F Stock and the Series H Stock, voting together as a single class, take any of the actions set forth in the following
covenants and provisions: 
 (a) Distributions. Neither the Company nor any
Subsidiary will purchase, redeem, retire, or otherwise acquire for value any shares of its capital stock (or rights, options or warrants to purchase such shares) now or hereafter outstanding, or return any capital to its stockholders, and neither
the Company nor any Subsidiary shall declare or pay any dividends or make any distribution of assets to its stockholders as such, except for repurchases of shares of Common Stock held by employees, consultants, directors, or officers of the Company
that are subject to stock repurchase agreements under which the Company has the right to repurchase such shares in the event of termination of employment.  
 (b) Merger and Sale of Assets; Liquidation and Dissolution. The Company will not merge or consolidate with any other Person or sell, assign, lease or otherwise dispose of all or substantially all
of its assets, in one transaction or in a series of transactions, nor dissolve, reorganize or liquidate the Company. 
 (c)
Indebtedness. The Company will not incur indebtedness in excess of Five Million Dollars ($5,000,000) outstanding at any time unless such indebtedness has been approved by each of the Series C Directors and the Series H Directors. 

(d) Option Plans and Equity Arrangements. The Company will not establish any new option plans or equity compensation arrangements.

 (e) Dealings with Affiliates. The Company will not enter into any transaction or agreement, other than indemnification
pursuant to statutory law and other than employment transactions in the ordinary course of the Company’s business approved in accordance with Section 5.3, with any employee, officer or director or any member of their families, or any
corporation or other entity in which any one or more of such persons holds, directly or indirectly, five percent (5%) or more of any class of capital stock, or with any other Affiliate of the Company, unless such transaction or agreement has
been approved by the each of the Series C Directors and the Series H Directors. 

  
 26 

 (f) Acquisitions. The Company will not purchase or acquire any stock or other
securities of, or all or substantially all of the assets or properties of, any Person, if such Person (or such assets) would constitute ten percent (10%) or more of the net worth of the Company. 

6.3 Termination of Negative Covenants. The covenants set forth in this Article 6 shall be of no further force or effect upon the consummation of
the Company’s Initial Public Offering. 
  

	7.	AFFIRMATIVE COVENANTS OF THE COMPANY 

 The Company covenants and agrees that, from the date of the Closing under the Securities Purchase Agreement and thereafter so long as any Investor owns Registrable Securities, it will perform and observe
the following covenants and provisions, and will cause each Subsidiary, if and when such Subsidiary exists, to perform and observe the following covenants and provisions as applicable to such Subsidiary. 

7.1 Financial Statements; Other Reports. The Company will maintain proper books of account and records in accordance with generally accepted
accounting principles applied on a consistent basis, and will deliver to each Investor and its Affiliates jointly owning at least two hundred and fifty thousand (250,000) shares of the Company’s capital stock, treating all Preferred Stock
on an as converted basis but excluding any unexercised options, warrants or purchase rights (each, a “Rights Holder”): 
 (a) as soon as available and in any event within forty five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, a balance sheet of the Company as
of the end of such quarter and the related statements of income and stockholders’ equity and of cash flows of the Company for the period commencing at the end of the previous fiscal year and ending with the end of such quarter, setting forth in
each case in comparative form the corresponding figures for the corresponding period of the preceding fiscal year and the budget for such current year, all in reasonable detail and prepared in accordance with generally accepted accounting principles
consistently applied; 
 (b) as soon as available and in any event within ninety (90) days after the end of each fiscal
year of the Company, a copy of the annual audit report for such year for the Company, including therein a balance sheet of the Company as of the end of such fiscal year and statements of income and stockholders’ equity and of cash flows of the
Company for such fiscal year, setting forth in each case in comparative form the corresponding figures for the preceding fiscal year, all duly certified by independent public accountants of recognized standing acceptable to the Rights Holders;

 (c) as soon as available and in any event within forty five (45) days after the end of each of the first 11 months of
each fiscal year of the Company, a balance sheet of the Company as of the end of such month and the related statements of income and stockholders’ equity for the period commencing at the end of the previous fiscal year and ending with the end
of such month, setting forth in each case in comparative form the corresponding figures for the corresponding period of the preceding fiscal year and the budget for such current year, all in reasonable detail and prepared in accordance with
generally accepted accounting principles consistently applied; 

  
 27 

 (d) as soon as available and, in any event at least thirty (30) days prior the start of
each fiscal year, a copy of the business plan for such year, including operating budgets, operating expenses and profit and loss projections, cash flow projections and capital expenditure budgets, as prepared for the Board of Directors and as
approved by the Board of Directors; and 
 (e) promptly after sending, making available, or filing the same, such reports and
financial statements as the Company shall send or make available to the stockholders of the Company. 
 7.2 Inspection and Other
Information. Each Rights Holder and such agents, advisors and counsel as such Rights Holder may designate, may, at its expense, visit and inspect any of the properties of the Company, examine the books of account of the Company, take extracts
therefrom and discuss the affairs, finances and accounts of the Company with its officers and employees at reasonable times and with reasonable prior notice during normal business hours. All such visits and inspections shall be conducted in a manner
which will not unreasonably interfere with the normal business operations of the Company. The Company will furnish to each such Rights Holder such other information as it from time to time may reasonably request. In addition, the Company will
provide such Rights Holders with a written notice reasonably describing the initiation of any legal action against the Company that, in the good faith determination of the Board of Directors, could have a material adverse effect on the Company.

 7.3 Maintenance of Key-Person Life and Director and Officer Liability Insurance. The Company will maintain, with a financially sound
and reputable insurance company or association, (i) term life insurance on the life of Stuart B. Levy, M.D., in the amount of Three Million Dollars ($3,000,000), which proceeds shall be payable to the order of the Company and (ii) director
and officer liability insurance pursuant to terms and in amounts that, in the good faith determination of the Company’s Board of Directors, is reasonable. The Company will not cause or permit any assignment of the proceeds of such policies or
change in beneficiaries, and will not borrow against such policies. The Company will include the Investors as a notice party to such policies, and will request that the issuer of each such policy provide each Investor with twenty
(20) days’ notice before the respective policy is terminated (for failure to pay premiums or otherwise) or assigned, or before any change is made in the designation of the beneficiary thereof. 

7.4 Preservation of Corporate Existence. The Company will preserve and maintain its corporate existence, rights, franchises and privileges in the
jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such qualification is necessary or desirable in view of its business and operations or the ownership of its properties.

 7.5 Availability of Common Stock. The Company will, from time to time, in accordance with the laws of the State of Delaware, increase
the authorized amount of Common Stock if at any time the number of shares of Common Stock remaining unissued and available for issuance shall be insufficient to permit conversion of all then outstanding shares of Investor Preferred Stock.

  
 28 

 7.6 Termination of Affirmative Covenants. The covenants set forth in this Article 7 shall be of no
further force or effect upon the consummation of the Company’s Initial Public Offering. 
  

	8.	MISCELLANEOUS 

 8.1 Notices. All
notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either
(i) delivered by hand, (ii) made by telecopy or facsimile transmission, (iii) sent by overnight courier, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. 

 

					
	If to an Investor:	    	To its address set forth on its signature page hereto or on the Exhibit pages attached hereto:
		
	If to the Company:	    	Paratek Pharmaceuticals, Inc.
		    	75 Kneeland Street
		    	Boston, MA 02111
		    	Tel:	  	(617) 275-0040
		    	Fax:	  	(617) 275-0039
		    	Attn:	  	Beverly A. Armstrong
		
	With a copy to:	    	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		    	One Financial Center
		    	Boston, MA 02111
		    	Tel:	  	(617) 542-6000
		    	Fax:	  	(617) 542-2241
		    	Attn:	  	Lewis J. Geffen, Esq.

 All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if
by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic
confirmation or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth business day following
the day such mailing is made, provided that, registered or certified mail shall not be used to effectuate delivery of any such notices, requests, consents and other communications to Investors located in any foreign country.

 8.2 Entire Agreement. This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the
subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement
shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 
 8.3 Modifications and
Amendments. This Agreement may not be amended or modified, and no provision hereof may be waived, without the written consent of the Company and the holders of at least sixty-six and two-thirds percent (66-2/3%) of the outstanding shares of

  
 29 

 
Investor Preferred Stock; provided that without the consent of a majority of the holders of Series H Stock, no amendment, modification or waiver shall be made (i) to
Section 3.5 or (ii) to Section 5.1, 5.3 or 5.4 (which, in the case of Section 5.1, 5.3 or 5.4, would affect the holders of Series H Stock); provided that if an amendment, modification or waiver would adversely
affect any holder of Investor Preferred Stock in a manner that does not similarly adversely affect all holders of Investor Preferred Stock, the consent of such holder shall be required, and provided further, that without the consent of
each Founder, no amendment, modification or waiver shall be made which affects such Founders. Any waiver or consent hereunder shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a
continuing waiver or consent. 
 8.4 Assignment. The rights and obligations under this Agreement may not be assigned by the Company
without the prior written consent of the holders of at least a majority of the Registrable Securities, unless specifically permitted by the terms hereof. 
 8.5 Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective
successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this
Agreement. 
 8.6 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance
with and governed by the law of the State of Delaware, without giving effect to the conflict of law principles thereof. 
 8.7 Venue. Any
legal action or proceeding with respect to this Agreement shall be brought in the courts of the Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts. 

8.8 Severability. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in
this Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem
any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect. 
 8.9 Interpretation. The parties hereto acknowledge and agree that: (i) each party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its
revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be
construed fairly as to all parties hereto and not in favor of or against any party, regardless of which party was generally responsible for the preparation of this Agreement. 
 8.10 Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify or affect the meaning or
construction of any of the terms or provisions hereof. 

  
 30 

 8.11 Enforcement. Each of the parties hereto acknowledges and agrees that the rights acquired by each
party hereunder are unique and that irreparable damage would occur in the event that any of the provisions of this Agreement to be performed by the other parties were not performed in accordance with their specific terms or were otherwise breached.
Accordingly, in addition to any other remedy to which the parties hereto are entitled at law or in equity, each party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by any other party and to enforce
specifically the terms and provisions hereof in any federal or state court to which the parties have agreed hereunder to submit to jurisdiction. 
 8.12 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing among the parties
hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such
right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of
such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other
circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 
 8.13 Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 [Signature pages follow] 

  
 31 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth above.

  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Beverly A. Armstrong

		 	Beverly A. Armstrong
		 	Vice President, Chief Compliance Officer & General Counsel

  
 32 

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and. Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

			
	AISLING CAPITAL II, LP
		
	By:	 	 /s/ Andrew P. Nicholson

	Name:	 	 Andrew P. Nicholson

	Title:	 	 Treasurer

	
	Address:
	
	 Aisling Capital II, LP
 c/o Aisling Capital

		
	Date:	 	  

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company” and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

					
	D. E. Shaw Composite Portfolios, L.L.C.
	By:	 	D. E. Shaw & Co., L.L.C., as managing member
			
		 	 By:
	 	 /s/ James Mackey

		 		 	Name: James Mackey
		 		 	Title: Authorized Signatory

  

			
	Address:	 	
		 	
		 	

 
			
		
	Date:	 	 October 5, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19 , 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Hercules Technology Growth Capital, Inc.

	Printed Name of Stockholder
	
	 /s/ Scott Harvey

	Signature of Stockholder
	Chief Legal Officer
	Hercules Technology Growth Capital, Inc.

  

			
	Title:	 	 Chief Legal Officer

			
		
	Address:	 	  

		
		 	  

 
			
		
	Date:	 	 10/10/2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Boston Life Sciences Venture Corp.

	Printed Name of Stockholder
	
	 /s/ Peter T.K. Wu

	Signature of Stockholder

  

			
	Title:	 	 Chairman

			
		
	Address:	 	  

		
		 	  

 
			
		
	Date:	 	  

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this Counterpart
Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 PGE Venture Fund, LLC

	Printed Name of Stockholder
	
	 /s/ Thomas Dietz

	Signature of Stockholder

  

			
	Name:	 	 Thomas Dietz

			
		
	Title:	 	 Managing Member, PGE Venture Fund
LLC

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 15, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007(the “Agreement”), among Paratek Pharmaceuticals, Inc, (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Sarah L Gordon

	Printed Name of Stockholder
	
	 /s/ Sarah L Gordon

	Signature of Stockholder

  

			
	Title:	 	 Mrs. Sarah Gordon

			
		
	Address:	 	  

		
		 	 
		
		 	  

 
			
		
	Date:	 	 12th Oct 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 William Slattery

	Printed Name of Stockholder
	
	 /s/ William Slattery

	Signature of Stockholder

  

			
	Name:	 	 William S Slattery

			
		
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

 
			
		
	Date:	 	 10/19/07

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Novartis Bioventures Ltd

	Printed Name of Stockholder
	
	 /s/ Emil Bock

	Signature of Stockholder

  

			
	Name:	 	 Emil Bock

			
		
	Title:	 	 Deputy Chairman

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 15, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Nomura Phase 4 Ventures LP

	Printed Name of Stockholder
	
	 /s/ D. Pollard-Knight

	Signature of Stockholder

  

			
	Name:	 	 Dr. D. Pollard-Knight, Nomura

	 Phase 4 Ventures Limited acting as manager

	 for Nomura Phase 4 Ventures
LP

 
			
		
	Title:	 	 Head of Phase 4 Ventures

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 16 October 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Bio Fund Ventures II Follow-On L.P.

	Printed Name of Stockholder
	
	 /s/ Kalevi Kurkijarvi

	Signature of Stockholder

  

			
	Name:	 	 Kalevi Kurkijarvi

			
		
	Title:	 	 General Partner

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 16th Oct., 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 HBM Bio Fund Ventures (Cayman) Ltd.

	Printed Name of Stockholder
	
	 /s/ John Arnold

	Signature of Stockholder

  

			
	Name:	 	 John Arnold

			
		
	Title:	 	 Chairman and Managing
Director

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October     , 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of October
19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this Counterpart
Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Lombard Order Darier Hentsch

	Printed Name of Stockholder
	
	 /s/ by proxy

	Signature of Stockholder

  

			
	Name:	 	 /s/ Alexandra Meyer    /s/ Eric
Menotti

 
			
		
	Title:	 	 Executive Vice President    Vice
President

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 Oct.18, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 BioVeda Fund Pte Ltd

	Printed Name of Stockholder
	
	 /s/ Damien Lim

	Signature of Stockholder

  

			
	Name:	 	 BioVeda Capital Pte Ltd, its Investment
Manager

 
			
		
	Title:	 	 Damien Lim, General
Partner

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 17 October 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Kenneth J. Novack, et al

	Printed Name of Stockholder
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Name:	 	 Patrick B. Maraghy

			
		
	Title:	 	 Agent

 
			
		
	Address:	 	 RINET Company LLC

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 16, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 PRAG Associates LLC

	Printed Name of Stockholder
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Name:	 	 Patrick B. Maraghy

			
		
	Title:	 	 Agent

 
			
		
	Address:	 	 RINET Company LLC

		
		 	  

		
		 	  

 
			
		
	Date:	 	 October 16, 2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Peter S. Lawrence

	Printed Name of Stockholder
	
	 /s/ Peter S. Lawrence

	Signature of Stockholder

  

			
	Name:	 	 Peter S. Lawrence

			
		
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

		
		 	  

 

			
		
	Date:	 	  

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 Patricia A. Suzman

	Printed Name of Stockholder
	
	 /s/ Patricia A. Suzman

	Signature of Stockholder

  

			
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 10/18/2007

 Counterpart Signature Page for Stockholders 

The undersigned hereby agrees to become a party to that certain Third Amended and Restated Investor Rights Agreement dated as of
October 19, 2007 (the “Agreement”), among Paratek Pharmaceuticals, Inc. (the “Company”) and others. From and after the undersigned’s execution and delivery and the Company’s acceptance of this
Counterpart Signature Page, the undersigned shall be a party to the Agreement. 
  

	
	 John P Dunphy

	Printed Name of Stockholder
	
	 /s/ John P Dunphy

	Signature of Stockholder

  

			
	Name:	 	 John P Dunphy

			
		
	Title:	 	  

 

			
		
	Address:	 	  

		
		 	  

		
		 	  

 

			
		
	Date:	 	  

							
	 /s/ Stuart B. Levy, M.D.
	 		 	Date:	 	Oct 9, 2007
				
	Stuart B. Levy, M.D.	 		 		 	
				
	 /s/ C. Pastel Levy
	 		 	Date:	 	10/9, 2007
	Cecile P. Levy	 		 		 	

  

									
	The Stuart and Cecile Levy Irrevocable Trust – 1996
					
	By:	 	 /s/ David Pastel
	 		 	Date:	 	10/09/, 2007

									
					
	Name:	 	 David Pastel
	 		 		 	

									
					
	Title:	 	 Trustee
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ Walter Gilbert, Ph.D
	 		 	Date:	 	  
	 	
	Walter Gilbert, Ph.D	 		 		 		 	
					
	 /s/ Cecile Gilbert
	 		 	Date:	 	  
	 	
	Cecile Gilbert	 		 		 		 	
					
	 /s/ John Gilbert
	 		 	Date:	 	 10/9/07
	 	
	John R. Gilbert	 		 		 		 	
					
	 /s/ Kate Gilbert
	 		 	Date:	 	 10/9/07
	 	
	Kate Gilbert	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Tufts University	 	
					
	By:	 	 /s/ Margaret E. Newell
	 		 	Date:	 	10/9/07

									
					
	Name:	 	 Margaret E. Newell
	 		 		 	

									
					
	Title:	 	 Vice Provost
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Craig L. Burr 1985 Childrens Trust	 		 	
					
	By:	 	 /s/ Francis F. Kingsley
	 		 	Date:	 	October 9, 2007

									
					
	Name:	 	 Francis F. Kingsley
	 		 		 	

									
					
	Title:	 	 Administrator UPOA
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

					
	 /s/ Frederick Frank
	 		 	Date:                  , 2007
			
	Frederick Frank	 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Genechem Therapeutics Venture Fund L.P.	 		 	
					
	By:	 	 /s/ Martial Lacroix
	 		 	Date:	 	September     , 2007

									
					
	Name:	 	 Martial Lacroix
	 		 		 	

									
					
	Title:	 	 VP GeneChem Management, Inc
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ Irwin M. Heller
	 		 	Date:	 	 Oct 6, 2007
	 	
	Irwin M. Heller	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ Peter S. Lawrence
	 		 	Date:	 	 10.10.07
	 	
	Peter S. Lawrence	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	Lombard Odier Darier Hentsch	 		 		 	
				
	 Successor to/On behalf of 
 Lombard Darier Hentsch & Cie
 Lombard Odier & Cie
	 		 		 	
					
	By:	 	 /s/ Alexandra
Meyer                /s/ Eric Menotti
	 		 	Date:	 	Oct 10th, 2007

											
					
	Name:	 	 Alexandra
Meyer                Eric Menotti
	 		 		 	

											
					
	Title:	 	 Executive Vice
President            Vice President
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	Mintz Levin Investments L.L.C	 		 	
					
	By:	 	 /s/ Jeffrey M. Wiesen
	 		 	Date:	 	10/5, 2007

									
					
	Name:	 	 Jeffrey M. Wiesen
	 		 		 	

									
					
	Title:	 	 Manager
	 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	Novartis Bio Ventures Ltd	 		 		 		 	
						
	By:	 	 /s/ Emil Bock
	 		 	Date:	 	 9/10/2007
	 	

											
						
	Name:	 	 Emil Bock
	 		 		 		 	

											
						
	Title:	 	 Deputy Chairman of the Board of Directors
	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

									
	 /s/ R. Robert Popeo
	 		 	Date:	 	 10/5/07
	 	
	R. Robert Popeo	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	Schweizerhall Holding AG	 		 		 		 	
						
	By:	 	 /s/ L.v. Bidder
	 		 	Date:	 	 9.10.2007
	 	

											
						
	Name:	 	 L. von Bidder
	 		 		 		 	

											
						
	Title:	 	 VRP
	 		 		 		 	
						
		 	/s/ M. Von Ah	 		 		 		 	
						
		 	M. Von Ah	 		 		 		 	
						
		 	CFO	 		 		 		 	

											
	 /s/ Harold Snyder
	 		 	Date:	 	Oct 8, 2007	 	
	Harold Snyder	 		 		 		 	
					
	HBJ Investments, LLC	 		 		 		 	
						
	By:	 	 /s/ Harold Snyder
	 		 	Date:	 	Oct 8, 2007	 	

											
	Name:	 	 Harold Snyder
	 		 		 		 	

											
	Title:	 	 Partner
	 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	FSC Corp.	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Becky Levin	 		 		 		 		 	
						
	Bio Fund Ventures II Ky/L.P.	 		 		 		 		 	

													
							
	By:	 	 /s/ Kalevi Kurkijarvi
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Kalevi Kurkijarvi
	 		 		 		 		 	

													
	Title:	 	 General Partner
	 		 		 		 		 	

													
						
	Bio Fund Ventures II Jaticofijoitusrahasto Ky	 		 		 		 		 	

													
							
	By:	 	 /s/ Kalevi Kurkijarvi
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Kalevi Kurkijarvi
	 		 		 		 		 	

													
	Title:	 	 General Partner
	 		 		 		 		 	

													
						
	BankInvest Biomedical Development I	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	BankInvest Biomedical Development II	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Mintz Levin Investment LLC	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Merifin Capital N.V.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Craig L. Burr 1986 Childrens Trust	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Charles and Ruth Levy	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Frederick Frank	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Frederick Frank – Lehman Brothers,	 		 		 		 		 	

													
	Custodian for Frederick Frank IRA	 		 		 		 		 	

													
	Account No. 	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	R. Robert Popeo	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Irwin M. Heller	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	Peter S. Lawrence	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	

													
	David Novack	 		 		 		 		 	

													
	
	Nomura Phase4 Ventures Limited as manager for Nomura International plc

													
							
	By:	 	 /s/ Denise Pollard - Knight
	 		 	Date:	 	 16/10/07
	 	,	 	

													
	Name:	 	 Dr. Denise Pollard - Knight
	 		 		 		 		 	

													
	Title:	 	 Head of Phase4 Ventures
	 		 		 		 		 	

													
						
	Lombard Odier & Cie	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

											
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	Novack Associates Limited Partnership II	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B. Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B. Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	

													
						
	Novartis BioVentures Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	HBM VioVentures (Cayman) Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	POD Holding, Inc.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	Novack Associates Limited Partnership II	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Novartis BioVentures Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	HBM BioVentures (Cayman) Ltd.	 		 		 		 		 	

													
							
	By:	 	 /s/ John Arnold
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 John Arnold
	 		 		 		 		 	

													
	Title:	 	 Chairman and Managing Director
	 		 		 		 		 	

													
						
	POD Holding, Inc.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	Novack Associates Limited Partnership II	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Novartis BioVentures Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	HBM VioVentures (Cayman) Ltd	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	POD Holding, Ltd	 		 		 		 		 	

													
							
	By:	 	 /s/ Peter Lawrence
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Peter S. Lawrence
	 		 		 		 		 	

													
	Title:	 	 Director
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Erhvervsudviklingsforeningen BankInvest Biomedicinsk Venture I	 		 	
							
	By:	 	 /s/ Jens Kindtler
	 		 	Date:	 	 Oct 10, 2007
	 	,	 	

													
	Name:	 	 Jens Kindtler
	 		 		 		 		 	

													
	Title:	 	 Partner
	 		 		 		 		 	
						
	A/S BI Biomedicinsk Venture II	 		 		 		 		 	

													
							
	By:	 	 /s/ Jens Kindtler
	 		 	Date:	 	 Oct 10, 2007
	 	,	 	

													
	Name:	 	 Jens Kindtler
	 		 		 		 		 	

													
	Title:	 	 Partner
	 		 		 		 		 	
						
	P/S BI Biomedicinsk Venture III	 		 		 		 		 	

													
							
	By:	 	 /s/ Jens Kindtler
	 		 	Date:	 	 Oct 10, 2007
	 	,	 	

													
	Name:	 	 Jens Kindtler
	 		 		 		 		 	

													
	Title:	 	 Partner
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Lahive & Cockfield, LLP	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Lehman Brothers As Custodian	 		 		 		 		 	
	For David Pastel IRA	 		 		 		 		 	
	Account No. 	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Formosa Healthcare Investments, L.P.	 		 		 		 		 	
							
	By:	 	 /s/ Howard Lee
	 		 	Date:	 	 Sept. 27, 2007
	 	,	 	

													
	Name:	 	 Howard Lee
	 		 		 		 		 	

													
	Title:	 	 General Partner
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Alden I. Gifford	 		 		 		 		 	
						
	Rockwood Capital Corporation	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	William G. Coughlin	 		 		 		 		 	
						
	Wheatley Med Tech Partners, LP	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Bioveda Fund Pte Ltd.	 		 		 		 		 	
							
	By:	 	 /s/ Damien Lim
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Anthony John Khuri	 		 		 		 		 	
						
	Lehman Brothers	 		 		 		 		 	
	As Custodian For Jay Levy	 		 		 		 		 	
	IRA Account # 	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Lehman Brothers	 		 		 		 		 	
	As Custodian For Sharon Levy	 		 		 		 		 	
	IRA Account	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Genechem Therapeutics Venture Fund L.P.	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	BI Biomedical Venture III	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	  
	 		 	Date:	 	  
	 	,	 	
	Harold Snyder	 		 		 		 		 	
						
	HBJ Investments	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	Jay Linn Trustee, Irrevocable Trust	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Norman and Suzanne Priebatsch	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Robert D. Ritchie	 		 		 		 		 	
						
	Winchester Capital Healthcare Partners	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	Kenneth J. Novack	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Ellen and Mario Koenig	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	David F. Pastel	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Jay and Sharon Levy	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Donald M. Phillips	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Winchester Capital Technology Partners	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	David R. Novack	 		 		 		 		 	
						
	K.B. (C.I.) Nominees Limited	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	BioFund Ventures II, L.P	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Squamata Limited	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Schweizerhall Investment Ltd.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Novack Associates Ltd Ptrshp II	 		 		 		 		 	
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	
						
	Novack Associates L.P.	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	
						
	Jeffrey N. Novack 1996 Trust	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	
						
	Madeline Gunilla Pontin 1997 Trust	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 	,	 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	

													
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Kenneth J. Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	David Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Emily K. Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Sara E. Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Helen Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Hyman Novack	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Laura Novack Pontin	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Judy and Peter Smith	 		 		 		 		 	
						
	 /s/ Patrick B Maraghy, Agent for
	 		 	Date:	 	 10/10/07
	 	,	 	
	Miriam and Steven White	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Craig L. Burr 1986 Childrens Trust	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

													
						
	  
	 		 	Date:	 	  
	 	,	 	
	Charles and Ruth Levy	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Frederick Frank	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Frederick Frank – Lehman Brothers,	 		 		 		 		 	
	Custodian for Frederick Frank IRA	 		 		 		 		 	
	Account No. 	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	R. Robert Popeo	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Irwin M. Heller	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Peter S. Lawrence	 		 		 		 		 	
						
	 /s/ Patrick B. Maraghy, Agent For
	 		 	Date:	 	 10/10/07
	 	,	 	
	David Novack	 		 		 		 		 	
						
	Nomura International plc	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Lombard Odier & Cie	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

													
	Lahive & Cockfield, LLP	 		 		 		 		 	
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	Lehman Brothers As Custodian	 		 		 		 		 	
	For David Pastel IRA	 		 		 		 		 	
	Account No. 	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	China Development Industrial Bank Inc.	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	Alden I. Gifford	 		 		 		 		 	
						
	Rockwood Capital Corporation	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 	,	 	
	William G. Coughlin	 		 		 		 		 	
						
	Wheatley Med Tech Partners, LP	 		 		 		 		 	

													
							
	By:	 	 /s/ Barry Rubenstein
	 		 	Date:	 	  
	 	,	 	

													
	Name:	 	 Barry Rubenstein
	 		 		 		 		 	

													
	Title:	 	 CEO Wheatley Med Tech
	 		 		 		 		 	
		 	 Partners, LLC, General Partner
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

  

													
	  
	 		 	Date:	 	  
	 		 	
	Walter Gilbert, Ph.D	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Cecile Gilbert	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Stuart B. Levy, M.D.	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Cecile P. Levy	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	John R. Gilbert	 		 		 		 		 	
						
	  
	 		 	Date:	 	  
	 		 	
	Kate Gilbert	 		 		 		 		 	
						
	Tufts University	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 		 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	The Stuart and Cecile Levy Irrevocable Trust – 1996	 		 		 		 		 	

													
							
	By:	 	  
	 		 	Date:	 	  
	 		 	

													
	Name:	 	  
	 		 		 		 		 	

													
	Title:	 	  
	 		 		 		 		 	
						
	PRAG Associates, LLC	 		 		 		 		 	

													
							
	By:	 	 /s/ Patrick B Maraghy
	 		 	Date:	 	 10/10/07
	 		 	

													
	Name:	 	 Patrick B Maraghy
	 		 		 		 		 	

													
	Title:	 	 Agent
	 		 		 		 		 	

  
 Preferred Stockholders
and Founders – Notice, Waiver, Election Form and Consent 

 EXHIBIT A 

FOUNDERS 
 The
Stuart and Cecile Levy 1996 Trust 
 Stuart B. Levy, M.D. 
 Cecile P. Levy, M.D. 
 Walter Gilbert, Ph.D. 

Celia Gilbert 
 John R. Gilbert 

Kate Gilbert 
 Tufts University 

Licensing Office 

  
 A-1

 EXHIBIT B 

SERIES C INVESTORS 

Nomura International plc 
 Lombard
Odier & Cie 
 FSC Corp. 

Kenneth J. Novack 
 Becky Levin 

Bio Fund Ventures II Ky 
 BANKINVEST

 Biomedical Development I & II 

Merifin Capital N.V. 
 c/o Finabel S.A., 254
route de Lausanne, 
 Harold Snyder 

c/o HBJ Investments, LLC 

  
 B-1

 HBJ Investments, LLC 
 Mintz Levin Investment LLC 
 c/o Mintz, Levin, Cohn, Ferris, 

Glovsky and Popeo, P.C. 
 Jay
Linn Trustee, Irrevocable Trust 
 Agreement Number III 
 Norman and Suzanne Priebatsch 
 Robert D. Ritchie 

Lehman Brothers as Custodian for David Pastel 

IRA Account No.  
 c/o Amy Mavrogian

 Lehman Brothers 
 Winchester Capital
Healthcare Partners LLC 
 c/o Pensar N. Anquillare, President 
 Lehman Brothers, Custodian for Frederick 
 Frank IRA Account No.  

Jay and Sharon Levy 

  
 B-2

 Ellen and Mario Koenig 
 Miriam and Steven White 
 c/o RINET Company, LLC 

Hyman Novack 
 c/o RINET Company, LLC

 Helen Novack 
 c/o RINET Company,
LLC 
 David Novack 
 c/o RINET
Company, LLC 
 Judy and Peter Smith 

c/o RINET Company, LLC 
 Novack Associates
Limited Partnership II 
 c/o RINET Company, LLC 
 Anthony John Khuri 

  
 B-3

 Donald J. M. Phillips 
 c/o Ted Thomas Associates 

  
 B-4

 EXHIBIT C 

SERIES D INVESTORS 

Novartis BioVentures Ltd. 
 Hurst Holme

 HBM BioVentures (Cayman) Ltd. 
 HBM
BioVentures AG 
 POD Holding, Inc. 

Kenneth J. Novack 
 Lahive &
Cockfield, LLP 
 Formosa Healthcare Investments, L.P. 
 c/o Howard Lee, Ph.D. 
 Wheatley MedTech Partners, LP 

			
	 With copies to:
	 	Wheatley Partners

  
 C-1

 FSC Corp. 
 c/o BancBoston Capital Inc. 
 Alden I. Gifford 

Rockwood Capital Corporation 
 c/o David H.
Carls 
 William G. Coughlin 
 Lehman
Brothers as Custodian for 
 David Pastel IRA Account No.  
 Lehman Brothers 
 BioVeda Fund Pte Ltd 
 Ellen and Mario Koenig 
 Lehman Brothers as Custodian for 

Sharon Levy IRA Account No.  

  
 C-2

 Lehman Brothers as Custodian for 
 Jay Levy IRA Account No.  
 Anthony Khuri 

c/o Khuri Consulting Group 
 Robert Ritchie

 Peter S. Lawrence 
 GeneChem
Therapeutics 
 Venture Fund L.P 

BankInvest 
 BI Biomedical Venture III

 Nomura International PLC 
 Mintz
Levin Investments, LLC 
 Mintz, Levin, Cohn, 
 Ferris, Glovsky and Popeo, P.C. 
 Irwin Heller 

  
 C-3

 Harold Snyder 
 HBJ Investments, LLC 
 PRAG Associates LLC 

c/o RINET Company, LLC 
 Merifin Capital N.V.

 c/o Finabel SA 
 Lombard
Odier & Cie 
 c/o Lombard Odier Darier Hentsch Group 
 Winchester Capital Technology 
 Partners LLC 

K.B.(C.I.) Nominees Limited 
 Bio Fund Ventures
II L.P. 
 Squamata Limited 

  
 C-4

 EXHIBIT D 

SERIES F INVESTORS 

June 2, 2004 
 POD Holding,
Inc. 
 Novartis BioVentures Ltd. 

Frederick Frank 
 Anthony John Khuri

 c/o Khuri Consulting Group 
 R.
Robert Popeo 
 Peter S. Lawrence 

Lahive & Cockfield, LLP 
 Kenneth J.
Novack 
 Novack Associates Limited Partnership II 
 c/o RINET Company, LLC 

  
 D-1

 David Novack 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Irrevocable Trust dated 2/14/96, Marianne M.
Novack, David R. Novack and Paul D. Bishop, Trustee 
 c/o RINET Company, LLC 
 Judy and Peter Smith 
 c/o RINET Company, LLC 

Hyman Novack 
 c/o RINET Company, LLC

 Helen Novack 
 c/o RINET Company,
LLC 
 Miriam and Steven White 
 c/o
RINET Company, LLC 
 Bio Fund Ventures II L.P. 
 Robert Cawthorn 

  
 D-2

 Emily K. Novack 
 c/o RINET Company, LLC 
 Sara E. Novack 
 c/o RINET Company, LLC 
 Madeline Gunilla Pontin 1997 Trust 

c/o RINET Company, LLC 
 Laura Novack Pontin

 c/o RINET Company, LLC 

June 11, 2004 
 Lombard
Darier Hentsch & Cie 
 Schweizerhall Holding AG 
 BioVeda Fund Pte Ltd 

  
 D-3

 Wheatley Med Tech Partners, LP 

 

			
	 With copies to:
	 	Wheatley Partners

 Rosemary Nguyen 

  
 D-4

 EXHIBIT E 

SERIES H INVESTORS 

Aisling Capital II, LP 
 c/o Aisling Capital

 With a copy to: 
 McKee Nelson LLP 
 D.E. Shaw Composite Portfolios, L.L.C. 

Hercules Technology Growth Capital, Inc. 

Boston Life Science Venture Corp. 
 PGE Venture
Fund, LLC 
 Sarah L. Gordon 

  
 E-1

 William Slattery 
 Novartis BioVentures Ltd 
 Nomura Phase4 Ventures LP 

Bio Fund Ventures II Follow-On L.P. 
 HBM
BioVentures (Cayman) Ltd. 
 Lombard Odier Darier Hentsch 
 BioVeda Fund Pte Ltd 
 Kenneth J. Novack 
 c/o RINET Company, LLC 

  
 E-2

 PRAG Associates LLC 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Trust 

c/o RINET Company, LLC 
 Emily K. Novack

 c/o RINET Company, LLC 
 Sara E.
Novack 
 c/o RINET Company, LLC 

Madeline Gunilla Pontin 1997 Present Interest Trust 
 c/o RINET Company, LLC 
 David Novack 
 c/o RINET Company, LLC 
 Judy & Peter Smith 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Emily Kate Novack 
 c/o RINET Company, LLC 

  
 E-3

 Novack Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Laura Pontin 
 c/o RINET Company, LLC 
 Helen Novack 
 c/o RINET Company LLC 
 Hyman Novack 
 c/o RINET Company, LLC 
 Miriam and Steven White 
 c/o RINET Company, LLC 

Laura Novack Pontin 
 c/o RINET Company, LLC

  
 E-4

 David and Lesley Novack 
 c/o RINET Company, LLC 
 Marianne M. Novack 

c/o RINET Company, LLC 
 Peter S. Lawrence

 Patricia A. Suzman 
 John P. Dunphy

  
 E-5

 PARATEK PHARMACEUTICALS, INC. 

FIRST AMENDMENT 
 TO THE 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 This First Amendment (the “Amendment”) to the Third Amended and Restated Investor Rights Agreement,
dated October 19, 2007, by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) the holders of the Company’s common stock listed on Exhibit A (referred to herein
individually as a “Founder” and collectively as the “Founders”), (iii) the Series C Investors listed on Exhibit B (the “Series C Investors”), (iv) the Series D Investors listed on
Exhibit C (the “Series D Investors”), (v) the Series F Investors listed on Exhibit D (the “Series F Investors”) and (vi) the Series H Investors listed on Exhibit E (the “Series
H Investors” and together with the Series C Investors, Series D Investors, Series F Investors, the “Investors”), is made as of August 6, 2009. 
 WHEREAS, the Company is entering into a Note Purchase Agreement with certain existing stockholders of the Company pursuant to which the Company will issue and sell and these certain stockholders will
purchase promissory notes of the Company; 
 WHEREAS, in connection with the execution of the Note Purchase Agreement, the
Company, the Investors and the Founders desire to amend certain provisions of Section 5 of the Investor Rights Agreement as set forth herein in order to modify the size and composition of the Company’s Board of Directors; and 

WHEREAS, in accordance with Section 8.3 of the Investor Rights Agreement, (i) Investors holding at least sixty-six and
two-thirds percent (66-2/3%) of the outstanding shares of the Investor Preferred Stock (as defined in the Investor Rights Agreement), (ii) Investors holding a majority of the outstanding shares of Series H Stock (as defined in the Investor
Rights Agreement) and (iii) the Founders have, in each case, provided their written consent and approval of this Amendment, and, by executing and delivering this Amendment, the Company has consented and approved of this Amendment. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained in this Amendment and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1.
Amendment of Investor Rights Agreement. 
 (i) The Investor Rights Agreement is hereby amended by deleting
Section 5.1 in its entirety and by substituting in lieu thereof the following new Section 5.1: 
 “5.1 Election
of Directors. Each Stockholder shall take or cause to be taken such actions as may be required from time to time to establish and maintain the number of persons comprising the Board of Directors of the Company at ten (10) or at such other
number as the Board of Directors (including at least one (1) Series H Director (as defined below)) may determine from time to time, and to elect as directors (i) two (2) representatives of the Series C Stock, (A) one (1) of
whom to be designated by Nomura 

 
International plc, and (B) one (1) of whom to be elected by a majority of the holders of Series C Stock issued and outstanding (together with the representative designated under clause
(A), the “Series C Directors”), (ii) three (3) representatives of the Series H Stock, to be designated by Aisling Capital II, LP (the “Series H Directors”), one of whom shall initially be Anthony Sun, MD
(iii) Walter Gilbert, Ph.D. or his designee, (iv) Stuart B. Levy, M.D. or his designee, (v) the Company’s Chief Executive Officer (who currently is Thomas J. Bigger), and (vi) two (2) outside independent directors
designated by Walter Gilbert, Ph.D., Stuart B. Levy, M.D. (or their respective designees) and the Company’s Chief Executive Officer (who currently are Kenneth J. Novack and Pieter Strijkert, Ph.D., the “Outside Directors”);
provided, however, in the event that less than all three Series H Directors are present at any meeting of the Board of Directors, then (1) in the event one Series H Director is present, such Series H Director shall have the right
to cast three votes and (2) in the event two Series H Directors are present, one of whom is Anthony Sun, then Dr. Sun shall have the right to cast two votes, in each case so that the Series H Director(s) shall have the right to cast three
(3) votes. Without limiting the generality of the foregoing, at each annual meeting of the stockholders, and at each special meeting of the stockholders called for the purpose of electing directors of the Company, and at any time at which the
stockholders have the right to, or shall, elect directors of the Company, then, and in each event, the Stockholders shall vote all Shares owned by them (or shall consent in writing in lieu of a meeting of stockholders, as the case may be) to set the
number of, and to elect persons as, directors of the Company in accordance with the preceding sentence. Notwithstanding anything contained herein or in that certain Securities Purchase Agreement, dated June 2, 2004, by and among the Series F
Investors and the Company to the contrary, subject to applicable law, Nomura International plc’s director nominee shall be permitted to disclose to Nomura International plc all information and materials furnished to directors at meetings or
otherwise.” 
 (ii) Section 5.2 of the Investor Rights Agreement is hereby amended by deleting the first sentence of
Section 5.2 in its entirety. 
 (iii) The Investor Rights Agreement is hereby amended by deleting Section 5.5 in its
entirety and by substituting in lieu thereof the following new Section 5.5: 
 “5.5 Contingent Expansion of the
Board. If, at any time after the fourth anniversary of the Series H Original Issue Date, a Triggering Event (as hereinafter defined) occurs, the number of persons then comprising the Board of Directors of the Company shall be increased
automatically from ten (10) to fifteen (15) and the Board of Directors shall be reconstituted (the “Reconstituted Board of Directors”) such that there shall be (i) two (2) Series C Directors, three
(3) Series H Directors and two (2) Outside Directors, in each case as required by Section 5.1 hereof, (ii) three (3) directors, other than the Outside Directors, elected by the holders of Common Stock and of any other class
or series of voting stock (including the Series C Stock and Series H Stock), voting together as a separate class, who shall be Walter Gilbert, Ph.D. or his designee, Stuart B. Levy, M.D. or his designee, and the Company’s Chief Executive
Officer, and (iii) five (5) directors elected by the Selling Investors identified in Section 3.5 hereof, voting together as a single class; provided, however, if the number of persons comprising the Board of Directors of
the Company at the time of the Triggering Event is less than or more than ten (10), then 

  
 2 

 
the total number of directors elected pursuant to clause (iii) above shall be such number of directors as, together with the three (3) Series H Directors, is sufficient to constitute a
majority of the full Board of Directors. For the purposes hereof, a “Triggering Event” shall occur when both of the following events take place: (a) the Selling Investors identified in Section 3.5 hereof approve the merger
or consolidation of the Company with or into another Person in which the Company’s stockholders will receive cash or securities of any other Person for their shares, thereby causing the Stockholders to be obligated to participate in such
transaction pursuant to Section 3.5 hereof (a “Merger”), and (b) the Board of Directors of the Company, after receipt of a bona fide offer regarding the Merger (in the form of a term sheet or otherwise), elects not
to approve the Merger at a duly called meeting or via written consent. Notwithstanding anything contained herein to the contrary, the Board of Directors of the Company shall only be expanded to become the Reconstituted Board of Directors pursuant to
this Section 5.5 solely for the purpose of obtaining approval by the Reconstituted Board of Directors of the Merger and the actions directly related thereto that are the subject of a Triggering Event. In the event that the consummation of such
Merger fails to occur for any reason within the time period set forth in any bona fide term sheet or other writing related to the Merger, in each case as may be amended or extended from time to time, or in the event that any action unrelated to such
Merger is required to be voted on, the composition of the Board of Directors of the Company shall automatically revert back to the composition in effect immediately prior to the Reconstituted Board of Directors becoming effective. The rights and
obligations contained in this Section 5.5 relating to the Merger that is the subject of a Triggering Event may be waived only by the Selling Investors identified in Section 3.5 hereof, voting together as a single class.” 

2. Miscellaneous. 
 Except as contemplated by this Amendment, all of the terms and conditions of the Investor Rights Agreement shall remain in full force and effect. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 3 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first above
written. 
  

			
	
	COMPANY:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Thomas J. Bigger

	Name: Thomas J. Bigger
	Title:   President and Chief Executive Officer

 Signature Page to First Amendment to Third Amended and Restated Investor Rights Agreement

 EXHIBIT A 

FOUNDERS 
 The
Stuart and Cecile Levy 1996 Trust 
 Stuart B. Levy, M.D. 
 Cecile P. Levy, M.D. 
 Walter Gilbert, Ph.D. 

Celia Gilbert 
 John R. Gilbert 

Kate Gilbert 
 Tufts University 

Licensing Office 

  
 Exhibit A-1

 EXHIBIT B 

SERIES C INVESTORS 

Nomura International plc 
 Omega Fund III, L.P.

 c/o Omega Fund Management Limited 

FSC Corp. 
 Kenneth J. Novack 

Becky Levin 
 Bio Fund Ventures II Ky

 BANKINVEST 
 Biomedical Development
I & II 
 Merifin Capital N.V. 

c/o Finabel S.A. 
 Harold Snyder 

c/o HBJ Investments, LLC 

  
 Exhibit B-1

 HBJ Investments, LLC 
 Mintz Levin Investment LLC 
 c/o Mintz, Levin, Cohn, Ferris, 

Glovsky and Popeo, P.C. 

Irrevocable Trust Agreement Number I, Jay Howard Linn, Trustee 
 Norman and Suzanne Priebatsch 
 Robert D. Ritchie 

Barclays Capital Inc. as Custodian for David Pastel IRA No.  
 Winchester Capital Healthcare Partners LLC 
 c/o Pensar N. Anquillare, President 

Barclays Capital Inc. as Custodian for Frederick Frank IRA No.  
 Jay and Sharon Levy 
 Ellen and Mario Koenig 

  
 Exhibit B-2

 Miriam and Steven White 
 c/o RINET Company, LLC 
 Hyman Novack 
 c/o RINET Company, LLC 
 Helen Novack 
 c/o RINET Company, LLC 
 David Novack 
 c/o RINET Company, LLC 
 Judy and Peter Smith 

c/o RINET Company, LLC 
 Novack Associates
Limited Partnership II 
 c/o RINET Company, LLC 
 Marianne M. Novack 
 c/o RINET Company, LLC 

  
 Exhibit B-3

 Kenneth J. Novack 1993 Revocable Trust 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o 

Emily K. Novack 
 c/o RINET Company, LLC

 Novack Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Sara Elizabeth Novack 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Laura Pontin 
 c/o RINET Company, LLC 
 Marianne M. Novack 
 c/o RINET Company, LLC 

Anthony John Khuri 
 c/o Khuri Consulting Group

 Donald J. M. Phillips 
 c/o Ted
Thomas Associates 

  
 Exhibit B-4

 EXHIBIT C 

SERIES D INVESTORS 

Novartis BioVentures Ltd. 
 HBM BioVentures
(Cayman) Ltd. 
 HBM BioVentures AG 

POD 1.0 AB (Reg No. 556744-9466) 
 Kenneth
J. Novack 
 L&C Participation, LLC 
 Ralph A. Loren, Personal 
 DeAnn F. Smith, Personal 

Formosa Healthcare Investments, L.P. 
 c/o
Howard Lee, Ph.D. 

  
 Exhibit C-1

 Wheatley MedTech Partners, LP 

			
	 With copies to:
	 	Wheatley Partners

 FSC Corp. 
 c/o
BancBoston Capital Inc. 
 Alden I. Gifford 
 Rockwood Capital Corporation 
 c/o David H. Carls 

William G. Coughlin 
 Barclays Capital Inc. as
Custodian for David Pastel IRA 
 BioVeda Fund Pte Ltd 
 Ellen and Mario Koenig 
 Barclays Capital Inc. as Custodian for Sharon Levy IRA No. 

  
 Exhibit C-2

 Barclays Capital Inc. as Custodian for Jay Levy IRA No. 

Anthony Khuri 
 c/o Khuri Consulting Group

 Robert Ritchie 
 Peter S. Lawrence

 GeneChem Therapeutics 
 Venture Fund
L.P 
 BankInvest 
 BI Biomedical
Venture III 
 Nomura International PLC 
 Mintz Levin Investments, LLC 
 Mintz, Levin, Cohn, 

Ferris, Glovsky and Popeo, P.C. 

Irwin Heller 

  
 Exhibit C-3

 Harold Snyder 
 HBJ Investments, LLC 
 PRAG Associates LLC 

c/o RINET Company, LLC 
 Merifin Capital N.V.

 c/o Finabel SA 
 Omega Fund III,
L.P. 
 c/o Omega Fund Management Limited 
 Winchester Capital Technology 
 Partners LLC 

David R. Novack 
 c/o RINET Company, LLC

 Peter and Judy Smith 
 c/o RINET
Company, LLC 
 Steven and Miriam White 

c/o RINET Company, LLC 

  
 Exhibit C-4

 K/S Danish Bioventure 
 Collier International Partners IV Limited 
 c/o Collier Capital 

POD Venture Partners AB (Reg. No. 556744-9441) 
 Robert E. Cawthorne 
 Bio Fund Ventures II L.P. 

Squamata Limited 

  
 Exhibit C-5

 EXHIBIT D 

SERIES F INVESTORS 

POD 1.0 AB (Reg No. 556744-9466) 

Novartis BioVentures Ltd. 
 Frederick Frank

 Anthony John Khuri 
 c/o Khuri
Consulting Group 
 R. Robert Popeo 

Robert Cawthorn 
 Peter S. Lawrence 

L&C Participation, LLC 
 DeAnn F. Smith,
PERSONAL 

  
 Exhibit D-1

 Kenneth J. Novack 
 David Novack 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Irrevocable Trust dated 2/14/96, Marianne M. Novack, David R. Novack and Paul D. Bishop, Trustee 
 c/o RINET Company, LLC 
 Judy and Peter Smith 

c/o RINET Company, LLC 
 Hyman Novack

 c/o RINET Company, LLC 
 Helen
Novack 
 c/o RINET Company, LLC 

Miriam and Steven White 
 c/o RINET Company, LLC

 Bio Fund Ventures II L.P. 

  
 Exhibit D-2

 Emily K. Novack 
 c/o RINET Company, LLC 
 Sara E. Novack 
 c/o RINET Company, LLC 
 Madeline Gunilla Pontin 1997 Trust 

c/o RINET Company, LLC 
 Laura Novack Pontin

 c/o RINET Company, LLC 
 Omega Fund
III, L.P. 
 c/o Omega Fund Management Limited 
 BioVeda Fund Pte Ltd 
 BioFund Ventures II Follow-On Fund L.P. 

  
 Exhibit D-3

 Wheatley Med Tech Partners, LP 

			
	 With copies to:
	 	Wheatley Partners

 Rosemary Nguyen 

  
 Exhibit D-4

 EXHIBIT E 

SERIES H INVESTORS 

Aisling Capital II, LP 
 c/o Aisling Capital

 With a copy to: 
 McDermott Will & Emery 
 D.E. Shaw Valence Portfolios, L.L.C. 

Hercules Technology Growth Capital, Inc. 

Boston Life Science Venture Corp. 
 Thomas J.
Dietz 
 c/o Wedbush Morgan Securities 

The Osgood Family Trust UAD 4/14/2000 
 c/o
Wedbush Morgan Securities 

  
 Exhibit E-1

 The Osgood Family Trust UAD 4/14/2000 
 c/o Wedbush Morgan Securities 
 Ben Perkins Custodian for William Beau Perkins Uniform Gift to
Minors Act CA 
 c/o Wedbush Morgan Securities 
 Ben Perkins Custodian for Charlotte Rose Perkins Uniform Gift to Minors Act CA 
 c/o Wedbush Morgan
Securities 
 The Ingram Family Trust U/A/D 11/23/96, as amended, Gregory J. Ingram & Heidi M. Ingram, Trustees 

c/o Wedbush Morgan Securities 
 Sarah L. Gordon

 Novartis BioVentures Ltd 
 Nomura
Phase4 Ventures LP 
 Bio Fund Ventures II Follow-On L.P. 

  
 Exhibit E-2

 HBM BioVentures (Cayman) Ltd. 
 Omega Fund III, L.P. 
 c/o Omega Fund Management Limited 

BioVeda Fund Pte Ltd 
 Kenneth J. Novack

 c/o RINET Company, LLC 
 PRAG
Associates LLC 
 c/o RINET Company, LLC 
 Jeffrey N. Novack 1996 Trust 
 c/o RINET Company, LLC 

Emily K. Novack 
 c/o RINET Company, LLC

 Sara E. Novack 
 c/o RINET Company,
LLC 

  
 Exhibit E-3

 Madeline Gunilla Pontin 1997 Present Interest Trust 
 c/o RINET Company, LLC 
 David Novack 
 c/o RINET Company, LLC 
 Judy & Peter Smith 

c/o RINET Company, LLC 
 Novack Family 1999
Trust f/b/o Emily Kate Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 

Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack 
 c/o RINET Company, LLC 
 Novack Family 1999 Trust f/b/o Laura Pontin 

c/o RINET Company, LLC 
 Helen Novack

 c/o RINET Company LLC 

  
 Exhibit E-4

 Hyman Novack 
 c/o RINET Company, LLC 
 Miriam and Steven White 

c/o RINET Company, LLC 
 Laura Novack Pontin

 c/o RINET Company, LLC 
 David and
Lesley Novack 
 c/o RINET Company, LLC 

Marianne M. Novack 
 c/o RINET Company, LLC

 Peter S. Lawrence 
 Patricia A.
Suzman 
 John P. Dunphy 

  
 Exhibit E-5

 PARATEK PHARMACEUTICALS, INC. 

ACKNOWLEDGEMENT, CONSENT AND SECOND AMENDMENT 
 TO THE 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 This Acknowledgement, Consent and Second Amendment (the “Amendment”) to the Third Amended and Restated
Investor Rights Agreement, dated October 19, 2007, as amended (the “Investor Rights Agreement”), by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) the
Founders party thereto, (iii) the Series C Investors listed on Exhibit B (the “Series C Investors”), (iv) the Series D Investors listed on Exhibit C (the “Series D Investors”), (v) the
Series F Investors listed on Exhibit D (the “Series F Investors”) and (v) the Series H Investors listed on Exhibit E (the “Series H Investors” and together with the Series C Investors, and Series
D Investors, Series F Investors, the “Investors”), is made as of November 29, 2010 and is effective as of the completion of the Transaction (as defined below). 

WHEREAS, the Company has been notified by Nomura International Plc (“NIP”), a holder of the Company’s Series C
Convertible Preferred Stock and Series D Convertible Preferred Stock and by Nomura Phase4 Ventures LP (“NPV2”), a holder of the Company’s Series H Convertible Preferred Stock (collectively the “NPV Stock”) that
NIP and NPV2 are in the process of transferring the entirety of the NPV Stock (together with all of the rights attached thereto) to a limited partnership to be known as Phase4 Ventures III LP (the “Transferee”); 

WHEREAS, the initial investor in the Transferee will be a Nomura entity (being an affiliate of NIP and of the sole Nomura investor in
NPV2), but it is intended that such affiliate will dispose of its limited partnership interest to a fund managed or advised by HarbourVest Partners, LLC or its affiliates, which will become the new majority limited partner in the Transferee;

 WHEREAS, Nomura Phase4 Ventures Limited (“NPVL”), the current manager of the NPV Stock for NIP and NPV2 will
also be appointed to manage the Transferee, and an affiliate of NPVL will be the general partner of each of the Transferee and NPV2; 
 WHEREAS, concurrently with the disposal of the limited partnership interest in the Transferee, NIP will transfer NPVL and its subsidiaries to the current management team comprising NPVL (the
“Transaction”); 
 WHEREAS, based on the foregoing, the Transaction will constitute a transfer by NIP and NPV2
to an “Affiliate” of such Stockholders and will thus constitute a transfer to a “Permitted Transferee” for purposes of Section 3.6 of the Investor Rights Agreement, such that the provisions of Sections 3.3, 3.4 and 3.5 of
the Investor Rights Agreement will not apply to the Transaction; 

 WHEREAS, each of NIP and NPV2 intend to assign all of their respective rights under the
Investor Rights Agreement to the Transferee and the Transferee will assume all of the obligations of NIP and NPV2 under the Investor Rights Agreement by executing an Instrument of Adherence to the Investor Rights Agreement in substantially the form
attached hereto as Exhibit A; 
 WHEREAS, while it is anticipated that NPV2 and the Transferee will remain under the
common management of NPVL, (i) the limited partnership agreement governing NPV2 contains provisions relating to the removal of the general partner and termination of the manager, and negotiated terms in relation to these provisions will be
included in the limited partnership governing the Transferee and (ii) NPV2 and the Transferee do not have the same term, as NPV2’s term is due to expire on 30 April 2012 (although it may be extended by two additional one year
periods); while this is not envisaged, it is therefore possible that NPV2 and the Transferee may cease to be commonly managed at some point in the future or that NPV2 may be dissolved prior to the liquidation of the Transferee; and 

WHEREAS, in accordance with Section 8.3 of the Investor Rights Agreement, Investors holding at least sixty-six and two-thirds
percent (66-2/3%) of the outstanding shares of the Investor Preferred Stock (as defined in the Investor Rights Agreement), have provided their written consent to, and approval of, this Amendment, and, by executing and delivering this Amendment, the
Company has consented to and approved this Amendment. 
 NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

1. Acknowledgement of Permitted Transferee. 
 The parties hereby confirm and acknowledge that the transfer of the NPV Stock by each of NIP and NPV2 to the Transferee is a transfer to an “Affiliate” (under and as defined in the Investor
Rights Agreement) and that the Transferee is a “Permitted Transferee” under Section 3.6 of the Investor Rights Agreement. 
 2. Amendment to Investor Rights Agreement. 
 Section 5.1 of the
Investor Rights Agreement is hereby amended such that each reference to “Nomura International Plc” is replaced with a reference to “Phase4 Ventures III LP”, such that the rights exercisable by NIP to designate one Series C
Director to the Board of Directors of the Company be exercisable by the Transferee going forwards. For purposes of clarification, the parties acknowledge that any other rights to elect persons to the Board of Directors of the Company which NIP (as
Series C and Series D Stockholder) and NPV2 (as Series H Stockholder) may have had pursuant to Article 5 of the Investor Rights Agreement shall be exercisable by the Transferee following completion of the Transaction. 

3. Effect of Amendment. 
 Except as contemplated by this Amendment, the terms and conditions of the Investor Rights Agreement shall remain in full force and effect. 

  
 2 

 4. Counterparts. This Amendment may be executed in one or more counterparts, and by
different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 5. Governing Law. This Amendment will be governed by and interpreted and construed in accordance with the internal laws of the State of Delaware, without giving effect to the conflict of law
principles thereof. 
 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first above written.

  

			
	COMPANY:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Beverly Armstrong

	Name:	 	Beverly Armstrong
	Title:	 	Vice President, Chief Compliance Officer, General Counsel and Secretary

 [counterpart signature pages for Investors follow] 

  
 3 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Aisling Capital II, LP

	Printed Name of Stockholder
	
	 /s/ Lloyd Appel

	Signature of Stockholder

  

			
	Title:	 	 Lloyd Appel, CFO

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 11/1/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 BioVeda Fund Pte Ltd

	Printed Name of Stockholder
	
	 /s/ BioVeda Fund Pte Ltd

	Signature of Stockholder

  

			
	Title:	 	 By BioVeda Capital Pte Ltd,

		 	 its Investment Manager

		 	 Damien Lim, General Partner

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 10/25/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 William G. Coughlin

	Printed Name of Stockholder
	
	 /s/ William G. Coughlin

	Signature of Stockholder

  

			
	Title:	 	  

 
			
		
	Address:	 	  

		
		 	  

		
		 	  

 
			
		
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 D.E. Shaw Valence Portfolios, L.L.C.

	Printed Name of Stockholder
	
	 /s/ Anne Dinning

	Signature of Stockholder

  

			
	Title:	 	 Managing Director

 

			
	 Address:
	 	  

		
		 	  

		
		 	  

 

			
	 Date:
	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Thomas J. Dietz

	Printed Name of Stockholder
	
	 /s/ Thomas J. Dietz

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/20/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Frederick Frank

	Printed Name of Stockholder
	
	 /s/ Frederick Frank

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Alden I. Gifford

	Printed Name of Stockholder
	
	 /s/ Alden I. Gifford

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 25 Oct 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Beryl L. Snyder, Partner

	Printed Name of Stockholder
	
	 /s/ Beryl L. Snyder, Partner

	Signature of Stockholder

  

			
	Title:	 	 Partner

 

			
	Address:	 	 HBJ Investments, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 26, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 HBM BioVentures (Cayman) Ltd.

	Printed Name of Stockholder
	
	 /s/ John Arnold

	Signature of Stockholder

  

			
		 	John Arnold
	Title:	 	 Chairman & Managing
Director

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 22 Oct/2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Irwin Heller

	Printed Name of Stockholder
	
	 /s/ Irwin Heller

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Hercules Technology Growth Capital, Inc.

	Printed Name of Stockholder
	
	 /s/ K. Nicholas Martitsch

	Signature of Stockholder

  

			
		 	K. Nicholas Martitsch
	Title:	 	 Associate General Counsel

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 October 29, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 

The Ingram Family Trust U/A/D 11/23/96 as amended 

	
	Printed Name of Stockholder
	
	 /s/ Gregory J. Ingram

	Signature of Stockholder

  

			
	Title:	 	 Trustee

 

			
	Address:	 	 The Ingram Family Trust

		
		 	 Attn: Gregory J. Ingram, TTEE

		
		 	  

	
	 Copy of all correspondence to:

		
		 	 The Ingram Family Trust

		
		 	 Attn: Diane Larson, Financial Mgr.

		
		 	  

		
		 	  

 

			
	Date:	 	 10/25/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Anthony John Khuri

	Printed Name of Stockholder
	
	 /s/ Anthony John Khuri

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Louis Lacasse

	Printed Name of Stockholder
	
	 /s/ Louis Lacasse

	Signature of Stockholder

  

			
		 	Louis Lacasse,
		 	    President
	Title:	 	 Genechem Management Inc.

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 Oct. 25, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Kevin J. Canning

	Printed Name of Stockholder
	
	 /s/ Kevin J. Canning

	Signature of Stockholder

  

			
	Title:	 	 Partner at Lahne and Manager of the
LLC

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Peter Lawrence

	Printed Name of Stockholder
	
	 /s/ Peter Lawrence

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Jay A. Levy

	Printed Name of Stockholder
	
	 /s/ Jay A. Levy

	Signature of Stockholder

  

			
	Title:	 	 Prof of Medicine

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Jay Levy/Sharon Levy

	Printed Name of Stockholder
	
	 /s/ Jay Levy /s/ Sharon Levy

	Signature of Stockholder

  

			
	Title:	 	 Shareholder

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	Jay Howard Linn, Trustee
	 Irrevocable Trust Agreement Number 1

	Printed Name of Stockholder
	
	 /s/ Jay Howard Linn

	Signature of Stockholder

  

			
	Title:	 	 Trustee

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 Oct 21 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Ralph A. Loren

	Printed Name of Stockholder
	
	 /s/ Ralph A. Loren

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 22 October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Merifin Capital N.V.

	Printed Name of Stockholder
	
	by: Finabel S.A., Management Director
	 /s/ Guillaume de Rham
 by: Guillaume de Rham, Director

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	 c/o Finabel SA

		
		 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 26 October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Mintz Levin Investments, LLC

	Printed Name of Stockholder
	
	 /s/ Jeffrey M. Wiesen, Manager

	Signature of Stockholder

  

			
	Title:	 	 Manager

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 October 20, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Nomura International PLC

	Printed Name of Stockholder
	
	 /s/ Denise Pallard-Knight

	Signature of Stockholder

  

			
	Title:	 	 Managing Director

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 27th October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Nomura Phase4 Ventures LP

	Printed Name of Stockholder
	
	 /s/ Denise Pallard-Knight

	Signature of Stockholder
	 Nomura Phase4 Ventures Limited

as Manager of Nomura Phase4 Ventures LP

  

			
	Title:	 	 Managing Director

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 27th October 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 David Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 

Novack Family 1999 Trust f/b/o Emily Kate Novack 

	
	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Emily K. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Helen Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Novack Family 1999 Trust f/b/o Jeffrey Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Jeffrey N. Novack 1996 Trust

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Kenneth J. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Kenneth J. Novack 1993 Revocable Trust

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Marianne M. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Sara E. Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	
Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 The Osgood Family Trust UAD 4/14/2000

	Printed Name of Stockholder
	
	 /s/ Richard H. Osgood, Trustee

	Signature of Stockholder

  

			
	Title:	 	 The Osgood Family Trust UAD
4/14/2000

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 David Pastel

	Printed Name of Stockholder
	
	 /s/ David Pastel

	Signature of Stockholder

  

			
	Title:	 	 Mr. David Pastel c/o Levy

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/27/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Donald J.M. Phillips

	Printed Name of Stockholder
	
	 /s/ Donald J.M. Phillips

	Signature of Stockholder

  

			
	Title:	 	 CEO

 

			
	Address:	 	 Vox MEDICA

		
		 	  

		
		 	  

 

			
	Date:	 	 10/22/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Novack Family 1999 Trust f/b/o Laura Pontin

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Laura Novack Pontin

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Madeline Gunilla Pontin 1997 Present Interest Trust

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 POD Venture Partners AB

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 R. Robert Popeo

	Printed Name of Stockholder
	
	 /s/ R. Robert Popeo

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 PRAG Associates LLC

	Printed Name of Stockholder
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Agent

 

			
	Address:	 	 RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Suzanne Priebatsch

	Printed Name of Stockholder
	
	 /s/ Suzanne Priebatsch

	Signature of Stockholder

  

			
	Title:	 	 Norman and Suzanne
Priebatsch

  

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/25/2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Robert D. Ritchie

	Printed Name of Stockholder
	
	 /s/ Robert D. Ritchie

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 21 Oct 10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Rockwood Capital Corporation

	Printed Name of Stockholder
	
	 /s/ David H. Carl

	Signature of Stockholder

  

			
	Title:	 	 President

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/26/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 July and Peter Smith

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Beryl L. Snyder, Executrix

	Printed Name of Stockholder
	
	 /s/ Beryl L. Snyder, Executrix

	Signature of Stockholder

  

			
	Title:	 	 Executrix

 

			
	Address:	 	 Estate of Harold Snyder

		
		 	  

		
		 	  

 

			
	Date:	 	 October 26, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Patricia A. Suzman

	Printed Name of Stockholder
	
	 /s/ Patricia A. Suzman

	Signature of Stockholder

  

			
	Title:	 	  

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 10/23/10

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

			
	 Wheatley Medtech Partners, L.P.

	Printed Name of Stockholder
	
	 /s/ Barry Rubenstein

	Signature of Stockholder
		
	By:	 	Barry Rubenstein

  

			
		 	CEO, Wheatley Medtech Partners, LLC,
	Title:	 	 General Partner

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	 Miriam and Steven White

	Printed Name of Stockholder, By
	
	 /s/ Patrick B. Maraghy

	Signature of Stockholder

  

			
	Title:	 	 Duly Authorized Agent

 

			
	Address:	 	 c/o RINET Company, LLC

		
		 	  

		
		 	  

 

			
	Date:	 	 October 21, 2010

  
 4 

 Counterpart Signature Page For Investors 

The undersigned hereby agrees and consents to the Acknowledgement, Consent and Second Amendment to the Third Amended and Restated
Investor Rights Agreement by and among the Paratek Pharmaceuticals, Inc. and the Stockholders (as defined therein) dated as of the date hereof. 
  

	
	Winchester Capital Technology Partners LLC
and Winchester Capital Healthcare Partners LLC
	 Ceasar N. Anquillare

	Printed Name of Stockholder
	
	 /s/ Ceasar N. Anquillare

	 Signature of Stockholder

  

			
	Title:	 	 President & CEO

 

			
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	 11/10/10

  
 4 

 EXHIBIT A 

PARATEK PHARMACEUTICALS, INC. 
 INSTRUMENT OF ADHERENCE 
 TO THIRD AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT 
 By execution and delivery of this signature page, Phase4 Ventures III LP hereby agrees to become a party to
that certain Third Amended and Restated Investor Rights Agreement (the “Investor Rights Agreement”) by and among Paratek Pharmaceuticals, Inc., a Delaware corporation, (the “Company”) and the Stockholders (as defined in the
Investor Rights Agreement), dated as of October 19, 2007, as amended, and is entitled to all of the benefits under and subject to all of the obligations, restrictions and limitations set forth in the Investor Rights Agreement that are
applicable to the Stockholders generally, and to Series C Investors, Series D Investors and Series H Investors in particular. This Instrument of Adherence shall take effect and shall become a part of said Investor Rights Agreement immediately upon
execution. 
 Executed, in counterpart, as of the date set forth below. 

 

			
	Phase4 Ventures III LP
	
	  

	By:	 	
	Its:	 	
		
	Address:	 	  

		
		 	  

		
		 	  

 

			
	Date:	 	  

  

			
	Accepted:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	  

		 	Thomas J. Bigger
		 	President and Chief Executive Officer

  
 Exhibit A-1

 EXHIBIT B 

SERIES C INVESTORS 

Nomura International plc 
 Omega Fund III, L.P.

 c/o Omega Fund Management Limited 

FSC Corp. 
 Kenneth J. Novack 

Becky Levin 
 Bio Fund Ventures II Ky

 K/S Danish BioVenture 
 Merifin
Capital N.V. 
 c/o Finabel S.A. 

Harold Snyder 
 c/o HBJ Investments, LLC

  
 Exhibit B-1

 HBJ Investments, LLC 
 Mintz Levin Investment LLC 
 c/o Mintz, Levin, Cohn, Ferris, 

      Glovsky and Popeo, P.C. 
 Irrevocable Trust Agreement Number I, Jay Howard Linn, Trustee 
 Norman and Suzanne Priebatsch

 Robert D. Ritchie 
 Barclays
Capital Inc. as Custodian for David Pastel IRA No.  
 Attn:  Louis Maione 

Winchester Capital Healthcare Partners LLC 
 c/o
Pensar N. Anquillare, President 
 Barclays Capital Inc. as Custodian for Frederick Frank IRA No.  

Attn:  Louis Maione 
 Jay and Sharon
Levy 
 R. Ellen and Mario Koenig 

  
 Exhibit B-2

 Miriam and Steven White 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Helen Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

David Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Judy and Peter Smith 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Novack Associates Limited Partnership II 
 c/o
RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Marianne M. Novack 
 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Kenneth J.
Novack 1993 Revocable Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

  
 Exhibit B-3

 Novack Family 1999 Trust f/b/o 
 Emily K. Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Novack Family 1999 Trust f/b/o Jeffrey Novack 

c/o RINET Company, LLC 
 Attn:  Patrick
B. Maraghy 
 Novack Family 1999 Trust f/b/o Sara Elizabeth Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Novack Family 1999 Trust f/b/o Laura Pontin 

c/o RINET Company, LLC 
 Attn:  Patrick
B. Maraghy 
 Anthony John Khuri 
 c/o
Khuri Consulting Group 
 Donald J. M. Phillips 
 c/o Ted Thomas Associates 

  
 Exhibit B-4

 EXHIBIT C 

SERIES D INVESTORS 

Novartis BioVentures Ltd. 
 HBM BioVentures
(Cayman) Ltd. 
 Attention John Arnold 

Kenneth J. Novack 
 L&C Participation, LLC

 Ralph A. Loren, Personal 
 DeAnn F.
Smith, Personal 
 Formosa Healthcare Investments, L.P. 
 c/o Howard Lee, Ph.D. 
 Managing Director 
 Silver Biotech Management, Inc. 

  
 Exhibit C-1

 Wheatley MedTech Partners, LP 
 Attention:  Maureen Wilson 

			
	        With copies to:	  	 Wheatley Partners
 Attention:
David R. Dantzker, MD / Lawrence Wagenberg

 FSC Corp. 
 c/o
BancBoston Capital Inc. 
 Attention:  John J. Quintal 
 Alden I. Gifford 
 Rockwood Capital Corporation 

c/o David H. Carts 
 William G. Coughlin

 Barclays Capital Inc. as Custodian for David Pastel IRA 
 Attn:  Louis Maione 
 BioVeda Fund Pte Ltd 

Attention:  Damien Lim 
 R. Ellen and
Mario Koenig 

  
 Exhibit C-2

 Barclays Capital Inc. as Custodian for Sharon Levy IRA No. 

Attn:  Louis Maione 
 Barclays Capital
Inc. as Custodian for Jay Levy IRA No.  
 Attn:  Louis Maione 
 Anthony Khuri 
 c/o Khuri Consulting Group 

Robert Ritchie 
 Peter S. Lawrence 

GeneChem Therapeutics 
 Venture Fund L.P

 Nomura International PLC 
 Mintz
Levin Investments, LLC 
 Mintz, Levin, Cohn, 
         Ferris, Glovsky and Popeo, P.C. 
 Irwin Heller

 Harold Snyder 

  
 Exhibit C-3

 HBJ Investments, LLC 
 PRAG Associates LLC 
 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Merifin
Capital N.V. 
 c/o Finabel SA 
 Omega
Fund III, L.P. 
 c/o Omega Fund Management Limited 
 Winchester Capital Technology 
 Partners LLC 

David R. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Peter and Judy Smith 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Steven and Miriam White 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

  
 Exhibit C-4

 Helen Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

K/S Danish Bioventure 
  

			
	Coller International Partners IV Limited	  	Copy to: Coller Capital
	c/o Coller Capital	  	Attn:  Hiro Mizuno, Remdo Haaxman
	Attention Mr. Paul McDonald	  	and Laura Bradshaw

 POD Venture Partners AB (Reg. No. 556744-9441) 
 Attention Axel Roos 
 Robert E. Cawthorne 

Bio Fund Ventures II L.P. 
 Squamata Limited

  
 Exhibit C-5

 EXHIBIT D 

SERIES F INVESTORS 

POD 1.0 AB (Reg No. 556744-9441) 
 Attention
Axel Roos 
 Novartis BioVentures Ltd. 

Frederick Frank 
 Anthony John Khuri

 Khuri Consulting Group 
 R. Robert
Popeo 
 Robert Cawthorn 
 Peter S.
Lawrence 
 L&C Participation, LLC 

DeAnn F. Smith, PERSONAL 

  
 Exhibit D-1

 Kenneth J. Novack 
 David Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Jeffrey N. Novack 1996 Irrevocable Trust dated 2/14/96,
Marianne M. Novack, David R. 
 Novack and Paul D. Bishop, Trustee 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Judy and Peter Smith 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Helen Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Miriam and Steven White 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Emily K. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Sara E. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

  
 Exhibit D-2

 Madeline Gunilla Pontin 1997 Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Laura Novack Pontin 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Omega Fund III, L.P. 
 c/o Omega Fund Management
Limited 
 BioVeda Fund Pte Ltd 

Attention:  Damien Lim, Ph.D. 

BioFund Ventures II Follow-On Fund L.P. 

Wheatley Med Tech Partners, LP 

Attention:  Maureen Wilson 

			
	        With copies to:	  	 Wheatley Partners

Attention:  David R. Dantzker, MD / Lawrence Wagenberg

 Rosemary Nguyen 

  
 Exhibit D-3

 EXHIBIT E 

SERIES H INVESTORS 

Aisling Capital II, LP 
 Aisling Capital

 Attn:  Anthony Sun 

        With a copy to: 
                 McDermott Will & Emery 
                 Attn:  Todd A. Finger 
 D.E. Shaw Valence Portfolios, L.L.C. 
 Attn:  James Mackey 

Hercules Technology Growth Capital, Inc. 

Attn:  Scott Harvey 
 Boston Life
Science Venture Corp. 
 Attn:  Dr. William Chung 
 Thomas J. Dietz 
 c/o Wedbush Morgan Securities 

Attention Kathleen Shea 
 The Osgood Family
Trust UAD 4/14/2000 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

  
 Exhibit E-1

 The Osgood Family Trust UAD 4/14/2000 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

Ben Perkins Custodian for William Beau Perkins Uniform Gift to Minors Act CA 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

Ben Perkins Custodian for Charlotte Rose Perkins Uniform Gift to Minors Act CA 
 c/o Wedbush Morgan Securities 
 Attention Kathleen Shea 

The Ingram Family Trust U/A/D 11/23/96, as amended, Gregory J. Ingram & Heidi M. Ingram, 

Trustees 
 c/o Wedbush’Morgan Securities

 Attention Kathleen Shea 
 Sarah L.
Gordon 
 Novartis BioVentures Ltd 

Attn:  Emil Bock 
 Nomura Phase4
Ventures LP 
 Attn:  Dr. Denise Pollard-Knight 
 Bio Fund Ventures II Follow-On L.P. 
 Attn:  Kalevi Kurkijarri 

  
 Exhibit E-2

 HBM BioVentures (Cayman) Ltd. 
 Attn:  John Arnold 
 Omega Fund III, L.P. 

c/o Omega Fund Management Limited 
 BioVeda Fund
Pte Ltd 
 Attn:  Damien Lim, Ph.D. 
 Kenneth J. Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 PRAG Associates LLC 

c/o RINET Company, LLC 
 Attn:  Patrick
B. Maraghy 
 Jeffrey N. Novack 1996 Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

Emily K. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Sara E. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

  
 Exhibit E-3

 Madeline Gunilla Pontin 1997 Present Interest Trust 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 

David Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Judy & Peter Smith 
 c/o RINET Company,
LLC 
 Attn:  Patrick B. Maraghy 
 Novack Family 1999 Trust f/b/o Emily Kate Novack 
 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Novack
Family 1999 Trust f/b/o Jeffrey Novack 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Novack Family 1999 Trust f/b/o Sarah Elizabeth Novack

 c/o RINET Company, LLC 

Attn:  Patrick B. Maraghy 
 Novack
Family 1999 Trust f/b/o Laura Pontin 
 c/o RINET Company, LLC 
 Attn:  Patrick B. Maraghy 
 Helen Novack 

c/o RINET Company LLC 
 101 Federal Street

 Boston, MA 02110 

Attn:  Patrick B. Maraghy 

  
 Exhibit E-4

 Miriam and Steven White 
 Boston, MA 02110 
 Attn:  Patrick B. Maraghy 

Laura Novack Pontin 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

David and Lesley Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Marianne M. Novack 
 c/o RINET Company, LLC

 Attn:  Patrick B. Maraghy 

Peter S. Lawrence 
 Patricia A. Suzman

 John P. Dunphy 
 KC Stone

 c/o Wedbush Morgan Securities 

Attention Kathleen Shea 

  
 Exhibit E-5

 PARATEK PHARMACEUTICALS, INC. 

THIRD AMENDMENT 
 TO THE 
 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 This Third Amendment (this “Amendment”) to the Third Amended and Restated Investor Rights Agreement,
dated October 19, 2007 (as amended, the “Investor Rights Agreement”), by and among (i) Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), (ii) the holders of the Company’s
common stock listed on Exhibit A thereto (referred to herein individually as a “Founder” and collectively as the “Founders”), (iii) the Series C Investors listed on Exhibit B thereto (the
“Series C Investors”), (iv) the Series D Investors listed on Exhibit C thereto (the “Series D Investors”), (v) the Series F Investors listed on Exhibit D thereto (the “Series F
Investors”) and (vi) the Series H Investors listed on Exhibit E thereto (the “Series H Investors” and together with the Series C Investors, Series D Investors, Series F Investors, the
“Investors”), is made as of October 2, 2012. 
 WHERAS the Company and the other parties thereto entered
into that certain Non-Convertible Note Purchase Agreement dated as of February 13, 2012 (the “Original Purchase Agreement”), pursuant to which the Company issued and sold an aggregate of $5,793,642 original principal amount of
notes substantially in the form attached as Exhibit A-1 to the Original Purchase Agreement (the “Prior Closing Notes”); 
 WHEREAS, the Company and the other parties thereto are contemporaneously entering into that certain Note and Stock Purchase Agreement of even date herewith (the “September Purchase
Agreement”; unless otherwise defined herein, capitalized terms used in this Amendment shall have the meanings assigned to them in such September Purchase Agreement), pursuant to which, among other things, the Company will issue and sell up
to $3,000,000 (or such higher amount not to exceed $5,000,000 as the Issuer’s Board of Directors and the Required Holders approves) of Pre-IPO Notes substantially in the form attached as Exhibit A-1 thereto (the “Third Closing
Notes”), together with the Third Closing Bonus Shares and the Third Closing IPO Shares on the terms and conditions set forth herein; 
 WHERAS, in connection with the issuance and sale of the Third Closing Notes, the Company and the holders of the Prior Closing Notes have exchanged or will exchange all of the Prior Closing Notes for notes
of the Company of like tenor substantially in the form attached as Exhibit A-1 to the September Purchase Agreement (the “Amended Pre-IPO Notes” and, together with the Third Closing Notes, the “Pre-IPO
Notes”); 
 WHERAS, in connection with a possible initial public offering of the Company’s Common Stock, the
September Purchase Agreement also provides for the automatic exchange of the Pre-IPO Notes for new notes of the Company of like tenor in substantially the form of Exhibit A-2 to the September Purchase Agreement (together with any replacement
or substitute note issued in respect of such note, the “Post-IPO Notes”); 
 WHEREAS, in connection with the
execution of the Note and Stock Purchase Agreement, the Company and the Investors desire to amend certain provisions of the Investor Rights Agreement as set forth herein in order to (i) include the Third Closing Bonus Shares, the

 
Third Closing IPO Shares, the Post-IPO Notes and the Conversion Shares in the definition of “Registrable Securities” therein, such that the holders of the Third Closing Bonus Shares,
the Third Closing IPO Shares, the Post-IPO Notes and the Conversion Shares are entitled to the same registration rights as the other holders of Registrable Securities party to the Investor Rights Agreement and (ii) at such time as the Company
is a registrant entitled to use Form S-3 or any comparable or successor form thereto, if any holder of the Third Closing Bonus Shares, the Third Closing IPO Shares, the Post-IPO Notes or the Conversion Shares is at such time an affiliate of the
Company (as defined in Rule 144 under the Securities Act), cause the Company to use its reasonable best efforts to register under the Securities Act such shares of Common Stock held by or issuable to such affiliates on Form S-3 or any comparable or
successor form thereto, for resale to the public, and to otherwise comply with the registration procedures set forth in Section 4.6 of the Investor Rights Agreement with respect to such shares and such registration statement. 

WHEREAS, in accordance with Section 8.3 of the Investor Rights Agreement, Investors holding at least sixty-six and two-thirds
percent (66-2/3%) of the outstanding shares of the Investor Preferred Stock (as defined in the Investor Rights Agreement) have provided their written consent and approval of this Amendment, and, by executing and delivering this Amendment, the
Company has consented and approved of this Amendment. 
 NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained in this Amendment and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Amendments to Investor Rights Agreement. 
 (i) In order to delete the existing definition of “Warrant Shares”, which are no longer outstanding, the Second Recital to the Investor Rights Agreement is hereby amended by deleting such Second
Recital Section in its entirety and by substituting in lieu thereof the following new Second Recital: 

“WHEREAS, the Company, the Founders, the Series C Investors, the Series D Investors and the Series F Investors are
each party to that certain Second Amended and Restated Investor Rights Agreement, dated June 2, 2004 (the “Second Amended and Restated IRA”) in connection with the issuance by the Company (a) to the Series C Investors of
5,100,500 shares of the Company’s Series C Convertible Preferred Stock, $.001 par value per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series C Stock”), (b) to the
Series D Investors of 6,390,866 shares of the Company’s Series D Convertible Preferred Stock, par value $.001 per share, convertible into shares of the Company’s common stock, $.001 par value per share (the “Series D
Stock”) and (c) to the Series F Investors of 925,412 shares of the Company’s Series F Convertible Preferred Stock, par value $.001 per share, convertible into shares of the Company’s common stock, $.001 par value per share
(the “Series F Stock”)” 
 (ii) Section 1.4 of the Investor Rights Agreement is hereby amended by
adding the following new definitions in the appropriate alphabetical order to such Section 1.4 

“Conversion Shares” shall mean the shares of Common Stock issuable upon conversion of the Post-IPO Notes
in accordance with their respective terms. 

  
 2 

 “Pre-IPO Notes” shall have the meaning ascribed to that
term in the September Purchase Agreement. 
 “Post-IPO Notes” shall have the meaning ascribed to
that term in the September Purchase Agreement. 
 “September Purchase Agreement” shall mean that
certain Note and Stock Purchase Agreement by and among the Company and the parties thereto. 
 “Series H
Warrant” shall mean that certain Warrant to purchase shares of Series H Preferred issued to MidCap Financial, LLC on March 26, 2009, as amended or modified in accordance with its terms. 

“Third Closing Bonus Shares” shall have the meaning ascribed to that term in the September Purchase
Agreement. 
 “Third Closing IPO” shall have the meaning ascribed to that term in the September
Purchase Agreement. 
 (iii) The definition of “Registrable Securities” contained in Section 1.4 of the Investor
Rights Agreement is hereby amended by deleting such definition in its entirety and by substituting in lieu thereof the following new definition of “Registrable Securities in Section 1.4: 

“Registrable Securities” shall mean (i) shares of Common Stock or other securities issued or
issuable pursuant to the conversion of the Investor Preferred Stock (including the shares of Series H Preferred issuable pursuant to the Series H Warrant); and (ii) any shares of Common Stock or other securities issued or issuable pursuant to
the conversion of the Investor Preferred Stock, (iii) any Third Closing Bonus Shares, (iv) any Third Closing IPO Shares and (v) any other shares of Common Stock issued in respect of the securities identified in clause (i) through
(iv) upon any stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event), excluding in each case any securities which have been (a) registered under the Securities Act pursuant to
an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them or (b) publicly sold pursuant to Rule 144 under the Securities Act; provided that, with respect to
any holder (other than Persons who are Affiliates of the Company), shares of Common Stock or other securities held by such holder shall cease to be Registrable Securities at such time when such holder can sell such shares of Common Stock or other
securities pursuant to Rule 144(b)(1) under the Securities Act. Wherever reference is made in this Agreement to a request or consent of holders of a certain percentage of Registrable Securities, the determination of such percentage shall be
calculated on the basis of shares of Common Stock issued or issuable upon conversion of the Investor Preferred Stock even if such conversion has not been effected. 
 (iv) Section 4.5 of the Investor Rights Agreement is hereby amended by adding a reference to subsection “(a)” immediately prior to the existing paragraph comprising such Section 4.5,
and inserting after such renumbered subsection 4.5(a) the following new subsection 4.5(b): 

  
 3 

 “(b) In addition to the rights provided in Sections 4.3 and 4.4
and the foregoing subsection 4.5(a), if at the time the Company becomes a registrant entitled to use Form S-3 or any comparable or successor form thereto there is one or more holders of the Third Closing Bonus Shares, Third Closing IPO Shares or the
Post-IPO Notes (or the Conversion Shares issued or issuable upon the conversion of such Post-IPO Notes) who is then an affiliate (as defined in Rule 405 under the Securities Act, or its successor for purposes of this Section 4.5(b)) of the
Company (each a “Resale Selling Stockholder” and collectively the “Resale Selling Stockholders”), then the Company shall use its reasonable best efforts to register under the Securities Act on Form S-3 or any
comparable or successor form thereto, for public resale from time to time, any Third Closing Bonus Shares, Third Closing IPO Shares and any shares of Common Stock issued or issuable upon conversion of the Post-IPO Notes held by such affiliate,
including the Conversion Shares held by such affiliate. Whenever the Company is required by this Section 4.5(b) to use its reasonable best efforts to effect the registration of such Registrable Securities by the Resale Selling Stockholders,
each of the procedures and requirements of Section 4.6 shall apply to such registration. Notwithstanding the foregoing, the obligations of the Company under this Section 4.5(b) shall cease and terminate upon the earlier to occur of
(i) the sale of all of such Registrable Securities by such Resale Selling Stockholders or (ii) the time when there are no affiliates of the Company that hold Post-IPO Notes (or the Conversion Shares issued or issuable upon the exercise or
conversion of such Post-IPO Notes).” 
 Section 2. Effect of Amendment. Except as expressly set forth
herein, no other terms or provisions of the Investor Rights Agreement are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 

Section 3. Counterparts. This Amendment may be executed in two or more counterparts, including by facsimile or Portable
Document Format (PDF), all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties and delivered to the other parties, including by facsimile or Portable Document
Format (PDF). 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 4 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first above
written. 
  

			
	COMPANY:
	
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Dennis P. Molnar

	Name: 	 	Dennis P. Molnar
	Title:	 	President and Chief Executive Officer

 [counterpart signatures on following pages] 

[Signature Page to Third Amendment To Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		  	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  
	 		  	 /s/ Lloyd Appel

	Name:	 		 		  	By: Lloyd Appel, CFO
		 		 		  	Name: Aisling Capital II, LP
					
	Address:	 	  
	 		  	Address:	  	  

			
	  
	 		  	  

			
	  
	 		  	  

					
	Email:	 	 	 		  	Email:	  	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	/s/ Walter Gilbert	 	 	 	  
	Name: Walter Gilbert	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Celia Gilbert	 	 	 	  
	Name: Celia Gilbert	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	 /s/ Denise Pollard-Knight

	Name:	 		 	By: Denise Pollard-Knight
		 		 		 	 Name: Director Phase4 Ventures LTD
        As Manager for Phase4 Ventures III LP

					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

							
	SIGNATURE FOR INDIVIDUAL HOLDER	 		    	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
				
		 		    	 /s/ H.S. Zivi
	 	 /s/ Rebecca White

	Name:	 		    	By: H.S. Zivi	 	Rebecca White
		 		    	Name: Deputy Chairman	 	Authorized Signatory
			
	Address:                            
                                         
   	 		    	Address:   Novartis Bioventures
LTD                                        
                              
			
	  
	 		    	  

			
		 		    	  

	  

Email:                        
                                         
           
	 		    	  

Email:                        
                                         
                                         
                       

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	 /s/ John Arnold

	Name:	 		 	By: HBM Healthcare Investments (Cayman) Ltd.
		 		 		 	 Name: John Arnold

Title: Chairman and Managing Director

					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Kenneth J. Novack	 	 	 	  

	Name:Kenneth J. Novack	 		 	By:
		 		 		 	 Name:

					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 /s/ Damien Lim

	Name:	 		 		 	By: BioVeda Capital Pte Ltd.
		 		 		 	 Name: its Investment Manager
             Damien Lim, General Partner

					
	Address:	 	  
	 		 	Address:	 	  

	  
	 		 	  

	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 /s/ Stefan Beil

	Name:	 		 		 	By: Sobera Capital Fund I GMBH & Co.KG
		 		 		 	 Name: Dr. Stefan Beil, Managing Director
             Of Sobera Capital Fund I GMBH & Co. KG

					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ David H. Halpert	 		 	  

	Name: David H. Halpert	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Lewis J. Geffen	 		 	  

	Name: Lewis J. Geffen	 		 	By:
		 		 		 	Name:
					
	Address:	 	 c/o Mintz Levin
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Sean Johnston	 		 	  

	Name: Sean Johnston	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Raina Gay Leahy	 		 	  

	Name: Raina Gay Leahy	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER
     Hercules Technology Growth Capital, Inc.

			
	 	 		 	 /s/ K. Nicholes Martitsch

	Name:	 		 		 	By: K. Nicholes Martitsch
		 		 		 	Name: Associate General Counsel
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 PRAG Associates LLC

	Name:	 		 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	  
	 		 	Address:	 	 c/o RINET Company LLC

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Michael P. Draper	 		 	  

	Name:	 		 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

	/s/ Joseph R. Ianelli	 		 		 	
			
	Joseph R. Ianelli	 		 	  

	Name:	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Stanton Ken Tanaka	 		 	  

	Name: Stanton Ken Tanaka	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER
     by: Finabel S.A., Managing Director

			
	 	 		 	 /s/ Guillaume de Rham

	Name:	 		 		 	By: Guillaume de Rham, Director
		 		 		 	Name: Merifin Capital N.V.
					
	Address:	 	  
	 		 	Address:	 	 Merifin Capital N.V.

			
	  
	 		 	 c/o Finabel S.A.

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ R. Robert Popeo	 		 	  

	Name:	 		 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER
     Lander Burr 1985 Trust

			
	 	 		 	 /s/ Francis F. Kingsley

	Name:	 		 		 	By:
		 		 		 	Name: Francis F. Kingsley U POA
					
	Address:	 	  
	 		 	Address:	 	 c/o Kingsley Business Service

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER
     Matthew Burr 1985 Trust

			
	 	 		 	 /s/ Francis F. Kingsley

	Name:	 		 		 	By:
		 		 		 	Name: Francis F. Kingsley U POA
					
	Address:	 	  
	 		 	Address:	 	 c/o Kingsley Business Service

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Stuart B. Levy	 		 	  

	Name:	 		 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Thomas J, Dietz	 		 	  

	Name: Thomas J. Dietz	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 Osgood Family Trust

	Name:	 		 		 	By: /s/ Richard Osgood
		 		 		 	Name: Richard Osgood, Trustee
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 /s/ Patricia A. Smith
	 	 	 	  
	Name: Patricia A. Smith	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	/s/ Jeffrey M. Wiesen
	Name:	 		 	By: Jeffrey Wiesen
		 		 		 	Name: Mintz Levin Investment LLC
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	Irrevocable Trust Agreement # I
	Name:	 		 	By: /s/ Jay Howard Linn, Trustee
		 		 		 	Name: Jay Howard Linn
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 Irrevocable Trust Agreement # III

	Name:	 		 		 	By: /s/ Jay Howard Linn, Trustee
		 		 		 	Name: Jay Howard Linn
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 /s/ Louis Lacasse

	Name:	 		 		 	By:
		 		 		 	Name: Genechem Therapeutics Venture Fund L.P.
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 /s/ Anne Dinning

	Name:	 		 		 	By: D.E. Shaw Valence Portfolios, L.L.C.
		 		 		 	Name: Anne Dinning
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ David McKenney	 		 	  

	Name: David McKenney	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Robert D. Ritchie	 		 	  

	Name:	 		 	By:
		 		 		 	Name:
					
	Address:	 	  
	 		 	Address:	 	  

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 	 		 	 Jeffrey N. Novack 1996
 Irrevocable Trust DTD 2/14/96

	Name:	 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	  
	 		 	Address:	 	 c/o RINET Company LLC

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	 	 		 	 Novack Family 1999 Trust
 F/B/O Sarah Elizabeth Novack

	Name:	 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	  
	 		 	Address:	 	 c/o RINET Company LLC

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	 	 		 	 Novack Family 1999 Trust
F/B/O Laura Pontin

	Name:	 		 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	  
	 		 	Address: 	 	 c/o RINET Company LLC

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER

			
	 	 		 	 Novack Family 1999 Trust
F/B/O Jeffrey Novack

	Name:	 		 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	  
	 		 	Address: 	 	 c/o RINET Company LLC

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER

			
	 	 		 	 Novack Family 1999 Trust
F/B/O Emily Kate Novack

	Name:	 		 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	  
	 		 	Address: 	 	 c/o RINET Company LLC

			
	  
	 		 	  

			
	  
	 		 	  

					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Marianne M. Novack	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Sara E. Novack	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Emily K. Novack	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  

 
 By execution and delivery of this signature page, the undersigned
hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a Delaware corporation, and the other parties thereto. 

Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	  	 	 	 	 Madeline Gunilla Pontin 1997
 Present Interest Trust

	Name:	 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	 	 		 	Address:	 	c/o RINET Company LLC
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Laura Novack Pontin	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: David R. Novack	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	SIGNATURE FOR CORPORATION,
PARTNERSHIP, TRUST OR OTHER
ENTITY HOLDER
			
	  	 	 	 	 Kenneth J. Novack 1993
 Revocable Trust

	Name:	 		 	By: /s/ Patrick B. Maraghy, Agent
		 		 		 	Name: Patrick B. Maraghy
					
	Address:	 	 	 		 	Address:	 	c/o RINET Company LLC
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Judith and Peter Smith	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Helen Novack	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: Miriam and Steven White	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Patrick Maraghy, Agent	 	 	 	  
	For Name: David Novack	 		 	By:
		 		 		 	Name:
					
	Address:	 	c/o RINET Company LLC	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 /s/ Amy E. Mandragouras
	 	 	 	  
	Name: Amy E. Mandragouras	 		 	By:
		 		 		 	Name:
				
	Address:                          
                                         
                                 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Theresa Dumont	 	 	 	  
	Name:	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Thomas Droumenq	 	 	 	  
	Name: Thomas Droumenq	 		 	By:
	            Managing Director	 		 	Name:
	            SG Americas Securities, LLC	 		 	
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	/s/ Mike Jager
	Name:	 		 	By: Coller International Partners IV Limited
		 		 		 	Name: Mike Jager – Alternate Director to
		 		 		 	    Paul McDonald
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Pieter J. Strijkert	 	 	 	  
	Name: Dr. Pieter J. Strijker	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Kathryn M. Boxmeyer	 	 	 	  
	Name:	 		 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Patricia A. Suzman	 	 	 	  
	Name:	 		 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Becky Levin	 	 	 	  
	Name: Becky Levin	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	/s/ Richard Lim
	Name:	 		 	 By: Danish BioVenture General Partner Aps
     As General Partner to K/S Danish BioVenture

		 		 		 	Name: Richard Lim, Director
					
	Address:	 	 	 		 	Address:	 	c/o Gorissen Federspiel
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  	 	 	 	/s/ Kevin Brennan
	Name:	 		 	By: Omega Fund III GP Ltd
		 		 	    as General Partner to Omega Fund III, G.P.
		 		 	    L.P. as General Partner to Omega Fund III L.P.
		 		 		 	Name: Kevin Brennan - Director
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Philip J. Newton	 	 	 	  
	Name: Philip J. Newton	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Jay A. Levy	 	 	 	/s/ Sharon Levy
	Name:	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Rachid Alami Mechiche	 	 	 	  
	Name: Rachid Alami Mechiche	 		 	By:
		 		 		 	Name:
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
  
 By execution and delivery of this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a
Delaware corporation, and the other parties thereto. 
 Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	/s/ Michael N. Alekshun	 	 	 	 
			
	 /s/ Anabela M. Alekshun
	 	 	 	  
	 Name: Michael N. Alekshun &
 Anabela M. Alekshun, JTWROS
	 		 	 By:

Name:

		 		 		 	
					
	Address:	 	 	 		 	Address:	 	 
			
	 	 		 	 
			
	 	 		 	 
					
	Email:	 	 	 		 	Email:	 	 

  

[Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
 By execution and delivery of
this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a Delaware corporation, and the other parties thereto. 

Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	 		 	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	 /s/ Adel Bakhtyari
	 		 	  

	Name:	 		 	By:
		 		 		 	Name:
					
	Address:	 	 Adel Bakhtyari
	 		 	Address:	 	  

	  
	 		 	  

	  
	 		 	  

	Email:	 	  
	 		 	Email:	 	  

 [Counterpart Signature Page to Third Amendment to Investor Rights Agreement] 

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
 By execution and delivery of
this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a Delaware corporation, and the other parties thereto. 

Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	  		  	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  
	  		  	 Inveni Secondaries Fund II Ky

	Name:	 		  		  	By:  /s/ Markku Fagerlund
		 		  		  	Name:  Markku Fagerlund
					
	Address:	 	  
	  		  	Address:	 	  

	  
	  		  	  

	  
	  		  	  

	Email:	 	  
	  		  	Email:	 	  

 PARATEK PHARMACEUTICALS, INC. 

Holder’s Counterpart Signature Page to 
 Third Amendment to Investor Rights Agreement 
 By execution and delivery of
this signature page, the undersigned hereby agrees to become a party to that certain Third Amendment to Investor Rights Agreement by and among Paratek Pharmaceuticals, Inc., a Delaware corporation, and the other parties thereto. 

Executed, in counterpart, as of the date set forth above. 

 

									
	SIGNATURE FOR INDIVIDUAL HOLDER	  		  	 SIGNATURE FOR CORPORATION,
 PARTNERSHIP, TRUST OR OTHER
 ENTITY HOLDER

			
	  
	  		  	 Inveni Secondaries Fund II Follow-On Ky

	Name:	 		  		  	By:  /s/ Markku Fagerlund
		 		  		  	Name:  Markku Fagerlund
					
	Address:	 	  
	  		  	Address:	 	  

	  
	  		  	  

	  
	  		  	  

	Email:	 	  
	  		  	Email:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]